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ABSTRACT 
This thesis aims to undertake health technology assessments in high risk pregnancies through 
the following objectives: 
1. In women with pre-eclampsia,  
a) To evaluate the association of maternal genotype and severe pre-eclampsia 
b) To assess the accuracy of tests in predicting adverse pregnancy outcomes 
c) To develop composite outcomes for reporting in trials on late onset pre-eclampsia  
2. In women with multiple pregnancy, 
a) To study the association between chorionicity and stillbirth 
b) To identify the optimal timing of delivery in monochorionic and dichorionic twin 
pregnancies 
3. In the field of prediction research in obstetrics 
a) To provide an overview of the existing prognostic models and their qualities  
b) To evaluate the methodological challenges and potential solutions in developing a 
prognostic model for complications in pre-eclampsia 
Methods 
The following research methodologies were used: Delphi survey, systematic reviews and 
meta-analyses. 
Results 
1. a) Maternal genotype and severe pre-eclampsia: 
57 studies evaluated 50 genotypes; increased risk of severe pre-eclampsia with 
thromobophilic genes.  
            b) Accuracy of tests in predicting pre-eclampsia complications: 
37 studies evaluated 13 tests. No single test showed high sensitivity and specificity.  
c) Delphi survey of 18/20 obstetricians and 18/24 neonatologists identified clinically 
important maternal and neonatal outcomes and maternal and neonatal composite 
outcomes were developed.  
2. Prospective risk of stillbirth and neonatal deaths in uncomplicated monochorionic and 
dichorionic twin pregnancies: 
 32 studies were included. In dichorionic twin pregnancies, the risk of stillbirths was 
balanced against neonatal death at 37 weeks’ gestation. In monochorionic 
pregnancies, there was a trend towards increase in stillbirths after 36 weeks but this 
was not significant. 
3. a) From 177 studies included, 263 obstetric prediction models were developed for 40 
different outcomes, most commonly pre-eclampsia, preterm delivery, mode of 
delivery and small for gestational age neonates.  
b) The obstetric prognostic model challenge of dealing with treatment paradox was 
explored and seven potential solutions proposed by expert consensus.  
Conclusion 
I have identified the strength of association for genes associated with complications in pre-
eclampsia, components for composite outcomes for reporting in studies on pre-eclampsia, 
and the optimal timing of delivery for twin pregnancies. My work has highlighted the gaps in 
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CHAPTER 1: BACKGROUND 
1.1. INTRODUCTION 
1.1.1. High risk pregnancy  
Antenatal care of mothers is focussed on identifying women and offspring at risk of 
complications. Early identification of high-risk women at risk will enable targeted care, 
including close monitoring and early delivery. Currently, women who enter pregnancy with 
underlying conditions such as chronic hypertension, diabetes mellitus, respiratory disease, 
cardiac disease, neurological conditions, renal disease, or develop conditions such as 
gestational diabetes, and pre-eclampsia in pregnancy are considered to be at high risk of 
adverse pregnancy outcomes. Additionally, the status of the pregnancy itself concurs risks to 
the mother and fetus such as in multiple pregnancy.  
 
Of the above conditions, pre-eclampsia, which affects around 6-8% of all pregnant women 
continues to be one of the major contributors to adverse outcomes in the mother and fetus 
both in the UK and worldwide. With the advancing maternal age, and sophisticated assisted 
reproductive technologies, multiple births are on the rise, accounting for 3% of all livebirths 
in the UK.1 Mothers often need close monitoring in both conditions, with high risks of 
admission to the high dependency unit (HDU) due to complications, and neonatal intensive 
care unit (NICU) admission for the fetus, leading to prolonged stays in the hospital.2, 3 They 
contribute significantly to spontaneous and iatrogenic prematurity of the newborn.  
 
In both pre-eclampsia and multiple pregnancy, clinicians face the challenge of deciding on 
the optimal timing the delivery of the fetus.4, 5 In pre-eclampsia, the delivery of the baby is 
considered to be the treatment for the condition.6 While expectant management may increase 
the risk of complications in the mother, early delivery could predispose to prematurity-related 
complications in the fetus.7 In multiple pregnancies, a delay in delivery could increase the 
risk of stillbirth compared to prematurity complications from early delivery.8 
 
Overall, premature births, complicate 7.2% of all pregnancies and continues to be one of the 
major factors of neonatal mortality,9 and adverse outcomes in the short and long term. 
Preterm birth is estimated to cost the UK public sector £2.9 billion over childhood (direct and 
indirect costs), equating to around £939 million per year.10 As pre-eclampsia and multiple 
pregnancy contribute greatly to iatrogenic prematurity, accurate prediction of risks in these 
conditions can help to select the cases where intervention is needed, thereby minimising 
unnecessary intervention and helping to lessen the burden of some cases of prematurity. 
 
My thesis focuses on optimising the maternal and offspring outcomes in women with pre-
eclampsia and multiple (twin) pregnancy, two common high-risk pregnancy conditions, 
through prognostic research. 
 
1.1.2. Pre-eclampsia 
Pre-eclampsia is characterised by hypertension and proteinuria in pregnancy and affects 6-8% 
of pregnant women.11, 12 This multi-systemic disorder is associated with significant maternal 
and fetal morbidity and mortality accounting for 10-15% of direct maternal deaths in the UK 
and 20% of stillbirths.13 The underlying pathophysiology is complex and as yet not fully 
understood. The prevailing theory is that pre-eclampsia is a disease of the placenta arising 
from incomplete invasion of the spiral arteries due to defective endovascular cytotrophoblast, 
combined with inappropriate endothelial cell activation and an exaggerated inflammatory 
response.14, 15 The two-stage model of pre-eclampsia proposes that the first stage consists of 
an increased inflammatory response associated with pregnancy and reduced fetal and/or 
placental perfusion. These can both interact with maternal constitutional factors (such as 
genetic, behavioural or environmental factors) that trigger off the maternal 
pathophysiological changes which cannot be tolerated resulting in the clinical and 
heterogeneous syndrome of pre-eclampsia.16, 17 
 
The timing of onset of pre-eclampsia has been recognised as being increasingly important in 
the underlying pathogenesis of the condition and the spectrum of severity and potential 
complications that may manifest. Early onset pre-eclampsia usually develops between 20 to 
34 weeks’ gestation of pregnancy. The abnormal placentation process is thought to render a 
state of placental hypoxia which results in the expression of factors that contribute towards 
maternal endothelial dysfunction.18 These factors include soluble fms tyrosine kinase-1 (sFlt-
1) and soluble endoglin (sEng), which can act upon the maternal endothelium to raise 
maternal blood pressure; and affect the fenestration of the glomerular capillaries resulting in 
proteinuria. Late onset pre-eclampsia, which develops after 34 weeks’ gestation of pregnancy 
is thought to arise due to compromise of the mother’s ability to adapt to the physiological 
haemodynamic and metabolic changes of the pregnancy resulting in difficulty maintaining a 
normal blood pressure and regulating insulin metabolism.  
 
Underlying genetic predisposition 
One of the underlying maternal constitutional factors, which has long been of interest is the 
genetic component to pre-eclampsia.  Epidemiological studies point towards a genetic 
aetiology for pre-eclampsia with a positive family history of pre-eclampsia conferring a 
threefold risk to developing the condition.19 The exact mode of inheritance still eludes us but 
appears to involve a complex interplay of maternal, fetal and paternal contributions.  Women 
with first-degree relatives who developed pre-eclampsia during pregnancy are five times 
more likely to develop pre-eclampsia than those without a positive family history.20 Men who 
were born from a pregnancy complicated by pre-eclampsia also have a higher risk of 
fathering a pregnancy affected by pre-eclampsia.21 Our understanding, albeit limited, of the 
different systems involved in the pathogenesis of pre-eclampsia has led to hypotheses of 
potential candidate genes that may have a single or combined role in developing the disease.  
Further work in the area of familial aggregation studies and genome-wide scans has 
generated other putative candidates. 
 
Complications in pre-eclampsia 
The adverse maternal outcomes that may progressively develop can affect one or more 
systems including the central nervous system (intraventricular haemorrhage, eclampsia, 
cortical blindness), respiratory (pulmonary oedema), renal (failure), hepatic (dysfunction, 
failure, hepatic capsule rupture or haemolysis, elevated liver enzymes and low platelets 
syndrome), systemic vasculature (severe hypertension) and coagulation system 
(coagulopathy).17 Fetal complications include placental abruption, intrauterine fetal death, 
fetal growth restriction and increased neonatal morbidity and mortality primarily due to 
preterm birth.  
 
The only known cure for pre-eclampsia is delivery of the fetus.22 However there is increasing 
evidence that this may only be a transient remission and that women who develop pre-
eclampsia are at increased risk of prematurely developing chronic conditions associated with 
subclinical endothelial dysfunction, insulin resistance and metabolic syndrome such as 
hypertension, cardiovascular disease, renal impairment and diabetes mellitus.23 Early onset 
pre-eclampsia, severe pre-eclampsia and recurrent pre-eclampsia are recognised independent 
risk factors for cardiovascular disease.24, 25  
 
Tests in pre-eclampsia 
The assessment of risk is based on a combination of patient characteristics, symptoms, signs 
and investigations.  Due to the multi-systemic nature of pre-eclampsia and heterogeneity of 
the manifestations of the syndrome in different individuals, there is no single test that has 
been proved to be sensitive and specific enough to predict complications of pre-eclampsia. 
 
The table 1 summarises the battery of tests that women being diagnosed with and who are 
being monitored with pre-eclampsia commonly undergo regularly to assess for and predict 
the disease and the development of any maternal and fetal complications.  
 




- pre-existing chronic conditions (hypertension, diabetes mellitus, renal disease, 
autoimmune disease) and previous pre-eclampsia 
Ultrasound 




- blood pressure 
 
Urine tests 





- symptoms (headache, visual disturbances, epigastric pain, abdominal pain, 





- pulse oximetry 
 
Urine tests 




- full blood count 
- urea & electrolytes (Na2+, K+, Urea, Creatinine) 
- liver function (ALT, AST, LDH) 
- serum uric acid 
 
Ultrasound 
- maternal uterine artery Doppler 
- fetal umbilical artery Doppler 
- fetal middle cerebral artery Doppler 
- fetal ductus venosus Doppler 
- fetal growth and liquor volume 
 
Biomarkers 
Biomarkers have received much interest and varying degrees of success in predicting the 
development of pre-eclampsia.  Normal placental vascular development is regulated by 
angiogenic factors such as vascular endothelial growth factor (VEGF-1), VEGF-2, placental 
growth factor (PlGF) in addition to soluble fms-like tyrosine kinase-1 (sFlt-1), a splice 
variant of the VEGF-1 receptor and soluble endoglin (sEng), a TGF-beta co-receptor.  These 
biomarkers have therefore been investigated for their role in diagnosing pre-eclampsia and 
prognosticating severity of the condition.18  Other popular biomarkers include placental 
protein 13 (PP-13), pregnancy-associated plasma protein A (PAPP-A) and neutrophil 
gelatinase-associated lipocalin (NGAL).26-28 
 
Genetic tests 
Over 70 different genes have been the focus of candidate genetic association studies to 
evaluate putative roles in causing pre-eclampsia.29 The clinical question that begs to be 
answered is whether underlying maternal genotype may contribute to development of the 
clinically relevant outcome, which is severe pre-eclampsia or complications of pre-eclampsia.  
Genetic tests could be incorporated into prognostic models together with routinely used 
predictive factors to better assess these women according to level of risk of complications 
from pre-eclampsia. 
 
The estimated cost for each women with pre-eclampsia in terms of commonly performed 
tests to diagnose and monitor her condition is in the region of £9000.30 As there is no clear 
guidance, management is determined by the clinician’s interpretation of the test results for 
that particular patient.  The roles of routinely performed tests in predicting risk of pre-
eclampsia complications; being cost-effective in allowing better targeted care and their 
results positively affecting clinical care of women with pre-eclampsia remain uncertain.  
There is a strong need to examine and evaluate the best testing strategies with which to 
predict the development of complications in pre-eclampsia and optimise delivery of care.   
 
Management of women with pre-eclampsia 
The mainstay of treatment for pre-eclampsia is to stabilise the mother and fetus and to 
prevent the development of adverse maternal and fetal outcomes or to intervene before these 
complications arise.  The diagnosis of pre-eclampsia is based on hypertension either newly 
diagnosed or superimposed on a background of chronic hypertension and the presence of 
significant proteinuria.   
 
Hypertension is primarily the focus of treatment, and various antihypertensives have been 
used to stabilise maternal blood pressure.  In the UK, these include selective beta blockers 
such as labetalol, calcium channel antagonists such as nifedipine, alpha channel blockers 
such as doxazosin, direct-acting smooth muscle relaxants such as hydralazine, and the alpha-
2 adrenergic receptor agonist methyldopa.  The firstline agent is usually labetalol but is 
tailored based on any contraindications, side effects and control of blood pressure. 
Combinations of antihypertensives may be required to achieve adequate control .  Current 
NICE guidance is to maintain the pregnant woman’s blood pressure within a target range 
below 150/100mmHg with a lower target range of 140/90mmHg in those with increased 
cardiovascular risk such as existing cardiovascular disease or target organ damage to 
minimise the risk of maternal complications.  This balance is off-set with the risk of 
excessively lowering the blood pressure to compromise perfusion of the fetoplacental unit 
and hence affects fetal growth.  
 
Magnesium sulphate is also given for its neuroprotective effect to women who are suspected 
of having a high risk of developing eclampsia or to those who have had an eclamptic seizure 
to prevent further seizures. Other treatment options are intervention with the delivery of the 
fetus to effectively ‘cure’ the condition, taking away the stimulus (pregnancy and the 
placenta).  Dependent on the gestational age of the pregnancy and the presence or absence of 
intrauterine fetal growth restriction, steroids may be given to promote lung maturity up to 
34+6 weeks in normally grown fetuses and up to 35+6 weeks if growth restriction is 
suspected.31, 32  Delivery is considered when the benefits of prolonging the pregnancy 
outweigh the risks.  This can often be a difficult decision balancing the risks of prematurity 
risks against developing complications of pre-eclampsia. Current national guidelines 
recommend considering delivery for women with pre-eclampsia at 37 weeks gestation.  
When pre-eclampsia is diagnosed at a preterm gestation, the answer is less clear, with 
ongoing trials trying to address this exact question for the moderately preterm gestation 
between 34 and 37 weeks of pregnancy.33-35  For early and extreme preterm gestations, the 
approach tends to be conservative unless severe pre-eclampsia is diagnosed.36, 37 
 
The national guidance by NICE in the UK recommend intervention with delivery mainly 
based on blood pressure thresholds, differentiating women with pre-eclampsia into two 
groups: severe hypertension and mild to moderate hypertension.38  Timing of birth is 
recommended after 34 weeks gestation for the former and between 34 to 36 weeks gestation 
for the latter.38 About 15% of these women will develop significant maternal morbidity17 and 
it is identifying this subgroup of women that will help not only with prevention, optimising 
treatment but also the difficult clinical decision-making of whether or not to expedite 
delivery.    
 
1.1.3. Multiple pregnancy 
Background 
There has been a steady increase in the rates of twin pregnancies over the past decade,9 owing 
to advancing maternal age and increased use of assisted reproductive technologies.  Multiple 
pregnancy is considered a high risk pregnancy due to increased maternal, fetal and neonatal 
morbidity and mortality.  The mother is at increased risk of conditions such as anaemia, pre-
eclampsia, preterm labour, operative delivery, antepartum and postpartum haemorrhage and 
mortality. The fetuses and neonates are at increased risk of fetal growth restriction, twin to 
twin transfusion syndrome (TTTS) in monochorionic twin pregnancies, neonatal death and 
adverse short and long term neonatal outcomes mainly secondary to preterm delivery.  Over 
50% of twins are born preterm.39 The lower the gestational age and birthweight at delivery, 
the higher the risk for long-term sequelae such as cerebral palsy, neurodevelopmental 
disability, learning difficulties and chronic respiratory illnesses. The costs of neonatal and 
long-term healthcare for twin births as a consequence of preterm delivery are thus a huge 
burden to the NHS.   
 
Dichorionic and monochorionic twin pregnancy 
The risks of twin pregnancies differ according to the chorionicity and amnionicity of the 
twins.  With regard to chorionicity, dichorionic twin pregnancies have separate placentas 
whereas monochorionic twins share the same placenta.  Due to the interconnections in the 
monochorionic twin placenta, these twins are at risk of twin to twin transfusion which occurs 
in about 15% of monochorionic twin pregnancies.40  One twin becomes a donor twin and the 
other a recipient twin resulting in a gross imbalance of amniotic fluid volumes for the former 
and potential cardiac failure for the latter, accounting for 20% of stillbirths in this group.1   
Amnionicity also increases the risks with twins in a single amniotic sac (monoamnionicity) at 
higher risk of morbidity and mortality due to the potential for umbilical cord entanglement. 
Complications in multiple pregnancy 
Fetal and neonatal 
Stillbirth risks in twin pregnancies are in the region of 2.6-5.8%.41, 42 In comparison to 
singleton pregnancies, monochorionic and dichorionic twin pregnancies have thirteen-fold 
and five-fold higher risks of stillbirth in respectively.43 The increased risk in the 
monochorionic twin pregnancies as aforementioned is mainly attributed to complications of 
placental and vascular sharing in a monochorionic placenta resulting in either fetal growth 
restriction or fetal transfusion syndrome.44 It is unclear whether monochorionic pregnancies 
unaffected by these complications remain at much higher risk.  Fetal growth restriction 
appears to affect both monochorionic and dichorionic twin pregnancies more than in 
singleton pregnancies.   
 
Prematurity and its complications 
Preterm delivery refers to birth before 37 completed weeks of pregnancy. According to the 
World Health Organisation, an estimated 15 million babies are born prematurely each year.45  
Globally it is the leading cause of death in infants under the age of 5 years of age and 
accounts for 1 million child deaths each year due to its associated complications.  Mortality 
aside, those who do survive are still at a risk of a lifetime of disability including learning 
difficulties, visual and hearing problems and physical handicap. The gestational age at which 
premature delivery presents together with birth weight greatly influences prognosis.  
 
There are many different causes, the primary being spontaneous premature delivery but 
medical indications resulting in early induction if labour or Caesarean delivery also have 
significant contributions. Conditions such as pre-eclampsia, multiple pregnancies are very 
common indications for iatrogenic prematurity in an attempt to deliver the fetus(es) before 
maternal and fetal complications develop. 
 
The preterm infant faces the challenge of the sudden need to adapt to extrauterine life with 
often both structurally and functionally underdeveloped organ systems.  There is, therefore, a 
large spectrum of prematurity complications, with certain complications more prevalent in 
the extremely preterm infant (less than 28 weeks) compared to the moderate preterm infant 
(28-34 weeks) and the late preterm infant (34-37 weeks).  As expected the more preterm the 
infant, the more complications the infant is at risk of.  The maturity of the lung organ system 
is the single most important factor in determining the prognosis of the premature infant.14   
 
Other common problems include difficulty regulating body temperature, establishing oral 
feeding and a higher risk of infection or sepsis. In the cardiovascular system, persistent patent 
ductus arteriosus can result in congestive cardiac failure; in the hepatic system, liver 
immaturity can be associated with severe neonatal jaundice leading to vulnerability to 
neurotoxic effects of unconjugated bilirubin; intracranial haemorrhage and necrotising 
enterocolitis are further risk factors.  In extreme prematurity, chronic lung disease, 
retinopathy, cerebral palsy and developmental delay are more likely in the longer term.46  
 
Management 
The relatively low population prevalence of monochorionic twins has resulted in a paucity of 
epidemiological evidence on which to base clinical decisions about the optimal timing of 
monochorionic twin pregnancy delivery to avoid intrauterine fetal demise.1 Currently, 
clinicians deliver monochorionic pregnancies electively at various late preterm gestations 
(usually before or at 36 weeks) and dichorionic twins at 38 weeks in efforts to minimise 
stillbirth risk. There is increasing evidence that late preterm births are associated with 
increased neonatal mortality, longer stays in the neonatal intensive care unit and an increased 
need for mechanical ventilation compared to term infants.47 The optimal timing of delivery to 
strike a balance between minimising the fetal risk of stillbirth versus neonatal morbidity and 
mortality due to prematurity is an important research objective. 
 
1.1.4. Role of prognostic research 
 
Prognostic models have been increasingly used in the field of medicine.48 In obstetrics, there 
are few prognostic models that are in everyday use such as the Bishop score for cervical 
ripeness for induction of labour49 and the Apgar score for need of resuscitation for the 
newborn50 but many have been and are continuing to be developed.51 The ability to predict 
the probability of a specified outcome empowers maternity caregivers to offer individualised 
risk counselling, and to target appropriate management stratified by the mother’s risk status. 
Furthermore, it has been suggested that statistical prediction models may provide a more 
accurate prognosis than clinicians can achieve working on their own.52   
 
Although many obstetric prediction models have been developed, they are not in clinical use. 
Prognostic modelling takes several stages, following development of a prediction model, 
external validity should be sought and assessment of the model’s impact on clinical 
outcomes. Without these next steps, the prediction model is only effective for that particular 
patient population it was developed in and hence is of little use clinically.  
 
Prognostic research presents specific challenges in obstetrics.  In many obstetric situations, 
prognostic factors undergo spontaneous or iatrogenic changes due to the advancing 
pregnancy or as a result of an intervention that cannot be ethically withheld. An effective 
treatment may prevent a certain proportion of adverse outcomes, making a good prognostic 
factor and factors associated with it look poorer in their predictive performance, a so-called 
‘treatment paradox’.53 An important research objective is to identify and evaluate the existing 
prognostic models in obstetrics, their clinical applicability and potential solutions to 
overcome this ‘treatment paradox’. 
 
1.1.5. Composite outcomes  
 
Composite outcomes are composed of multiple endpoints that are combined and the 
attainment of one or more of these individual endpoints results in a primary outcome.  They 
help to increase statistical efficiency by increasing event rates and are often used in 
randomised trials.  The improvement of population health, advances in and availability of 
new treatments contribute to overall lower event rates of outcomes. Composite outcomes 
have an important role to play in these circumstances,  otherwise prohibitively and often 
unfeasibly large numbers would be needed for trials.   
 
They are used widely in many different fields of research including prognostication such as 
prediction of pre-eclampsia outcomes based on angiogenic profiles,54 diagnosis such as use of 
pulmonary function testing for chronic obstructive pulmonary disease55 and treatment such as 
tranexamic acid versus placebo for bleeding trauma patients56.   
 
In the context of pre-eclampsia, the multisystemic disease that can cause a variety of 
complications, the rates of which are low, composite outcomes can be very helpful in the 
design of the trial. An example includes fullPIERS (Pre-eclampsia Integrated Estimate of 
RiSk Score), an outcome prediction model for adverse maternal outcomes in women admitted 
to hospital with pre-eclampsia.  The individual components of their composite outcome were 
selected by a Delphi survey of experts.57 Another pre-eclampsia trial using composite 
outcomes HYPITAT, a randomised trial of induction of labour versus expectant management 
for women after 36 weeks and who have either pregnancy-induced hypertension or non-
severe preeclampsia.35 
 
Composite outcomes are often used in obstetrics as the important outcomes such as maternal 
or neonatal deaths are rare.  Other examples of obstetric randomised trials using composite 
outcomes include hbvthe Term Breech Trial and the Australasian Collaborative Trial of 
Magnesium Sulphate.58, 59 
Gaps in evidence 
The individual components of the composite outcome can vary in their importance to clinical 
care with death invariably being the most severe.  As such the development of primary 
composite outcome can be driven by less important components and actually not include any 
of the most important components such as deaths. .  
 
In the current age where trials are increasingly limited by resources for both funding and 
recruitment of patients, composite outcomes present an attractive solution towards the 
prohibitively large numbers needed when event rates are low and enabling more timely 
completion of the trial.  Caution is however needed in the interpretation of the research when 
composite outcomes are used.  
 
Conclusion 
I have focused on two high risk pregnancy conditions in this thesis that account for many of 
the antenatal clinic and day assessment unit attendances in hospitals in the UK.  Both pre-
eclampsia and multiple pregnancy contribute greatly to preterm delivery, maternal and 
neonatal morbidity and mortality.  The ability to predict or stratify a pregnant woman’s risk 
of complications for these two common conditions is an important research objective.  In 
hand with identifying important predictors of adverse outcomes is their potential utility in 
developing prediction models.  This thesis has also looked into an overview of the existing 
obstetric prediction models and dealing with some of the challenges that may arise during 




CHAPTER 2: AIMS AND OBJECTIVES 
2.1. AIMS OF THESIS 
My thesis aims to undertake health technology assessments in high-risk pregnancy through 
the following objectives:- 
1. In women with pre-eclampsia, 
a. To evaluate the association of maternal genetic factors and adverse outcomes 
b. To assess the accuracy of tests in predicting adverse maternal and fetal 
outcomes  
c. To develop composite outcomes for reporting in clinical trials on late onset 
pre-eclampsia by undertaking a Delphi survey 
2. In women with multiple pregnancy, 
a. To study the association between chorionicity and the prospective risk of 
stillbirth 
b. To identify the optimal timing of delivery in monochorionic and dichorionic 
twin pregnancies 
3. In the field of obstetrics 
a. To provide an overview of the existing prognostic models, their qualities and 
clinical applicability 
b. To evaluate the methodological challenges and potential solutions in 
developing a prognostic model for complications in women with pre-eclampsia 
  
2.2. QUESTIONS ADDRESSED 
The specific research questions that I have attempted to answer in this thesis are: 
 What maternal genetic factors predispose women with pre-eclampsia to 
complications in pregnancy? 
 How accurate are the routinely performed tests in women with pre-eclampsia to 
predict maternal and fetal complications? 
 What outcomes are clinically relevant for evaluation in clinical trials on late onset 
pre-eclampsia? 
 What are the prospective risks of stillbirth, neonatal morbidity and mortality 
associated with delivery at different gestational ages in monochorionic and 
dichorionic twin pregnancies?   
 What is the optimal timing of delivery with the lowest stillbirth risk and serious 
neonatal adverse outcomes in uncomplicated monochorionic and dichorionic twin 
pregnancies? 
 What is the quality of published obstetric prognostic models and what is their 
clinical usefulness? 
 What are the methodological challenges of developing and applying an obstetric 
prognostic model and how can they be overcome? 
 Which adverse maternal and neonatal outcomes are reported in trials on pre-






Table 2.1 Structured questions for each chapter of this thesis  
Chapter 
number 
Population Intervention or Test Outcome(s) Research 
Design 
4.1 Women with pre-
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In this section, I discuss the methodology used in this thesis: systematic review of the 


















CHAPTER 3: METHODS 
3.1. Systematic review of literature 
One of the main methodologies used in this thesis to answer the research questions posed is a 
systematic review of the literature.  This involves a rigorous, systematic approach with 
explicit methods to find, appraise, summarise and interpret the available research to answer 
the research question.   
 
I employed the five-step approach to the conduct of systematic reviews.60 The first step 
involved framing a question for reviews, by formulating a clear and focused question 
specifying the population(s) at hand, intervention (or exposures), specific outcomes related to 
the problem posed, and which study designs were suitable for addressing it.  The subject 
matter included substantive research question where empirical studies have been published, 
but there was uncertainty about the results.  
 
The second step was to identify the available evidence.  This involved a thorough and 
usually, complex search strategy to adequately interrogate as many evidence sources as 
possible including electronic databases such as Medline, EMBASE, and the Cochrane library 
in addition to attempts to search the grey and unpublished literature, hand searching of 
references and conference proceedings.  There was a pre-specified list of inclusion and 
exclusion criteria for identifying relevant studies.  This step of screening and identifying 
relevant studies was conducted by at least two independent reviewers to eliminate bias in 
study selection with a discussion between the reviewers or involving a third reviewer where 
disputes arose.  Reasons for study rejection were documented, and these details were 
demonstrated in a flow chart for transparent reporting. 
 
The third step involved assessing the quality of the literature.  This was performed by at least 
two independent reviewers to assess the risk of bias, and the quality assessment was based on 
each study’s design, conduct and analysis.  Based on the type of study, I used different 
published quality assessment checklists for use in systematic reviews.61, 62 The qualities of the 
individual studies included in the review were described, and any variations in the quality 
were explored to help explain any differences in effect from study to study.  Sensitivity 
analyses were be performed based on the different levels of quality of the studies. The quality 
assessment also helped direct future research recommendations on the conduct of studies.  
 
The fourth step was summarising the evidence, which involved describing the data from the 
included studies and the measures of effect.  The differences in effects between studies were 
investigated, and quantitative or qualitative synthesis was carried out where possible.  Meta-
analysis is a statistical method of quantitative synthesis, combining or pooling the individual 
effects of a number of studies addressing the same question to produce a summary effect. 
Any heterogeneity was explored both from clinical and methodological standpoints, and 
subgroup analyses were performed for different clinical groups, study designs or risk of bias.  
Publication or reporting bias was assessed, with a graphical representation using funnel plot 
for degrees of symmetry based on the results.63  
 
The final step involved interpretation of the findings, with a critical evaluation of the conduct 





Strengths and limitations of systematic reviews: 
Systematic reviews of literature enable an objective and reproducible assessment of a well-
framed research question according to the current state of clinical knowledge.  The process 
incorporates critical evaluation of the included evidence. Hence, this forms a reliable basis 
for clinical decision-making and allows policy and guideline makers to come to evidence-
based conclusions.  They are considered the gold standard of research and reduce the biases 
that can occur with other approaches to reviewing research evidence.  Furthermore 
quantitative synthesis using meta-analysis increases statistical power and provides narrower 
confidence intervals for statistical inference.  Where there is variability with heterogeneity 
and inconsistency, meta-regression can be used.  The latter can also enable indirect 
comparisons or network meta-analyses. 
 
Transparency and reproducibility of the conduct of systematic reviews of literature are 
encouraged with the prospective enrolment of systematic reviews in publicly available 
databases such as PROSPERO,64 Cochrane (for interventional and diagnostic accuracy 
studies) and clear reporting guidance of these papers for example with PRISMA and MOOSE 
guidelines.65, 66 
 
Despite being hailed high in the hierarchy of research evidence, there are potential limitations 
with systematic reviews.  The small study effect is one of these drawbacks; often there are 
only a few studies that may focus on the research question at hand and be of such low quality 
that inclusion of these studies may be misleading.  Also, small studies with negative findings 
are often less likely to get published and hence the publication bias that arises may skew the 
summary effect estimates away from the true value.  Another limitation is knowing when it is 
appropriate to conduct a quantitative synthesis of the evidence as meta-analysis may not 
always be suitable.   
 
Systematic reviews of genetic association studies 
The systematic reviews performed in this thesis appraised a range of studies including 
observational studies, genetic association studies and studies of diagnostic test accuracy.  
Different techniques are required for analysis, assessment of quality for each type of study 
and they each encompass different challenges in their conduct and interpretation.  
 
Genetic association studies identify whether candidate genes or genetic variants are 
associated with a specific disease. They generally have small effect magnitudes67 and are 
particularly vulnerable to biases. Compared to conventional systematic reviews of 
observational studies, systematic reviews of genetic association studies need to account for 
extra factors for bias such as population stratification (confounding can arise due to different 
subpopulations within the sample differing in genotype prevalence and risk of disease), 
methods used in the collecting, handling, processing of deoxyribonucleic acid (DNA), 
blinding of laboratory staff and genotyping error.68  The STrengthening the REporting of 
Genetic Association studies (STREGA) initiative has helped to address the transparency of 
reporting in individual genetic association studies and the checklist is useful in appraising the 
validity of such studies in systematic reviews.69  The potential biases identified in individual 
studies can be addressed with sensitivity analyses during meta-analysis.   
 
Systematic reviews of genetic association studies can follow published guidance on reporting 
set by the Human Genome Epidemiology network (HuGENet™), registering the review as a 
HuGE review.70  The criteria for HuGE reviews are to describe population-based data on the 
frequency of the identified genetic variant(s), to use a systematic search strategy to identify 
data and statistical methods such as meta-analysis to summarise the association, to assess for 
epidemiologic credibility, to present the findings in a population context and finally to 
highlight knowledge gaps for further research.70  The guidance provides a template and set 
standard for systematic reviews of genetic association studies to adhere to. 
 
Systematic reviews of diagnostic test accuracy studies 
Diagnostic test accuracy studies investigate the ability of a test (the index test) to distinguish 
between patients with a condition and those without.71 It is often difficult to capture studies 
of diagnostic test accuracy in literature searches as they are inadequately indexed. As such 
this often results in the need to screen thousands of studies when performing a systematic 
review.72  There is often poor reporting of research methodology, study population 
characteristics and test procedures. Study quality can be appraised by recommended tools 
such as the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 
checklist taking into account the internal and external validity of the studies.62  Meta-analysis 
may not be suitable as diagnostic test accuracy studies are often heterogeneous.73 When this 
is not advisable, a qualitative descriptive analysis of the diagnostic research available can be 
done. Finally the results should be interpreted based on the impact upon the patient and not 
just on the accuracy of the test.   
 
Clinical and statistical heterogeneity 
The different studies combined in a meta-analysis will differ and the measure of this is the 
heterogeneity.  Clinical heterogeneity is when there is variability or differences in participant 
or intervention characteristics, for example patient populations and treatment protocols.  
Statistical heterogeneity is when there are larger differences in the outcome of the individual 
studies (summary treatment effects) than we would expect from chance alone. Clinical and 
methodological heterogeneity (variability in study design and risk of bias) can contribute to 
statistical heterogeneity. Preplanned subgroup analyses can help to investigate and explain 
clinical heterogeneity, for example stratifying for certain characteristics.74  It is currently 
difficult to quantify the amount of clinical heterogeneity. Statistical heterogeneity can be 
assessed by tests such as the I2 statistic which gives a percentage for the level of 
heterogeneity. By taking into account clinical and statistical heterogeneity, we can be guided 
to when it may not be appropriate to provide a pooled estimate in a meta-analysis.   
 
The aim of systematic reviews is to provide the best research evidence through rigorous, 
objective and transparent methods. There are many checklists and standards to guide 
researchers on how to perform and report the different types of systematic reviews. The 
systematic review is not without its flaws though.  It is important to be aware of the pitfalls 
and acknowledge any heterogeneity, potential for bias within the included studies and 
publication bias. Although meta-analysis can increase the precision of a result, it is also 
important to know when it is inappropriate to conduct a meta-analysis to ensure reliable and 
accurate results.  
 
Delphi technique 
The Delphi technique is a structured method of collating anonymous responses from an 
expert panel over several rounds to reach a consensus.75 It is commonly used in healthcare 
and is useful in situations where there is a lack of agreement or incomplete state of 
knowledge.   
 
The Delphi technique is also known as the Delphi method or Delphi survey.  It consists of 
asking one or more questions over a series of rounds to a panel of experts often by means of 
an online survey.  After the first round, the facilitator feeds back to the panel of experts a 
summary of the answers anonymously so that the experts can reconsider their answers with 
the option to revise their initial response. Over the series of rounds, the range of answers 
decreases, gradually leading to a consensus.  The endpoint is usually after a predetermined 
number of rounds or level of consensus. The answers can be assigned points so that the final 
results are based on mean or median scores of the answers from the last round, thereby using 
a statistical measure of average and dispersion for the level of agreement or consensus.  
 
The original Delphi technique has the following essential features: a panel of experts; 
anonymity throughout the process; a minimum of three rounds with the first consisting of 
open-ended questions and the subsequent rounds of scoring responses based on their 
significance and feedback of the responses to the panel.  The researcher selects the experts on 
the panel.  They are often considered ‘experts' due to their knowledge and expertise regarding 
the question at hand.  This is a potential area of bias as there is no clear guidance on selection 
criteria for Delphi panels and one panel of experts may well give very different responses to 
another panel of experts.  Regarding the size of the panel, there are no specifications although 
Linstone suggests that the minimum number should be 7.76  A recent systematic review of the 
use of the Delphi technique to determine which clinical outcomes to measure in clinical trials 
has recommended involving patients in addition to clinicians on the panel as often 
perspectives on the importance of outcomes differs among these two groups.77  Anonymity is 
an important aspect as this prevents domination by certain individuals, which may well occur 
in a group of experts due to seniority or some being more outspoken than others.  The lack of 
interaction also enables this process to be more efficient, less costly and more feasible to 
organise compared to the traditional round table group discussion.    
 
I used the Delphi technique to identify the components of composite outcomes. The first 
round was qualitative and was used to identify the issues around a certain topic by open-
ended questions.  The responses were collected and edited for the second round when the list 
of items was provided for the panellists to rate or rank quantitatively regarding their 
significance.  After each round, the responses of the panel scoring and the participant's 
individual scoring was fed back so that each participant’s decision can be reconsidered and 
their score revised.  There are no criteria on how consensus is defined.  Commonly used 
assessment tools include a Likert scale,78 where median scores are calculated for each item 
and then fed back to the panellists. With this scale, the interquartile range can provide an 
indication of differing opinions and narrowing of the interquartile range between rounds, 
suggests increasing consensus.    
 
Strengths and limitations of Delphi survey: 
The strengths of this technique are that it structures and organises group communication 
effectively and democratically to develop consensus.  In particular, with regard to 
determining outcomes to measure in clinical trials, this provides a form of standardisation to 
minimise bias from researchers randomly selecting the outcomes as the alternative.  It also 
enables the combination of different groups such as patients and clinicians to seek agreement, 
an example being the international initiative OMERACT, with the integration of patients for 
outcome measures in Rheumatology.79  The process allows impartial feedback and has the 
potential to educate the participants through the responses of successive rounds. 
 
The weaknesses are that the process is dependent on that particular panel of members and 
their experiential knowledge of the topic.  It also relies on their co-operation with every 
round and is likely to be subjective to attrition bias with those with minority opinions perhaps 
being more likely to drop out.  There is little guidance on specific methodological criteria on 
the use of rating or ranking scales and more importantly how to define achievement of 
consensus.  Furthermore, the consensus is reached by expert opinion without robust tools to 
assess and validate the underlying scientific merit.  However, with the advent of recent 
recommendations for more transparent reporting, a clear and objective explanation of the 
























In this section, I have undertaken a systematic review and meta-analysis of genetic 
association studies to identify candidate genes associated with severe pre-eclampsia; I have 
assessed the accuracy of tests in predicting severe pre-eclampsia and its complications by 
systematic review; I have identified the outcomes which are considered to be clinically 
relevant in the management of women with pre-eclampsia, and have developed composite 












CHAPTER 4.1. MATERNAL GENOTYPE AND SEVERE PRE-ECLAMPSIA 
 
Background: Severe pre-eclampsia is a major cause of maternal and perinatal mortality and 
morbidity worldwide.  Genetic factors are strongly implicated, and early identification of 
women at high risk of adverse events would allow targeted prevention and timely obstetric 
management.  Individual genetic studies are underpowered to assess the risk of pre-eclampsia 
complications. 
Objective: To perform a systematic review and meta-analysis of all maternal genotypes and 
severe pre-eclampsia. 
Results: We compared genotype frequencies in women with severe pre-eclampsia (pre-
eclampsia complicated by severe hypertension, eclampsia, HELLP syndrome or fetal growth 
restriction) to women without complications.  Fifty-seven studies evaluated 50 genotypes in 
5,049 cases and 16,989 controls.  Meta-analysis by pre-defined gene function (thrombophilic, 
vasoactive, metabolic, immune, cell-signalling) showed increased risk of severe pre-
eclampsia with thrombophilic genes (F5 rs6025 and MTHFR rs1801133). There were no 
associations with the other gene groups: vasoactive, metabolic, immune-related and cell-
signalling.  Individual genotype meta-analysis showed positive associations with severe pre-
eclampsia for F5 (rs6025) (OR 1.90, 95% CI 1.42, 2.54, 23 studies, I2=29%), F2 mutation 
G20210A (rs1799963) (OR 2.01, 95% CI 1.14, 3.55, 9 studies, I2=0%) and leptin receptor 
(LEPR) polymorphism (rs1137100) (OR 1.75, 95% CI 1.15, 2.65, 2 studies I2=0%) and the 
thrombophilic gene group (OR 1.87, 95% CI 1.43, 2.45, I2= 27%).  Heterogeneity between 
studies was moderate with bias from the inconsistent phenotypic definition and poor quality 
reporting of genotyping methods and success.   
Conclusion:  Pregnant women with genetic variants associated with thrombophilia appear to 
be at higher risk of severe pre-eclampsia. However, there is insufficient epidemiological 
credibility to establish causality. More rigorously designed studies with larger sample sizes 
are needed to provide robust estimates of genetic risk for adverse outcomes of pregnancy 
related to pre-eclampsia and to evaluate the potential benefits of genetic screening in clinical 
practice.  
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Pre-eclampsia is a multisystemic disorder of pregnancy associated with hypertension and 
proteinuria.  The condition affects between 6- 8% of pregnancies worldwide and is one of the 
leading causes of maternal mortality and morbidity, accounting for more than 63,000 
maternal deaths each year globally.11, 12  In the UK alone, approximately 10-15% of direct 
maternal deaths and 20% of stillbirths are associated with pre-eclampsia.13  The morbidity 
and mortality rates are even higher when severe pre-eclampsia develops, and complications 
of organ dysfunction ensue.11   
 
Maternal complications include eclampsia (tonic-clonic seizures in a pregnant or recently 
delivered woman); HELLP syndrome, causing substantial widespread endothelial damage; 
stroke; renal failure; placental abruption; pulmonary oedema and venous 
thromboembolism.80, 81  When pre-eclampsia is diagnosed around 20 weeks (early-onset pre-
eclampsia), neonatal survival rates range between 18-50%.17  Severe pre-eclampsia is 
associated with a stillbirth rate of 21 per 1000.82  The prevalence of fetal growth restriction 
varies from 8.7% in pre-eclampsia to 18.2% in early-onset pre-eclampsia.83  As delivery 
remains the only proven treatment option, iatrogenic prematurity resulting from early 
induction of labour contributes greatly to neonatal morbidity and mortality.  Both fetal 
growth restriction and prematurity have serious and long-term implications for the health of 
the child.  Care for preterm babies incurs extra costs to the NHS at around £939 million per 
year from neonatal intensive care admissions and hospital readmissions.10 
 
 
Despite extensive research, it remains difficult to predict the risk of complications in women 
with pre-eclampsia in time for early intervention. With regard to preventative strategies, low-
dose aspirin, if given early on in pregnancy, has been shown to prevent severe pre-eclampsia 
and perinatal death. Following a diagnosis of pre-eclampsia, delivery remains the most 
effective way of preventing complications and is often expedited to avoid increasing the risk 
to mother and child. Accurate estimates of risk could aid both in targeting preventative 
strategies and in decision-making on the timing of delivery to optimise maternal and neonatal 
outcomes. We are unable to reliably stratify for risk of complications with conventional 
methods of evaluation by clinical history, symptoms and investigations.84-88  
 
Pre-eclampsia is known to cluster in families and evidence from twin and family genetic 
studies suggest a strong hereditary component.19, 89, 90  The exact mode of inheritance is as yet 
unknown and appears complex, possibly polygenic with environmental influences.91 The 
potential pathogenic roles of different pathways in developing pre-eclampsia such as the 
immune system, control of vascular resistance, blood coagulation, cell signalling and 
metabolic processes have resulted in various candidate genes implemented through these 
pathways in genetic association studies. Very few genetic studies to date have specifically 
addressed the inherited contribution to the severity of disease and development of 
complications. Furthermore, these studies are often underpowered to detect associations due 
to the small sample sizes. Systematic reviews in this area have focussed on the development 
of pre-eclampsia itself, with severe or complicated pre-eclampsia as a subanalysis or in 
combination with other adverse outcomes not necessarily associated with pre-eclampsia.92-94 
 
Thus we systematically reviewed all available published evidence and conducted a meta-
analysis to identify candidate genes associated with severe pre-eclampsia.  
 
Methods 
We conducted the systematic review in compliance with Human Genome Epidemiology 
(HuGE) recommendations for genetic meta-analysis.70 A prospective protocol was registered 
in PROSPERO.95 We defined severe pre-eclampsia as pre-eclampsia (hypertension (blood 
pressure ≥140/90mmHg) and proteinuria (≥300mg/24 hours or protein-creatinine ratio 
≥30mg/dL) and at least one of the following complications: severe hypertension (systolic 
blood pressure ≥160mmHg and/or diastolic blood pressure ≥110mmHg); eclampsia 
(convulsions that could not be attributed to other causes); haemolysis, elevated liver enzymes 
and low platelets (HELLP) syndrome, (with platelet count <100,000/dl and raised serum 
transaminases above the upper limits of normal) or intrauterine fetal growth restriction 
(estimated fetal weight below than the 10th centile)).   
 
There is currently no international consensus on criteria for the definition of severe pre-
eclampsia.  The definition for severe pre-eclampsia in our review was based on the recent 
classification and agreement from the International Society for the Study of Hypertension in 
Pregnancy96 where difficulty controlling blood pressure, deterioration of the clinical 
condition such as development of HELLP syndrome, impending eclampsia, worsening 
thrombocytopenia and fetal growth restriction were considered to be indicators of severity 
and an indication to expedite delivery. If studies contained separate populations of cases of 
mild pre-eclampsia and severe pre-eclampsia, but their definition of severe pre-eclampsia 
differed slightly from that of the International Society for the Study of Hypertension in 
Pregnancy, we took a pragmatic decision to include such studies.   
Identification of studies and study selection 
We searched Medline and Embase electronic databases from inception to August 2013 
without language restrictions to include prospective and retrospective observational studies 
that examined an association between severe pre-eclampsia and maternal genotype variation 
(e.g., single nucleotide polymorphisms, microsatellite markers, insertion/deletions, repeat 
sequences). This search was subsequently updated to March 2017. The search strategy was 
developed with advice from an experienced librarian (DY) and details are found in Appendix 
1.  
 
We selected the studies in two stages: initially relevant citations were identified by titles and 
abstracts; this was followed by retrieval and review of full texts by four independent 
reviewers (FC, MS, GH, RE).  The citations were divided into two groups, and two reviewers 
were assigned per group.  Independent screening, study selection and data extraction were 
performed and any disagreements were resolved by consulting another reviewer (ST or RW).  
We included those studies that compared the genotype frequencies in women with severe pre-
eclampsia to a control group comprising pregnant women with normal pregnancy, gestational 
hypertension or mild pre-eclampsia, without complications.  Studies that provided genotype 
frequencies enabling 2x2 tables to be constructed for each genotype and severe pre-eclampsia 
were included.  If the genotype frequency for the homozygous minor, homozygous and 
heterozygous groups combined was zero, the study was excluded. 
 
 
Assessing the risk of bias in individual studies 
We adapted the Newcastle-Ottawa Scale (NOS) and STrengthening the REporting of Genetic 
Association studies (STREGA) recommendations to form a modified quality assessment.61, 69, 
97 The Newcastle-Ottawa Scale assessed the selected studies for methodological quality.  In 
cohort studies, we evaluated the representativeness, selection of the exposed and non-exposed 
cohorts, ascertainment of exposure, whether the outcome of interest was present from the 
start; comparability of the cohorts and outcome bias with length and adequacy of follow-up.61  
For case-control studies, representativeness, selection of cases and controls, comparability of 
the groups, ascertainment of exposure, ascertainment of outcome for cases and controls and 
the non-response rate were assessed.  Stars for each category were awarded according to the 
criteria for the Newcastle-Ottawa Scale manual61, if a study obtained four stars for selection 
(two for comparability, and three for the ascertainment of exposure, the risk of bias was low. 
Studies that received two or three stars for selection, one for comparability and two for 
exposure were considered to have a moderate risk of bias.  Studies receiving none or one star 
for selection, comparability or exposure represented a high risk of bias.  
 
We assessed reporting of genotyping methodology, success rates of genotyping, population 
stratification and whether genotypes were in Hardy-Weinberg equilibrium98 were also taken 
into account following STREGA recommendations.  We calculated statistics for Hardy-
Weinberg equilibrium and compared results to those given by authors.  We assessed 
epidemiologic credibility for maternal genotypes that showed a positive association with 
severe pre-eclampsia using the Venice criteria.  This takes into account sample size, 
replication of results and level of protection from bias.99, 100  
Data extraction and analysis 
Four reviewers extracted data independently from the included studies.  We compared 
heterozygous and homozygous genotypes of the minor allele combined to homozygous 
genotypes of the major allele.  When percentages of groups were given in the studies, these 
were converted into actual numbers.  We calculated odds ratios with 95% confidence 
intervals by comparing women with severe pre-eclampsia to a control group comprising 
normal pregnant women, women with gestational hypertension and uncomplicated pre-
eclampsia.  Random effects meta-analyses of the maternal genotypes were performed 
according to predefined gene function groups: thrombophilic; vasoactive; metabolic; 
immune-related and cell-signalling.  
 
We performed subgroup analyses on individual genotypes taking into account study design, 
sample size >100 and ethnicity of the study populations for each genotype (comparing 
different ethnic groups with homogenous populations if there were sufficient numbers).  We 
performed sensitivity analyses excluding studies where the definition of severe pre-eclampsia 
was unclear.  Where there was more than one outcome reported for severe pre-eclampsia in 
the same study population, we included data for the ‘worst’ outcome (ranked in order of 
importance by prior consensus, namely eclampsia, severe pre-eclampsia, HELLP, intrauterine 
fetal growth restriction).  When the same study population assessed more than one genotype, 
we included the genotype with the largest dataset.  In cases of similarly important genotypes 
and complications, we undertook sensitivity analyses substituting for the other potential 
genotypes to assess for any difference in the overall results based on the study numbers that 
were included. We assessed heterogeneity in the meta-analysis using the I2 statistic.  We used 
Harbord's modified test for small-study effects to assess for publication bias.101  All analyses 
were carried out using RevMan, version 5.1.102  
 
Results 
Study identification and selection 
We identified 917 citations from our search in Medline and Embase.  After removing 
duplicated titles and assessment against inclusion criteria, 117 relevant studies were 
identified.  The full texts of these studies were retrieved, and 57 studies were included in the 
review. (Figure 4.1.1)  
  
Figure 4.1.1 Study identification and selection process for meta-analysis of relationships 
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Citations identified from electronic databases (n=917) 
Total number of citations retrieved (n=440) 
Articles excluded after evaluation of 
abstracts (n=389) 
Full text articles assessed for eligibility (n=117) 
Articles excluded (n=60) 
- Insufficient data available for 2 
x 2 tables (n=18) 
- Genome Wide Association 
Studies (n=2)  
- No specific gene (n=1) 




- Review (n=10) 
Studies included in review (n=57)  
Characteristics of the included studies 
The effects of 37 candidate genes and 50 maternal genetic variants on complications of pre-
eclampsia were examined in 22,038 women (5,049 cases and 16,989 controls).  The maternal 
genetic variants included single nucleotide polymorphisms, microsatellite markers and 
insertion/deletions.  The definitions for severe pre-eclampsia for each study are summarised 
in Table 4.1.   
 
There were four studies that did not provide a clear definition of severe pre-eclampsia.103-106 
Thirteen studies did not describe exclusion criteria and one study excluded the use of aspirin 
in pregnancy.107  Detailed study characteristics including population demographics, ethnicity, 
inclusion and exclusion criteria are provided in Appendix 2.  Fifty-one of the included fifty-
seven studies were cohort studies (41 prospective and 10 retrospective) and the remaining six 
were case-control studies.103, 108-112 The publication years were from 1996 to 2012.  The 
majority of the included studies did not assess severe pre-eclampsia as the primary outcome.  
Only 16 out of the 57 studies had study populations with more than 100 cases of severe pre-
eclampsia. 
 
Quality of the included studies 
Of the included studies, 30% (17/57) had low levels of bias for selection of the exposed and 
non-exposed groups, 46% (26/57) had medium levels of bias and 24% (14/57), high levels of 
bias.  Eleven of the included studies (19%, 11/57) had high levels of bias for comparability of 
the cohorts, 37% (21/57) had medium bias and 44% (25/57) had low levels of bias. Poor 
documentation of follow-up of the patients and insufficient length of time to identify relevant 
complications resulted in high levels of bias in 42% (24/57) of the studies regarding 
identification of outcome (Figure 4.1.2). 
 
Figure 4.1.2 Bar chart of the Newcastle Ottawa Scale methodological quality assessment 






     Low level of bias 
  Medium level of bias 
 High level of bias 
 
Numbers of studies with each different level of bias are marked on each bar.  
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Using the STREGA criteria,69 we demonstrated that the majority of studies (49/57, 86%) had 
homogenous ethnic population groups. The ethnicities included Caucasian (Europe, USA, 
Australia and New Zealand), East Asian (India), Middle East Asian (Iran, Israel), South 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Outcome
Comparability
Selection 13 11 12
18 11 7
10 28
Asian (Korea, Japan, China), Black African, South African, Latin American and mixed 
(Brazil/Mulatto, Israeli Ashkenazi/non-Ashkenazi, USA/African-American/Hispanic, France 
Caucasian/Maghrebian) (Appendix 3). There was documentation of genotyping success in 
5% (3/57).  Only five studies113-116 documented methods of genotyping quality control with 
the use of repeated samples or additional controls.  Thirty-two studies (56%) provided 
sufficient data for us to calculate the Hardy-Weinberg equilibrium and of these, ten deviated 
from equilibrium. In the reporting of Hardy-Weinberg equilibrium by the studies, twenty-
three (40%) studies documented the genotypes to be in equilibrium but on recalculation, five 
were found to deviate from equilibrium. 
 
Blinding of the staff performing the genotyping to the clinical outcome was reported in only 
four studies.116-118  Power calculations were performed a priori in 17 studies (30%).  Many of 
the included studies examined pre-eclampsia in addition to complications but for nine of the 
studies,114, 118-122 power calculations were made a priori for severe pre-eclampsia. (Appendix 
3) 
 
Genetic association with severe pre-eclampsia 
Individual genotypes 
Meta-analysis was possible with the following genotypes ACE DD rs4646994 (4 studies)115, 
123-125; Angiotensinogen M235T rs699 (3 studies)115, 126, 127; Estrogen receptor 1 PvuII 
rs2234693 (2 studies)120, 127; Factor V Leiden rs6025 (23 studies)107-110, 112, 117, 122, 123, 127-141; 
Leptin TTTNc (2 studies)104, 142; Leptin G1019A rs1137100 (2 studies)118, 143 Leptin R223Q 
rs1137101 (4 studies)104, 118, 143, 144; MTHFR C677T rs1801133 (10 studies)107, 109, 112, 122, 123, 
131-133, 135, 145; Factor 2 Prothrombin G20210A rs1799963 (9 studies)107, 109, 122, 127, 129, 132, 134, 
135, 139; TGF beta 1 codon 10 rs1982073 (2 studies)111, 146; TNF alpha G308A rs1800629 (4 
studies)146-149. (Figure 4.1.3) 
  
Figure 4.1.3 Summary estimates of maternal genotype and severe pre-eclampsia (Part 
1/5) Permission granted to reproduce this supplementary figure from American Journal of 
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M-H, Random, 95% CI
2. Adiponectin 45TG rs2241766
Youpeng 2010 (Severe) (56)
3. Adiponectin 276GT rs1501299
Youpeng 2010 (Severe) (56)
4. Aldosterone C344T  rs1799998
Percin 2005 (Eclampsia) (37)
Percin 2005 (HELLP) (37)
5. ANGPT1 rs2507800































6. AGTR1 A1166C rs5186
Kvehaugen 2012 (Eclampsia) (23)
7. Angiotensinogen M235T rs699
Roberts 2004 (Eclampsia) (43)
Procopciuc 2002 (Severe) (38)
Tempfer 2004 (Severe) (50)
8. Apolipoprotein E (E2)
Ahmadi 2012 (Severe) (3)
9. CD28 (+17TC) rs3116496
Pendeloski 2011 (Severe) (36)
10. COMT rs4680
Lim 2010 (FGR) (25)

















































11. CTL4 (+49AG) rs231775
Pendeloski 2011 (Severe) (36)
12. CYP17A1 34TC
Lim 2010 (FGR) (25)
Lim 2010 (Severe) (25)
13. CX3CR1 T280M rs3732378
Stepanian 2009 (Severe) (47)
14. CX3CR1 V249I
Stepanian 2009 (Severe) (47)
15. Deiodinase D1 Asp727Glu





































16. DBH locus 589GA rs5320
Zhu 2006 (Severe) (57)
Zhu 2006 (Eclampsia) (57)
17. E Selectin Ser128Arg
Derzbach 2007 (Severe) (10)
18. Epithelial Na channel beta subunit T594

























19. ESR1 PvuII rs2234693
Molvarec 2007 (Severe) (29)
Tempfer 2004 (Severe) (50)
20. ESR1 XbaI rs9340799




















Genotype, First Author, Year
(Complication) (Reference)
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26. IFNγ 874AT rs2430561
Barbosa de Lima 2009 (Ecl) (6)
27. IL6 - 174GC rs1800795













28. IL10 - 592CA rs1800872
Barbosa de Lima 2009 (Ecl) (6) 41 145 21 100 1.2% 1.48 [0.81, 2.71]
29. IL10 -819CT rs1800871
Barbosa de Lima 2009 (Ecl) (6) 41 145 21 100 1.2% 1.48 [0.81, 2.71]
Events Total Events Total Weight M-H, Random, 95% CI
Genotype present Genotype absent Odds Ratio Odds Ratio
M-H, Random, 95% CI
21. Factor V Leiden F5 G1691A rs6025
Hiltunen 2008 (Severe) (15)
Seremak-Mrokiewicz 2010(Sev) (46)
Nagy 1998 (Severe) (32)
Rigo 2000 (HELLP) (41)
van Pampus 1999 (Severe) (51)
Hiltunen 2008 (FGR) (15)
Rigo 2000 (Severe) (41)
de Groot 1999 (Severe) (9)
Alfirevic 2001 (Severe) (4)
Malek-Khosravi 2012 (Severe) (27)
Rigo 2000 (FGR) (41)
Rigo 2000 (Eclampsia) (41)
Dizon-Townson 1996 (Severe) (12)
Kupferminc 1999 (Severe) (21)
Kupferminc 2000 (Severe) (22)
von Tempelhoff 2000 (HELLP) (53)
Kim 2001 (Severe) (18)
Agorastos 2002 (Severe) (2)
Benedetto 2002 (HELLP) (7)
Currie 2002 (Severe) (8)
Schlembach 2003 (HELLP) (45)
Tempfer 2004 (Severe) (50)
Gerhardt 2005 (Severe) (13)
Muetze 2008 (HELLP) (31)
Aggarwal 2011 (Severe) (1)





























































































































































22. Fas TNFRSF6AG 
Sziller 2005 (FGR) (48) 6 82 8 45 0.6% 0.37 [0.12, 1.13]
23. GNB3 C825T rs4606
Kvehaugen 2012 (Eclampsia) (23) 19 1681 24 1794 1.2% 0.84 [0.46, 1.54]
24. ICAM-1 K469E rs5498
Kwon 2012 (Severe) (24) 11 103 16 104 0.9% 0.66 [0.29, 1.50]
25. ICOS(-1564TC) rs4675378
Pendeloski 2011 (Severe) (36) 41 140 36 151 1.3% 1.32 [0.78, 2.23]
30. IL10 - 1082AG rs1800896
Barbosa de Lima 2009 (Ecl) (6) 33 128 29 117 1.2% 1.05 [0.59, 1.88]
31. KIR3DL2 A52G
Wang 2011 (Severe) (54) 18 51 70 157 1.1% 0.68 [0.35, 1.30]
32. KIR3DL2 C32T
Wang 2011 (Severe) (54) 79 189 9 19 0.7% 0.80 [0.31, 2.05]
33. Leptin TTTCn
Nagy 2009 (Severe) (33)
Wiedemann 2009 (HELLP) (55)
Nagy 2009 (HELLP) (33)

























34. LEPR c1968 G>C rs8179183
Varkonyi 2010 (HELLP) (52) 27 51 48 107 1.1% 1.38 [0.71, 2.70]
Genotype, First Author, Year
(Complication) (Reference)
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Events Total Events Total Weight M-H, Random, 95% CI
Genotype present Genotype absent Odds Ratio Odds Ratio
M-H, Random, 95% CI
35. LEPR c3024 A>G rs6403506
Varkonyi 2010 (HELLP) (52) 49 92 26 66 1.1% 1.75 [0.92, 3.33]
36. LEPR c326AG rs1137100
Varkonyi 2010 (HELLP) (52) 35 64 40 94 1.1% 1.63 [0.86, 3.09]
37. LEPR G1019A
Rigo 2006 (Severe) (42)













38. Leptin PPAR γ2 rs1801282
Wiedemann 2009 (Eclampsia) (55)













39. Leptin R223Q rs1137101
Wiedemann 2009 (HELLP) (55)
Varkonyi 2010 (HELLP) (52)
Rigo 2006 (Severe) (42)
Wiedemann 2009 (Eclampsia) (55)































40. MBL2 Codon 54 rs1800450
Sziller 2007 (FGR) (49)













41. MTHFR C677T rs1801133
Rigo 2000 (Severe) (41)
Kobashi 2000 (Severe) (20)
Alfirevic 2001 (Severe) (4)
Kupferminc 2000 (Severe) (22)
Kim 2001 (Severe) (18)
Livingston 2001 (Severe) (26)
Gerhardt 2005 (Severe) (13)
Muetze 2008 (HELLP) (31)
Aggarwal 2011(Severe) (1)





























































42. NADPH/NADH oxidase C242T
Raijmakers 2002 (HELLP) (40) 27 85 28 88 1.1% 1.00 [0.53, 1.89]
43. P Selectin Thr715Pro
Derzbach 2007 (Severe) (10) 16 37 110 195 1.0% 0.59 [0.29, 1.20]
44. Prothrombin F2 G2021A rs1799963
Malek-Khosravi 2012 (Severe) (27)
Alfirevic 2001 (Severe) (4)
Seremak-M 2010 (Severe) (46)
Kupferminc 1999 (Severe) (21)
Benedetto 2002 (HELLP) (7)
Tempfer 2004 (Severe) (50)
Gerhardt 2005 (Severe) (13)
Muetze 2008 (HELLP) (31)























































45. RGS2 C114G rs5443
Kvehaugen 2012 (Eclampsia) (23) 25 114 18 109 1.1% 1.42 [0.72, 2.78]
46. SOD3 G172A rs1799895
Rosta 2009 (FGR) (44) 32 160 15 113 1.1% 1.63 [0.84, 3.18]
47. TGF β1 codon 10 +869TC rs1982073
Kim 2010 (FGR) (19)
Barbosa de Lima 2009 (Ecl) (6)



















48. TGF β1 codon 25 +915GC rs1800471
Barbosa de Lima 2009 (Ecl) (6) 10 35 42 192 0.8% 1.43 [0.64, 3.21]
Genotype, First Author, Year
(Complication) (Reference)
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Events Total Events Total Weight M-H, Random, 95% CI
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M-H, Random, 95% CI
49. TNFα G308A rs1800629
Molvarec 2008 (HELLP) (30)
Pazarbasi 2007 (Eclampsia) (34)
Molvarec 2008 (FGR) (30)
Barbosa de Lima 2009 (Ecl) (6)































50. TNFα C850T rs1799895
Pazarbasi 2007 (Eclampsia) (34) 24 118 16 104 1.0% 1.40 [0.70, 2.82]
Genotype, First Author, Year
(Complication) (Reference)
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Genotype, First Author, Year
(Complication) (Reference) Events Total Events Total Weight M-H, Random, 95% CI
Genotype present Genotype absent Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
1. ACE DD
Mando 2009 (Severe) (28)
Kaur 2005 (Eclampsia) (17)
Roberts 2004 (Eclampsia) (43)
Aggarwal 2011 (Severe) (1)
Subtotal (95% CI)
Total events
































Procopciuc 2002 (Severe) (38)
Roberts 2004 (Eclampsia) (43)
Tempfer 2004 (Severe) (50)
Subtotal (95% CI)
Total events


























Molvarec 2006 (Severe) (29)
Tempfer 2004 (Severe) (50)
Subtotal (95% CI)
Total events




















Nagy 2009 (Severe) (33) 50 103 29 64 4.7% 1.14 [0.61, 2.13]
Wiedemann 2009 (Eclampsia) (55)
Subtotal (95% CI)
Total events













5. Leptin LEPR G1019A
Rigo 2006 (Severe) (42)
Guan 2011 (Severe) (14)
Subtotal (95% CI)
Total events




















Varkonyi 2010 (HELLP) (52)













Wiedemann 2009 (Eclampsia) (55)
Guan 2011 (Severe) (14)
Subtotal (95% CI)
Total events



















7. TGF β1 codon 10 +869TC
Kim 2010 (Severe) (19)



















199 10.3% 1.30 [0.88, 1.91]
8. TNFα G308A
Molvarec 2008 (HELLP) (30)













Barbosa de Lima 2009 (Ecl) (6)
Kaiser 2004 (Eclampsia) (16)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.26; Chi² = 8.60, df = 3 (P = 0.04); I² = 65%




















Positive associations were seen with severe pre-eclampsia and Factor V Leiden rs6025, (OR 
1.9, 95% CI 1.42, 2.54; LR 1.66, 95% CI 1.38, 2.00, 23 studies I2=29%), Factor 2 
Prothrombin G20210A rs1799963 (OR 2.01, 95% CI 1.14, 3.55; LR 1.80, 95% CI 1.30, 2.49, 
9 studies I2=0%) and LEPR G1019A rs1137100 (OR 1.75, 95% CI 1.15, 2.65, LR 1.38, 95% 
CI 1.18, 1.61, 2 studies I2=0%).  (Figure 4.1.4) 
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Figure 4.1.4 Summary Estimates for Thrombophilic Genotypes and Severe Pre-
eclampsia compared with Controls Permission granted to reproduce this figure from 


























van Pampus 1999 (51)
von Tempelhoff 2000 (53)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.14; Chi² = 31.06, df = 22 (P = 0.09); I² = 29%
Test for overall effect: Z = 4.34 (P < 0.0001)













Heterogeneity: Tau² = 0.09; Chi² = 16.39, df = 9 (P = 0.06); I² = 45%













Heterogeneity: Tau² = 0.00; Chi² = 7.60, df = 8 (P = 0.47); I² = 0%
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The prevalences in the respective control populations were 5.8% for Factor V Leiden rs6025 
was 5.8%, 2.1% for Factor 2 Prothrombin G20210A rs1799963 and 34.8% for LEPR 
G1019A rs 1137100. For the other maternal genotypes, there were no significant 
associations.  Subgroup analyses for Factor V Leiden rs6025 and Factor 2 Prothrombin 
G20210A rs1799963 stratifying for study design, ethnicity and sample size did not show any 
significant differences.  (Table 4.1.2 and Table 4.1.3)  A sensitivity analysis of the studies 
with an unclear definition of severe pre-eclampsia revealed no difference in results. 
 
Predefined gene function groups 
Thrombophilic genes were significantly associated with any adverse outcome compared to 
the control group (OR 1.87, 95% CI 1.43, 2.45; 24 studies, I2=27%).  There were no 
significant associations with vasoactive genes (OR 0.94, 95% CI 0.72, 1.24), metabolic genes 
(OR 1.08, 95% 0.76, 1.55), immunogenetic genes (OR 1.05, 95% 0.75, 1.46) and genes 












Figure 4.1.5 Summary odds ratio estimates for genotype by gene function with severe 
pre-eclampsia compared with controls (normal pregnancies and uncomplicated pre-
eclampsia) 
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In some studies, the same population was tested for different genotypes with the same 
underlying gene function.  All possible combinations of the genotypes without overlapping of 
populations were tested by sensitivity analyses for each gene function group with no 
significant differences were observed in the results.   
Epidemiologic credibility of significant associations 
Using the Venice criteria, the positive associations between severe pre-eclampsia and F5 
rs6025, F2 G20210A rs 1799963, and LEPR rs11371000 were assessed for epidemiologic 
credibility.  There was weak evidence of epidemiologic credibility for all three genetic 
variants.  For F5 rs6025, there was moderate heterogeneity amongst the studies (I2 = 29%), 
and risk of biases was present due to variations in phenotype definition, poor reporting of 
genotype methods, stratification for ethnicity and evidence based on published data only.  For 
F2 G20210A rs1799963 and LEPR rs1137100, there was low heterogeneity, but the risk of 





Genetic variants related to thrombophilia are significantly higher in women with severe pre-
eclampsia.  While most pregnancies with pre-eclampsia are uneventful, preventable 
complications pose a risk to mother and child and thus accurate estimation of baseline risk is 
an urgent priority because timely obstetric intervention can prevent maternal and fetal deaths 
and minimise illness in mother and child. 
 
Genetic effects on pre-eclampsia 
Incomplete understanding of the underlying pathophysiology and the complex mode of 
inheritance of pre-eclampsia have rendered genetic studies on pre-eclampsia difficult.29 
Candidate genes with diverse biological pathways have been tested including genes related to 
vasoactive proteins,150 thrombophilia,151 metabolic processes,142, 144 cell signalling152 and 
immunogenetic pathways.153 However, individual studies are small, and their results are 
conflicting.  Two recent large meta-analyses of genetic variants in pre-eclampsia found 
positive associations with polymorphisms of angiotensin-converting enzyme (ACE), 
cytotoxic T-lymphocyte antigen-4 (CTLA4), prothrombin factor 2 (F2), Factor V Leiden 
(F5), lipoprotein lipase (LPL) genes154 and pre-eclampsia but that care should be taken into 
interpretation due to possible bias.94 
 
Perhaps the most consistent associations with pre-eclampsia have been with thrombophilia 
which is a hypercoagulable state that may potentiate placental micro and macrovascular 
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thrombosis and in turn, cause placental insufficiency leading to the development of pre-
eclampsia and complications.155  The most common inherited thrombophilic disorders during 
pregnancy result from mutations in Factor V Leiden, prothrombin and MTHFR, all of which 
have been previously studied in the context of predisposition to pre-eclampsia.  Here we 
show that several of the genes related to pre-eclampsia are also associated with the clinically 
more important endpoint of complications such as eclampsia, HELLP syndrome and fetal 
growth restriction.  
The initial literature search was from inception to August 2013 and subsequently the search 
was updated to March 2017. From this update, there have been many more studies that meet 
the inclusion criteria for this review but investigating novel maternal genetic variants that 
have not been included in this review.156-161 There has been one study published since August 
2013 addressing the association of the genotypes already studied in this review (immune-
related genes) with severe pre-eclampsia that we could update our analysis with.162   Some 
have addressed early-onset pre-eclampsia as the outcome instead of ‘severe’ pre-
eclampsia.157, 159, 163 In line with our findings, Wang et al performed a systematic review 
looking at the association between thrombophilia gene polymorphisms and pre-eclampsia and 
found increased risk of pre-eclampsia and severe pre-eclampsia for Factor V Leiden rs6025 
and prothrombin G20210A.164  
 
Strengths and limitations 
This is the first systematic review to assess the association between maternal genotype and 
complications of pre-eclampsia.  We undertook a detailed search to identify all relevant 
publications without language restrictions. The quality of the individual studies was assessed, 
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and we took into account variations in assessing and reporting of effects amongst studies, 
following a standardised approach to data extraction.   
 
However, the studies differed in population characteristics, ethnicity, polymorphisms 
evaluated, the definition of phenotype and outcomes.  The quality of the studies also varied. 
Genome-wide association studies were excluded as it was not possible to perform the 
standardised extraction of data or to pool outcomes. A large number of conventional genetic 
association studies were excluded due to insufficient data on genotype frequencies, and most 
of the included studies in our review had small numbers of cases. Allele frequencies for many 
genes differ greatly between ethnicities.  This was not accounted for in our limited meta-
analyses because of the paucity of data in non-Europeans. 
Implications for clinical practice and future research 
The identification of further genetic risk factors for complications of pre-eclampsia is an 
important research objective, which may lead to early identification and targeted 
management of high-risk pregnancies.  Currently, the NICE guideline for the management of 
hypertension in pregnancy38 does not recommend routinely screening for thrombophilia.The 
population prevalence of Factor V Leiden rs6025 is around 3-15% in Europe,165 which may 
limit the clinical utility of this finding. Future work is needed to evaluate the potential 
benefits of integrating genetic data with clinical information to develop more accurate 
predictive algorithms.   
 
There is a need for high-quality studies on a much larger scale to obtain robust and precise 
estimates of the association between genotypes and pre-eclampsia complications.  Our study 
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highlights the need for evaluation of the quality of genotyping.  Deviation from Hardy-
Weinberg equilibrium is very rare in outbred natural populations and most often results from 
genotyping error.  Hence studies should always state whether the genetic marker is in 
equilibrium and should consider excluding those that deviate from the analysis.   
 
Furthermore, there is a need for potential confounding factors such as the use of aspirin, 
family history to be addressed and allowed for in the analysis of studies.  None of the studies 
included in our review evaluated the fetal genotype that seems likely to play a part in this 
multifactorial disease.  Recruitment methods and genotyping methodology and accuracy 
should be more clearly declared.  Studies with adequate statistical power to investigate pre-
eclampsia complications as primary outcomes will yield the most useful results for clinical 
practice.   
 
Hypothesis generating studies 
Genome-wide studies may be a useful tool for future work.  Dissimilar to candidate gene 
studies, they adopt an unbiased approach to genetic hypotheses and allow investigation of 
many genetic polymorphisms simultaneously.  This is important because the understanding 
of pathophysiology is incomplete so a candidate gene approach may miss an important 
genetic factor.  Also, non-hypothesis driven genetic investigations may identify new 




Linkage analysis has been helpful in the past in localising and mapping ‘disease genes' to 
known ‘genetic markers' in other conditions.  Genome-wide linkage studies have pointed to 
several maternal pre-eclampsia susceptibility loci.166-170  Loci at 2p13 (lod score 4.7),166 4q 
(lod score 2.9),167  12q (lod score 1.99),168 2q23 (lod score 2.58), 11q23-24 (lod score 
2.02),170 2p25 (non-parametric linkage [NPL] score 3.74) and 9p13 (NPL score 3.74).169  At 
the time of these studies, however, no candidate genes were identified in these regions, and 
there has been little success in replicating the results in population-based studies.   
 
Genome-wide association studies (GWAS) have been a more promising approach and two 
such studies have identified candidate genes for pre-eclampsia.171, 172  A study of 293 
Caucasian women from Iowa (177 cases, 116 controls) found copy number variants 
consisting of an enrichment of case deletions in 19q13.31, which encompasses the 
pregnancy-specific glycoprotein PSG11 gene.172 This study did not identify any associations 
with single nucleotide polymorphism (SNPs), possibly due to insufficient statistical power. 
Another GWAS for pre-eclampsia with 538 cases and 540 controls in Caucasian women 
based in Australia found a risk locus on 2q14.2, an intergenic region near the Inhibin, beta B 
(INHBB) gene.171 Three SNPs in this region - rs7579169, rs12711941 and rs7576192 - were 
significant and in strong linkage disequilibrium with each other. INHBB is a subunit of both 
inhibin and activin, two closely related glycoproteins with opposing effects on the action of 
follicle stimulating hormone (FSH) and sex hormone synthesis. There is a body of 
substantive evidence to support the role of inhibins, activins and other members of the TGF-β 
family in the development of pre-eclampsia.173-180   
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To date, GWAS studies have focused on women with a predisposition to pre-eclampsia itself 
and not increased morbidity from significant complications of pre-eclampsia.  There have 
been interesting findings from a recent study that identified three separate subgroups of pre-
eclampsia based on expression of plasma membrane proteins involved in angiogenesis, 
mitogen-activated proteinase (MAP) kinase signalling and hormone biosynthesis and 
metabolism.181  The genes involved in these physiological processes have not yet been 
examined as predictors of pre-eclampsia or its complications.  
 
Conclusion 
These findings point to a potentially causative role for thrombophilia genes in complications 
of pre-eclampsia responsible for substantial maternal and fetal morbidity worldwide.  Further 
studies will be necessary to examine the full repertoire of thrombophilia genes and their 
polymorphisms systematically.  Unfortunately at present there is insufficient evidence to 
justify incorporating genetic data into clinical algorithms for risk assessment but .  
Since the evidence increasingly suggests that pre-eclampsia complications represent the 
severe end of a spectrum of disease, future genetic studies might profitably concentrate on 
such pregnancies.  By focussing on this rich and clinically relevant phenotype, we may 
develop a better understanding of the underlying pathophysiology and genetic mechanisms of 





My contribution to this work: 
Formulation of the question, assisted clinical librarian with search, study selection in stages 1 




CHAPTER 4.2 ACCURACY OF INDIVIDUAL TESTS TO PREDICT 




Pre-eclampsia is associated with significant maternal and fetal morbidity and mortality.  The 
predictive values of tests such as maternal history, clinical examination and investigations for 
individual complications need evaluation.  
Objective 
To systematically review the accuracy of all routinely performed tests for predicting adverse 
maternal and fetal outcomes in women with pre-eclampsia.  
Methods  
We searched the electronic databases MEDLINE, EMBASE and Cochrane without language 
restrictions from inception to July 2015 for studies evaluating routinely performed tests 
(history, symptoms, clinical signs and haematological and biochemical investigations) for 
their predictive performance for development of  maternal or neonatal complications in pre-
eclampsia.  Two independent reviewers undertook study selection, data extraction and quality 
assessment using the QUADAS-2 tool. Sensitivities and specificities for each test and 
outcome combination were pooled together and corresponding 95% confidence intervals 
were calculated.  
Results  
From 20,431 citations, 37 studies (9969 women) were included.  Thirteen tests were 
evaluated for ten maternal complications and seven fetal complications. For maternal 
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outcomes, urine protein creatinine ratio (PCR), uric acid, mean arterial pressure >105 mmHg 
and symptoms of headache were highly sensitive (80% or more) in predicting eclampsia. The 
sensitivity was high for urine PCR in predicting caesarean delivery. The specificities were 
80% or greater for blood pressure values greater than 160/110 mm Hg in predicting 
eclampsia, placental abruption, pulmonary oedema, caesarean delivery and hepatic 
dysfunction. Symptoms of nausea, abdominal pain and visual disturbances were highly 
specific in predicting eclampsia. For fetal outcomes, urine PCR was highly sensitive in 
predicting small for gestational age fetus, and fetal death. None of the tests were highly 
specific for fetal complications. 
Conclusions  
Individual tests vary in performance and predict maternal outcomes better than fetal 
outcomes. Collaborative individual patient data meta-analysis with prognostic modelling will 




Pre-eclampsia, a multisystemic disorder associated with hypertension and proteinuria in 
pregnancy, remains one of the leading direct causes of maternal mortality.182 Worldwide, this 
progressive condition is responsible for over 60,000 maternal and 500,000 perinatal deaths 
each year.11, 183 The management of pre-eclampsia is underpinned by a variety of tests, which 
are interpreted by clinicians to decide on optimal timing of delivery, the only definitive cure 
of the condition.  Identification of the 6% of women who develop severe pre-eclampsia with 
increased morbidity and mortality is needed to safely prolong gestation in the rest.17 
 
Current management following a diagnosis of pre-eclampsia includes obtaining a history, 
assessment of clinical symptoms, examination and tests at the bedside and laboratory 
investigations, which are routinely done in all healthcare facilities in the developed world.38 
However, despite this comprehensive array of tests, the accuracy estimates of individual tests 
are imprecise due to small numbers of women who develop severe complications.84, 86-88 
Observational studies of prediction models for pre-eclampsia complications have included 
clinically less important outcomes such as need for blood transfusion as part of composite 
maternal outcomes and lack sufficient power to predict individual serious complications such 
as eclampsia and placental abruption.57  
 
We sought to systematically review the accuracy of routinely performed individual tests 
including symptoms, bedside investigations, haematological and biochemical indices for 
individual complications, to identify a set of tests that have maximum predictive value to aid 





We conducted the systematic review using a prospective protocol184  in line with current 
recommendations and reported according to PRISMA guidelines.185 (Appendix 4)   
  
Identification of studies and study selection 
The initial search had been conducted in the electronic databases MEDLINE, EMBASE and 
Cochrane for previous systematic reviews of tests in pre-eclampsia without language 
restrictions from inception until December 2013. The full search strategy can be found in our 
published protocol.184 The search was updated (January 2014 to July 2015)184. Study 
selection was in a two stage process with two sets of independent reviewers.  The titles and 
abstracts were screened for relevance in the first stage and the full texts obtained in the 
second stage for evaluation. Any discrepancies were resolved by consensus. Authors were 
contacted for additional information if required. 
 
We included studies that evaluated routinely performed tests (history, examination and 
investigations) and the risk of maternal or fetal complications in women with pre-eclampsia. 
Primary observational studies or those nested within a randomised trial were included. 
Studies were excluded if there was insufficient data to populate a 2 x 2 table for the test and 
outcome, or if the publication date was prior to 1990. 
 
Quality Assessment and data extraction 
Two independent reviewers (FC, JA) evaluated the risk of bias and the applicability of the 
included primary studies using the QUADAS-2 tool,62 for patient selection, index test, 
reference standard, flow and timing of test. Low risk of selection bias was assigned if two or 
more of the following were present: consecutive or random enrolment, absence of case 
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control design, appropriate exclusions; medium risk of bias was assigned if one of the 
aforementioned criteria were present; and high risk of bias or unclear risk of bias if none of 
the criteria were present. Low risk of bias was assigned for the index test if one or more of 
the following were present: index test results interpreted without knowledge of the results of 
the reference standard, and pre-specified threshold for the test was used and high or unclear 
risk of bias if none of the criteria were present.  If the conduct or interpretation of test 
differed from the review question, this was assessed as low risk of bias if there were no 
concerns, and high or unclear risk of bias if there were any. 
 
Low risk of bias for the reference standard was assigned if one or more of the following 
criteria were present: the reference standard correctly classified the target condition, and the 
results were interpreted blindly. Low risk of bias was assigned for flow and timing of test if 
three or more of the following criteria were present: appropriate interval between index test 
and reference standard, all patients received the reference standard, all patients received the 
same reference standard, and all patients were included in the analysis. High risk of bias was 
assigned if two of the criteria were present. Unclear risk of bias was assigned if one or none 
of the criteria were present. Two independent researchers extracted data into 2x2 tables. 
 
Analysis 
We considered every combination of test threshold and complication of pre-eclampsia 
outcome.  In order to avoid overlap of study constituents, the test threshold with the highest 
sensitivity was selected to represent that study population.  Sensitivities and specificities were 
pooled for each test and outcome combination using a bivariate multi-level model when there 
were sufficient numbers to estimate all the model parameters (i.e. more than 4 studies for the 
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test-outcome combination). Where there were fewer than 4 studies, a univariate random 
effects 
model was used to pool accuracy indices. Corresponding 95% confidence intervals were 
calculated. For each test and outcome, sensitivity and specificity were graded as high >80%, 
moderate 60-80% and low <60%. Although we planned to synthesise results from the 
individual studies to perform a meta-analysis, we encountered challenges due to the sheer 
heterogeneity of results arising from the different tests and test cut-off levels and the varying 
severity of individual maternal and fetal complications.  Accurate likelihood ratios or 
diagnostic odds ratios were unable to be estimated.  Among observational studies, there is no 




From 20,431 citations, we included thirty-seven studies (9969 women) in the review.  There 
were thirty-nine studies were eligible for inclusion but two studies187, 188 had to be excluded 
after data extraction as there were insufficient studies with the same test threshold and 
outcome combination to pool the studies with. (Figure 4.2.1). Authors from three large 
studies provided additional primary data.57, 189, 190 The included studies evaluated 14 tests, 10 









Figure 4.2.1 Study Selection Process in the Systematic Review of Tests to Predict 


























Citations Identified From Electronic Databases (n = 29,021) 
Articles Excluded After Evaluation   
 of Abstracts (n = 28,358) 




 Articles Excluded (n = 624) 
 Publication date prior to 1990 (n = 21) 
 Cannot data extract (n = 143) 
 No specific complication (n = 39) 
 Not pre-eclampsia (n = 209) 
 Review / meta-analysis (n = 28) 
 Inappropriate study (n = 12) 
 Not routine test (n = 111) 
 Cannot obtain / translate article (n = 42) 
 Duplicate article/population (n = 19) 
  
Studies Included in Review (n = 39)  
Studies Included in Quantitative 
Synthesis (n = 37)  
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Characteristics of included studies 
There were 29 cohort studies, one cohort nested within a randomised trial and seven case 
control studies.  Sixteen studies were prospective and 21 were retrospective. The study 
population included women with pre-eclampsia and severe pre-eclampsia. The tests 
comprised 24 hour urinary protein level, urinary protein-creatinine ratio, serum alanine 
aminotransferase, serum aspartate aminotransferase, serum lactate dehydrogenase, serum uric 
acid, symptoms of abdominal pain, symptoms of visual disturbances, symptoms of headache, 
symptoms of nausea, blood pressure above 160/110mmHg, mean arterial pressure above 
105mmHg, systolic blood pressure above 160mmHg and diastolic blood pressure above 
110mmHg.    
 
Adverse maternal outcomes were reported in 34 studies, and fetal and neonatal outcomes in 
28 studies. Adverse maternal outcomes included eclampsia (13 studies)57, 191-202, pulmonary 
oedema (3 studies)57, 194, 198, severe hypertension (3 studies)190, 203, 204, haemolysis, elevated 
liver enzymes and low platelets (HELLP) syndrome (5 studies)196, 197, 199, 205, 206, hepatic 
dysfunction (2 studies)57, 190, renal failure (3 studies)57, 198, 207, placental abruption (10 
studies)57, 192, 194-196, 198-200, 208, 209, and Caesarean delivery (9 studies)57, 188, 194, 198, 202, 203, 207, 210, 
211.  The adverse fetal outcomes included small for gestational age (14 studies), fetal or 
neonatal death (17 studies), admission to the neonatal intensive care unit (NICU) (3 studies), 
bronchopulmonary dysplasia (BPD) (2 studies), intraventricular haemorrhage (IVH) (3 
studies), respiratory distress syndrome (RDS) (2 studies) and necrotising enterocolitis (NEC) 





Quality of the included studies 
About two-thirds of the included studies had low risk of bias for patient selection (59%, 
22/37). Most of the studies had low risk of bias for the test evaluated (91%, 34/37). 3% (1/37) 
had high risk of bias and 5% (2/37) unclear risk of bias) for test assessment. There was low 
risk of concerns regarding applicability for the index test in 70% (26/37) and unclear in the 
remainder. Almost 90% of the studies had low risk of bias for determination of the reference 
standard (89%, 33/37), with well defined adverse outcomes, and 5% (2/37) had high risk of 
bias. There was low risk of concerns regarding applicability for the reference test in 92% 
(34/37), unclear in 5% (2/37) and high risk in 3% (1/37). Evaluation of the quality of the flow 
and timing of the tests showed that 62% (23/37) of included studies had low risk of bias, 22% 
(8/37) had high risk of bias and 16% (6/37) had unclear risk of bias.  There was very little 
information provided about the timing and gestational ages at which the tests were performed 
and the completeness of follow-up for the included patients. Study quality parameters 













Figure 4.2.2 Risk of bias in studies included in the systematic review on accuracy of 
individual tests to predict complications in women with pre-eclampsia  
 
Key:  
     Low level of bias 
  High level of bias 
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Data presented as 100% stacked bars; figures in the stacks represent number of studies. 
 




A high sensitivity of 80% or more was observed for urine protein creatinine ratio (PCR) 
(81%, 95% CI 52-95%), serum uric acid (82%, 95% CI 53-95%), a mean arterial blood 
pressure >105 mmHg (93%, 95% CI 82-98%) and history of headache (84%, 95% CI 50-
97%) in predicting eclampsia. Clinical symptoms such as nausea (89%, 95% CI 81-94%).and 
an elevated alanine aminotransferase (ALT) level (90%, 95% CI 50-99%) were highly 
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specific for eclampsia.  Both sensitivity and specificity were poor for elevated AST level 
(sensitivity 55%, 95% CI 29-79%; specificity 52%, 95% CI 20-83%) and systolic blood 
pressure >160 mmHg in predicting eclampsia (sensitivity 44%; 95% CI 4-94%; specificity 
40%, 95% CI 37-43%). 
 
Placental abruption 
A mean arterial pressure >105 mmHg (92%, 95% CI 75-98%) and elevated urine PCR (81%, 
95% CI 64-91%) predicted placental abruption with high sensitivity. Visual disturbances 
were highly specific for placental abruption (80%, 95% CI 78-82%). Both sensitivity and 
specificity were poor for systolic blood pressure >160 mmHg (sensitivity 59%; 95% CI 43-
73%; specificity 41%, 95% CI 36-45%) and history of headache (sensitivity 51%; 95% CI 
32-69%; specificity 58%, 95% CI 50-65%) predicting placental abruption.  
 
Caesarean delivery 
Urine PCR was highly sensitive for caesarean delivery (97%, 95% CI 26-100%).Sensitivity 
and specificity were poor for elevated AST level in predicting Caesarean delivery (sensitivity 
57%, 95% CI 31-79%; specificity 35%, 95% CI 11-69%). Both sensitivity and specificity 
were poor for elevated AST level (sensitivity 57%, 95% CI 31-79%; specificity 35%, 95% CI 
11-69%) and elevated lactate dehydrogenase (LDH) level (sensitivity 13%, 95% CI 1-68%; 
specificity 40%, 95% CI 11-78%) in predicting caesarean delivery.  
 
 
Pulmonary oedema  
Urine PCR was highly sensitive for pulmonary oedema (85%, 95% CI 71-93%).  
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Hepatic dysfunction  
Raised blood pressure of 160/110 mm Hg showed high specificity in predicting hepatic 
dysfunction (81%, 95% CI 75-85%).  
 
HELLP syndrome 
Clinical symptoms such as nausea (89%, 95% CI 79-94%) and abdominal pain (89%, 95% CI 
84-93%) were highly specific for HELLP syndrome. 
 
The radar plots in Figure 4.2.3, provide an overview of the performance of the various tests 
for individual maternal outcomes.  
 
Figure 4.2.3 Radar plots of pooled sensitivities and specificities for tests to predict 
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Small for gestational age  
We observed a high sensitivity for urine PCR in predicting small for gestational age fetuses 
(87%, 95% CI 8-99%).  
 
Perinatal death 




Both sensitivity and specificity were poor for elevated AST level in predicting 
intraventricular haemorrhage (sensitivity 41%, 95% CI 3-94%; specificity 47%, 95% CI 16-
80%). 
 
Respiratory distress syndrome 
Sensitivity and specificity were poor for elevated ALT level in predicting respiratory distress 
syndrome (sensitivity 51%, 95% CI 40-62%; specificity 50%, 95% CI 12-88%). 
 
Necrotising enterocolitis 
Sensitivity and specificity were poor for elevated ALT level in predicting necrotising 






We provide a comprehensive descriptive overview of the accuracy of routinely performed 
tests for the prediction of complications of pre-eclampsia.   
 
Individual tests undertaken in women with pre-eclampsia vary widely in their accuracy for 
predicting maternal and fetal complications. Clinical symptoms have poor sensitivity and 
moderate to high specificity for complications. A blood pressure of 160/110 mmHg or more 
is highly specific, with poor sensitivity for maternal complications. Of the laboratory tests, 
urine PCR performance showed high sensitivity for complications in mother and fetus, but 
had very low specificity. Overall, for fetal complications, tests had moderate specificity but 
low sensitivity.  
 
We performed a very comprehensive search to identify all relevant studies without any 
language restrictions. Since the final analysis in 2015, the search was further updated to April 
2017. There have not been many published studies assessing commonly performed tests and 
the complications of pre-eclampsia but a relevant study that could be included in the review 
is the large prospective multicentre cohort study used to develop a prediction model for 
complications in early-onset pre-eclampsia.212, 213 It is unlikely however for the addition of 
this study to significantly alter our results.  
 
We evaluated the quality of the included studies in detail, and captured all relevant tests and 
outcomes. Ours is the largest evidence synthesis on predictive value of tests for 
complications in women with pre-eclampsia. We evaluated tests that are routinely performed 
in clinical practice, to aid in the generalisability of the findings. Radar plots were used to 
provide an overview of estimates for individual tests and complications to facilitate 
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interpretation.  We pooled sensitivity and specificity of tests where relevant.  We were able to 
provide robust estimates of test performance of individual complications, which were not 
estimated in existing prediction models. 
 
We were limited by the paucity in reported data, with studies varying in the description of 
population, tests, thresholds and outcomes. The resultant heterogeneity limited our ability to 
combine all relevant data, and increased the heterogeneity of our findings. Despite contacting 
authors for raw data where possible, more than a hundred studies had to be excluded due to 
lack of comparative cohorts. Most studies evaluated individual tests, and we were unable to 
assess the impact of other tests on the overall performance. The studies were conducted in 
different countries and spanned temporal periods hence the differences in treatment protocols 
provided for pre-eclampsia might have biased the outcomes. Treatment or intervention may 
lead to a so-called treatment paradox with the predictive potential of a particular test in 
association with a specific complication inaccurately represented.  The outcome or 
complication may not manifest as the intervention (namely delivery) may have prevented it 
from occurring.  The decisions usually follow the clinical acumen of the attending physician 
as there is no standardised algorithm of management of pre-eclampsia in practice. If he or she 
were perceiving a particular test to be more predictive of adverse outcomes, they may be 
more inclined to act upon that test and therefore biasing the outcomes towards the null 
hypothesis.214  
 
Current NICE guidelines consider platelet count, serum creatinine levels, transaminases as 
potential indicators of progression to severe disease in women with pre-eclampsia.38 We did 
not find sufficient evidence to summarise estimates for platelet count and serum creatinine in 
predicting maternal or fetal complications. Our review did show that the transaminases, in 
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particular AST (aspartate transaminase) were moderately predictive of maternal 
complications including combined adverse maternal outcome, pulmonary oedema, placental 
abruption, eclampsia and Caesarean delivery.  The predictive accuracy was less for fetal 
complications such as IVH, RDS and NEC but moderately predictive for BPD.  
 
In the fullPIERS prediction model (pre-eclampsia integrated estimate of risk) which was 
developed and internally validated in a cohort of 2023 women with pre-eclampsia,57 the 
predictors for a composite adverse maternal outcome included gestational age at diagnosis, 
presence of chest pain or dyspnoea, oxygen saturation level, platelet count, creatinine level 
and aspartate transaminase level.  Similar to fullPIERS, we found AST to be most predictive 
and consistently so across the different maternal complications. Unfortunately we did not 
have enough datasets to evaluate the performance of the other predictors in their prediction 
model. 
 
Relevance to clinicians 
Consistent with what is already known on this subject, this review lends further support to the 
notion that individual test performances are very limited for accurately predicting adverse 
maternal and fetal outcomes in pre-eclampsia.  Interestingly, we highlight that in certain tests 
such as the presence of symptoms of pre-eclampsia (abdominal pain, visual disturbances and 
headache) and elevated urinary protein creatinine ratio, their presence appears to be more 
likely to rule in the woman developing a complication of pre-eclampsia. Conversely, their 
absence is not more likely to rule out a complication.  Blood pressure readings appear to be 
most predictive when taken as a combination of systolic and diastolic rather than individual 
systolic or diastolic blood pressure readings. With regard to routinely performed blood tests, 
individually, they have limited accuracy in predicting maternal complications.  Similarly, 
 99 
individual tests cannot be relied upon to predict fetal complications except for elevated PCR, 
which appears to be highly sensitive in predicting small for gestational age and fetal death.  
 
Relevance to research 
This review provides a comprehensive overview of individual test performances for 
predicting adverse maternal and fetal outcomes in pre-eclampsia.  A further step would be to 
look at a combination of tests to women at risk such as the subset of women who develop 
early onset pre-eclampsia. We identified a wide variation in reporting of maternal and fetal 
outcomes in pre-eclampsia. This reiterates the urgent need to develop and utilise core 
outcome sets in future studies on pre-eclampsia.215  An individual patient data meta-analysis 
(IPD) will allow us to assess the differential performance of individual in addition to 
combinations of tests in subgroups of women.  
 
Biomarkers such as placental growth factor,216 have received much interest and promise in 
the prediction of development of pre-eclampsia.  It would be interesting to evaluate the 
performance of biomarkers added to the existing tests for predictive performance of 
developing maternal and fetal adverse outcomes associated with pre-eclampsia. The impetus 
behind further research in this area is to get one step nearer to identifying a set of tests that 
may enable us to risk stratify women with pre-eclampsia in order to significantly optimise 
their management and counselling for this serious condition.  
 
Conclusions 
No single test is sufficiently sensitive and specific in predicting complications in pre-
eclampsia. Collaborative efforts in standardising core outcomes, IPD meta-analysis, and 
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prognostic modelling by including biomarkers will improve accurate prediction of risks of 
individual complications in pre-eclampsia.  
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CHAPTER 4.3: PRIORITISATION OF ADVERSE MATERNAL AND NEONATAL 
OUTCOMES IN LATE-ONSET MILD TO MODERATE PRE-ECLAMPSIA AND 
DEVELOPMENT OF COMPOSITE OUTCOMES 
 
Abstract 
Objective:  Pre-eclampsia is a multi-systemic disorder, leading to maternal and neonatal 
complications; women are often delivered to avoid progression of the disease. Clinical trials 
vary in the reporting of outcomes. More than one outcome is important in the evaluation of 
interventions in women with pre-eclampsia.  We developed composite maternal and neonatal 
outcome measures for reporting in clinical trials on interventions in women with late-onset 
mild and moderate pre-eclampsia.  
 
Methods: We used a two-stage Delphi survey of experts in obstetrics and neonatology to 
identify the clinically important maternal and neonatal outcomes. The identified outcomes 
were used to develop the composite outcomes.  We took into account various criteria such as 
importance of each outcome, their frequency of occurrence, biological plausibility and 
independence from the other outcomes. 
 
Results: Eighteen (18/20, 90%) obstetricians and eighteen neonatologists (18/24, 75%) 
participated in the first round of the Delphi survey. In the second iteration, 100% (18/18) of 
the obstetricians and 94% (17/18) of the neonatologists took part.  The final maternal 
composite outcome consisted of maternal death, eclampsia, placental abruption, major 
obstetric haemorrhage, pulmonary oedema, need for positive ionotropic support, stroke, 
reversible ischaemic neurological deficit (RIND) or HELLP (haemolysis, elevated liver 
enzymes and low platelets) syndrome; and the neonatal composite outcome comprised 
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neonatal death, respiratory distress syndrome (RDS) needing ventilation, grade III/IV 
intraventricular haemorrhage or cystic periventricular leukomalacia.  
Conclusion: Our work will inform trials on timing of delivery in women with mild to 
moderate pre-eclampsia, thereby standardising reporting of relevant outcomes.   
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Determination of the most suitable primary outcome(s) to measure in clinical trials is of great 
importance to the design and credibility of clinical trials.  It is often difficult to choose the 
primary outcome that is both clinically relevant and be adequately evaluated.  This is 
especially so in conditions where there is more than one clinically important outcome, 
making where selection of one representative outcome is; and with conditions with low rates 
of outcomes requiring a large sample size.   
 
When the rates of individual outcomes are low, robust evaluation could be performed by 
systematic reviews and meta-analyses for individual outcomes, or by the development of 
composite outcomes.  The former relies on several trials to answer the clinical question; the 
latter is a more feasible option. Composite outcomes combine individual outcomes of similar 
importance such that the attainment of one or more of these outcomes will represent an event.  
Composite outcomes enable trials to answer clinical questions without the need for 
prohibitively huge sample sizes and enable recruitment over a shorter timeframe.   
 
Pre-eclampsia affects 6-8% of pregnancies and can be associated with maternal, fetal and 
neonatal complications.182  It can lead to various equally important maternal and fetal 
complications.  The only known cure for pre-eclampsia is delivery.  Evaluation of any 
intervention in pre-eclampsia will need to take into account both maternal and fetal 
outcomes. The incidence of individual complications of pre-eclampsia such as eclampsia, 
placental abruption, and stroke vary, but are generally quite low. Any clinical trial that 
evaluates the optimal timing of delivery before term in a high-risk women, should address the 
benefits of early delivery to the mother compared to prematurity-related risks to the fetus. In 
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view of this, composite outcomes are often used in clinical studies involving women with 
pre-eclampsia.57, 217   
 
Clinicians have a relatively low threshold for delivery in women with late onset than early 
onset pre-eclampsia. However, it is increasingly evident that infants born at late preterm 
gestation are physiologically immature compared to their term-born counterparts with 
increased risk of mortality, short and long-term morbidity218.  The neonatal and infant 
mortality rates are 5.5 and 3.5 fold higher respectively in infants born at late preterm 
gestation compared to those born at term219, 220.  The burden in costs to the NHS is double 
that of infants born at 39 weeks’ gestation due to increased intensive care stays and longer 
hospitalisations as a consequence of increased morbidity.221  With regard to long-term 
neurodevelopment in infants born late preterm, there appears to be a higher incidence of 
neuropsychological impairment which persists into late childhood222-224.  There is limited 
evidence on the morbidity of late preterm infants born to women specifically with pre-
eclampsia,225 however the increased oxidative stress state from pre-eclampsia is a known 
adverse effect on the neurodevelopment of the fetus.225 
 
Existing composite outcomes for pre-eclampsia, particularly for late onset disease are not 
relevant or not developed by using robust methodological processes. We aimed to develop 
composite maternal and neonatal outcomes, particularly in women with mild and moderate 






Materials and Methods  
 
The development of the composite outcomes occurred in three stages. In the first stage, we 
performed a literature search to identify complications of pre-eclampsia reported in pre-
eclampsia trials, outcomes of consensus surveys, and any composite outcomes developed in 
this area. In the second stage, the list of individual components identified from the search was 
sent to a group of experts to prioritise the clinical importance of each outcome.  In the final 
stage, the components of the composite outcomes were chosen from those that were 
prioritised by the panel using pre-specified criteria.226   
 
Identification of maternal and fetal components 
We searched the electronic databases MEDLINE and EMBASE from inception to June 2012 
for pre-eclampsia complications.  This was part of our separate project on a systematic 
review on tests in pre-eclampsia of literature.86, 87 Maternal and neonatal outcomes that 
showed a clear biological plausibility for association with pre-eclampsia or prematurity were 
included for consideration in the next stage.    
 
Delphi survey to prioritise the components for clinical importance  
We undertook a two-generational Delphi survey in line with published recommendations.77, 85 
This was in the form of two online questionnaire surveys (one regarding obstetric outcomes 
and the other neonatal outcomes) emailed out to an obstetric expert panel and a neonatal 
expert panel respectively.  There were two rounds to the surveys such that in the first round 
or iteration, the initial surveys were sent out to the panels; the responses were collated and the 
surveys were sent out again with an anonymised summary of the initial responses by the 
panels, providing a chance for the panellists to revise their answers if they wished. 
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The Delphi panels consisted of senior clinicians and clinical academics in the UK.  The 
obstetric expert panel included individuals who had clinical expertise, (or) were involved in 
studies on pre-eclampsia.  The neonatal expert panel included senior clinicians from our 
regional research network. The panel members were informed that their contribution is 
crucial to the development of maternal and neonatal composite outcomes. We requested the 
panel members to prioritise the maternal and neonatal outcomes that they considered were 
clinically important in the management of women with mild and moderate pre-eclampsia 
between 34 and 37 weeks gestation.   
 
We maintained anonymity throughout the process by using an online tool 
(www.surveymonkey.com).227 The constituents of the panel and the individual scores were 
known only to the pollster (FC).  
 
The questionnaires were administered in an online electronic format.  In the first iteration, 
panellists were asked to grade the clinical importance of maternal or neonatal outcomes that 
might influence the decision to deliver mothers with mild and moderate pre-eclampsia at late 
preterm gestation.  They were requested to grade their responses from ‘1’ to ‘5’ on a Likert 
scale with ‘1’ denoting ‘strongly disagree’ to ‘5’ denoting ‘strongly agree’, for an outcome to 
be considered important. 
 
We sent reminders to panel members if no responses were received after 2 weeks. In the first 
round, the members were also given the opportunity to introduce outcomes that they 
considered to be important but were missing in out the initial list.  Members who did not 
respond in the first round were excluded from the subsequent rounds.  For each outcome, we 
calculated median scores and interquartile ranges. An interquartile range of 2 or more in the 
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second round was pre-specified to indicate consensus.  Outcomes that generated a median 
score of 4 or more with consensus (IQR≤2) were selected for evaluation in the third stage for 
consideration in the development of the composite outcome.  
 
Development of the composite outcome 
The components of the maternal and neonatal composite outcomes were selected by a group 
of experts in the field of pre-eclampsia, academics and clinicians in neonatology and those 
with expertise in outcome development. A semi-structured discussion was undertaken to 
consider inclusion of each component, identified by the Delphi survey. The selection of 
components was based on the following pre-specified criteria: similar rates of occurrence; 
evidence of biological plausibility; independent of each other; evidence of same direction of 
the effect with the intervention.226, 228  Components that fulfilled these criteria were included 
in the final maternal and neonatal composite outcomes. 
 
Results 
Identification of maternal and neonatal outcomes 
Through our systematic reviews, 57, 85 randomised controlled trial,217 and two surveys,57, 217 
we initially identified 21 maternal and 24 relevant neonatal outcomes.  Appendix 6 provides 
the list of the outcomes.  Maternal outcomes included neurological, respiratory, 
cardiovascular, haematological, renal, gastroenterological and other complications.  Neonatal 
outcomes included complications related to prematurity at delivery involving neurological, 
respiratory and cardiovascular systems.  Additionally, it included management-based 




Prioritisation of the maternal and neonatal outcomes 
The Delphi panel consisted of 44 clinicians and clinical academics, of whom 20 were 
obstetricians and 24 were neonatologists.   
 
First round  
The questionnaire on the importance of individual maternal outcomes relevant to the timing 
of delivery in women with mild and moderate pre-eclampsia at late preterm gestations was 
completed by 90% (18/20) of obstetricians.  Six of the 21 outcomes (29%) were scored as 
very important, and 12 outcomes (52%) were considered to be important. (Figure 4.3.1)   
The median score was below 4 for three outcomes in the first round: Bell’s palsy, Glasgow 
Coma Scale <13 and retinal detachment.  These outcomes were excluded from the second 
round. Additional outcomes such as need for magnesium sulphate, placental abruption, and 
HELLP (Haemolysis, Elevated Liver enzymes and Low Platelets) syndrome, were suggested 
for consideration by the panellists, and these were added to the list for the second iteration.  
Six maternal outcomes were prioritised to be very important with an interquartile range (IQR) 
≤1. These included eclampsia, pulmonary oedema, severe pre-eclampsia, maternal death, 









Figure 4.3.1: Prioritisation of maternal outcomes relevant to the timing of delivery 












































































(1= Strongly disagree, 2 = Disagree, 3 = Neutral, 4 = Agree, 5 = Strongly agree)



















































 Permission granted to reproduce this figure from Hypertension in Pregnancy, Informa 




Eighteen neonatologists (18/24, 75%) prioritised neonatal outcomes in the first iteration. 
Three (12.5%) outcomes were scored as very important and 16 (67%) as important (Figure 
2).  Five outcomes including transient tachypnoea of the newborn, respiratory illness 
requiring admission to hospital during the first year of life, bronchopulmonary dysplasia, 
stage 3 to 5 retinopathy of prematurity and need for assisted ventilation more than 4 hours 






















Figure 4.3.2: Prioritisation of neonatal outcomes relevant to the time of delivery 
management in women with mild and moderate pre-eclampsia at late preterm 
gestations 
 
Permission granted to reproduce this figure from Hypertension in Pregnancy, Informa 
Healthcare.  Licence number 3998151234270.  
 
The neonatal expert panel suggested eight new items to be considered in the second round.  
These included estimated birth weight, Clinical Risk Index for Babies (CRIB) scores, need 
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days), day of life tolerating enteral feeds, late onset sepsis (>72 hours) and neonatal jaundice. 
The outcome, hypoxic ischaemic encephalopathy was missed by the online system and did 
not proceed to the next round. We included this outcome in the third stage for consideration 
as a component in the development of composite outcomes. 
 
Second round 
During the second round, seventeen (17/18, 94%) obstetricians and 18 (18/18, 100%) 
neonatologists participated.  Ten maternal outcomes (10/21, 48%) were considered to be very 
important (median score of 5); eleven maternal outcomes (11/21, 52%) were considered to be 
important (median score of 4).  Ten maternal outcomes had a narrowing of the IQR, 
indicating consensus between the panellists. (Figure 4.3.1) 
 
Three neonatal outcomes (3/25, 12%) were considered to be very important (median score of 
5); they included neonatal death, neurodevelopmental status at 2 years of age and days of 
BAPM (British Association of Perinatal Medicine) level 3 care.  Fourteen neonatal outcomes 
(14/25, 56%) were prioritised as important (median score of 4).  The remaining eight 
outcomes had median scores of less than 4.  Eight outcomes had narrowing of the IQR 
indicating consensus. (Figure 4.3.2) 
 
Development of the composite outcome 
In the final stage, we evaluated the ten maternal outcomes and seventeen neonatal outcomes 




The final maternal composite outcome consisted of seven components: maternal death, 
eclampsia, pulmonary oedema, major obstetric haemorrhage with need for transfusion of 
blood products or need for positive ionotropic support, HELLP syndrome and placental 
abruption. (Table 4.3.1) We excluded outcomes with very low prevalence, such as cortical 
blindness, myocardial ischaemia or infarction and hepatic capsule rupture. Components that 
overlapped significantly with other components were excluded.  Outcomes such as hepatic 
dysfunction and hepatic failure with HELLP syndrome; severe pre-eclampsia and the need 
for a 3rd antihypertensive; acute renal insufficiency and need for dialysis were excluded. Less 




The final neonatal composite endpoint comprised of neonatal death, respiratory distress 
syndrome needing ventilatory support, and neurological morbidity such as cystic 
periventricular leukomalacia and grade III/IV intraventricular haemorrhage.  (Table 4.3.2) 
Clinician-driven outcomes such as admission to the neonatal intensive care unit (NICU) at 
any time, length of stay more than seven days on the NICU and days of BAPM Level 2 care 
were excluded.  We also excluded long-term outcomes such as 2-year follow up.  The 
outcomes whose IQR increased in the second round, suggesting variation in consensus 
(neonatal seizures and Apgar <4 at 5 minutes) were not included. In many countries, 
including the UK, therapeutic hypothermia for neuroprotection of late preterm infants is not 
routinely administered to infants under 36 weeks gestation and hence it was not included.  
Although grade III/IV intraventricular haemorrhage and cystic periventricular leukomalacia 
are less common complications for neonates born at late preterm gestations, they were 
included in our composite outcome due to the severity and importance of these conditions.  
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Table 2:  Criteria for developing the neonatal composite outcome 
 
Discussion 
We developed maternal and neonatal composite outcomes for clinical trials on women with 
mild and moderate pre-eclampsia at late preterm gestation using rigorous methodology. 
These composite outcomes can contribute to reducing the bias in both the design and 
reporting of randomised trials in this area. Studies reporting the effects of the intervention 
should also provide the effect of the intervention on the individual components of the 
composite outcome.  
 
There are clear recommendations on the timing of delivery at early preterm gestation (<34 
weeks), with the advice of delivery in women with severe pre-eclampsia, and expectant 
management in mild and moderate pre-eclampsia.22, 38  However, clinical equipoise exists for 
the management of women in this somewhat ‘grey’ area of mild to moderate pre-eclampsia 
developing at a late preterm gestation.  When the condition is mild to moderate pre-
eclampsia, expectant management is usually adopted prior to 34 weeks’ gestation; elective 
delivery at 37 weeks’ gestation or thereafter but between 34 to 37 weeks’ gestation, there is 
little guidance and the optimal management is currently unclear.  
 
This has been identified as an area of much needed research, to determine the optimal timing 
of delivery of women with mild to moderate pre-eclampsia at late preterm gestations between 
34 and 37 weeks.  Multiple outcomes for both mother and baby need to be taken into 
consideration to adequately assess the effect of intervention or non-intervention of this subset 
of women.   
 
 115 
Strengths and limitations 
There are several strengths to this study.  Firstly the Delphi survey involved clinicians and 
academics with expertise in the area, thereby ensuring face validity.  Secondly, identification 
of components through systematic reviews and surveys provided content validity. Thirdly, 
there was minimal loss to follow up with high response rates between each iteration.  
Fourthly we measured each individual outcome against pre-specified and well-accepted 
criteria for the development of the composite outcomes.229 We provided a clear definition for 
each outcome in order to minimise bias.  (Appendix 7) 
 
The Delphi technique is a consensus method commonly used to measure uncertainty in health 
research, enabling researchers to derive quantitative estimates through a qualitative 
approach.230 Alternative consensus methods include the nominal group technique (also 
known as the expert panel),231 and the consensus development conference.230 These 
alternative methods are more focussed on developing consensus and are highly structured 
group meetings with relevant experts usually in a face-to-face setting.  
 
The strengths of the Delphi technique in comparison to the alternative consensus methods are 
that it is easy and of low cost to organise, administer and analyse since there is no need for a 
face-to-face meeting; individuals can freely express their opinions due to the anonymous 
nature and a consensus is usually achieved rapidly. Its limitations are that it relies on the 
motivation of the panellists to respond to each round; without the face to face meeting, it is 
difficult to ‘discuss’ differing opinions or points and can be time consuming with the several 
rounds, awaiting responses and collating them together compared an expert panel meeting or 
conference.  
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Our selection of the components was heavily dependent on the opinions and knowledge of 
the panel members. It is possible that a panel of different members may have prioritised a 
different set of outcomes.  Furthermore, despite our efforts to use stringent criteria for the 
development of composite endpoints, it is often difficult to identify components of absolute 
equal importance.  Despite our efforts, the individual components of our final composite 
outcomes have variation in the frequency of occurrence of outcomes.  These are well-
recognised limitations of composite outcomes, with the effect being smallest for the most 
important component and largest for the least important component. The onus lies upon the 
researcher to ensure there is thorough and consistent reporting, and interpretation of the effect 
of an intervention on a composite outcome. 
 
Use of Delphi technique 
The Delphi technique provided a platform for structured group communication in order to 
answer a question in the absence of known consensus.232  Pre-eclampsia is a condition with 
complex pathophysiology and requires intuitive interpretation of evidence.  The Delphi 
enabled us to draw upon the experience and knowledge of a selected group of experts to 
reach consensus anonymously.  Furthermore the two-stage process provides the opportunity 
for participants to acknowledge the opinions of the other panel members and modify their 
responses.  Consensus was achieved for most outcomes. 
 
Challenges in the development and reporting of composite outcomes 
Composite outcomes have become increasingly popular in their use in clinical trials.  
However, the robustness of their development and the reporting of the composite outcomes 
have received much criticism.  This is mainly due to the lack of transparency in the selection 
of the components and the relevance to clinical practice.  We have attempted to address these 
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issues by undertaking a systematic search and prioritisation of the components by the Delphi 
technique.  Another challenge is the frequency of occurrence of the individual components 
varies, often one component of the outcome may dominate the findings.  In our example, 
maternal and neonatal deaths are very infrequent but we included these two components in 
both composite outcomes since death has a censuring effect on other components.   
 
Certain outcomes may be more likely to be ‘clinician-driven’ and hence have a potential for 
bias, particularly in unblinded clinical trials.  We therefore excluded clinician-driven 
outcomes such as admission to the neonatal intensive care unit (NICU) at any time with 
length of stay more than seven days on the NICU and days of BAPM Level 2 care.  The 
change in the rates of all the outcomes may not be in the same direction resulting in 
conflicting results.  The above limitations need to be acknowledged and clearly taken into 
account in the interpretation of results.   
 
A recent systematic review on reporting of composite outcomes in randomised clinical trials 
on evaluating the highlighted that only one trial (out of 40) rationalised the selection of the 
individual components. About 70% of these trials had composite outcomes that included 
components of differing levels of importance.228   
 
As identified in our searches, there have been other composite maternal and neonatal 
outcomes developed for pre-eclampsia.57, 217, 233 The study by von Dadelszen also identified 
the individual components by the Delphi technique but the underlying clinical question 
differed. They focussed on maternal and neonatal outcomes in women with pre-eclampsia of 
any severity and development at any gestational age, to be evaluated in a prediction model.57  
In our study, the focus has been on a subset of women with the milder end of the spectrum 
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and late presentation of the disease.  In comparison with von Dadelszen’s study, we included 
HELLP syndrome and severe pre-eclampsia components in our study.57 Our Delphi expert 
panel members were from the UK whereas their study was based in Canada. The variation in 
population and the panel may explain the difference in the prioritisation of outcomes. 
 
Patient involvement 
Patient and family involvement is often overlooked in the development of composite 
outcomes.  Parents may consider a different set of outcomes to be important compared to the 
clinicians. There has been great success in the field of rheumatology, the development of core 
outcome measures has integrated patient prioritisation of outcomes at each step alongside 
clinician’s views.234 We were unable to obtain patient and public involvement on important 
outcomes for the management of women with late-onset pre-eclampsia due to time restraints.   
  
Future recommendations 
Future randomised controlled trials on women with mild or moderate pre-eclampsia, 
especially at late preterm gestations, should consider these composite outcomes and their 
components to assess the effect of intervention.  Caution and acknowledgement of the 
limitations are needed in the interpretation of the incidence of these outcomes and 
components.77  Additional input from the patient and public is needed in the development of 




The composite maternal and neonatal outcomes developed in this study provide a more 
realistic primary outcome measure for a feasible number of patients to be recruited to studies 
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attempting to answer the question of optimal timing of delivery in women with late-onset 
mild and moderate pre-eclampsia.   
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In this section, I have undertaken a systematic review of prospective risk of stillbirth and 
neonatal deaths in uncomplicated monochorionic and dichorionic twin pregnancies.  I have 















CHAPTER 5.1:  PROSPECTIVE RISK OF STILLBIRTH AND NEONATAL 
DEATHS IN UNCOMPLICATED MONOCHORIONIC AND DICHORIONIC TWIN 
PREGNANCIES AND OPTIMAL TIMING OF DELIVERY 
Abstract 
Background 
The high rate of stillbirth in twins has led to a policy of planned early delivery. There is no 
consensus on optimal timing due to lack of robust data.  
Objective 
To quantify the risks of stillbirth and neonatal complications by gestational age in 
uncomplicated monochorionic and dichorionic twin pregnancies. 
Methods 
We searched major databases (Medline, Embase and Cochrane) for relevant studies (until 
December 2015) without language restrictions for studies of women with uncomplicated twin 
pregnancies, which reported rates of stillbirth and neonatal outcomes at various gestational 
ages.  We also included unpublished data from collaborative research networks. We excluded 
pregnancies with unclear chorionicity, monoamnionicity and twin-to-twin transfusion 
syndrome. Meta-analyses of observational studies and cohorts nested within randomised 
studies were undertaken. We computed prospective risk of stillbirth for each study at a given 
week of gestation, and compared this with the risk of neonatal death amongst deliveries in the 
same week. We estimated the gestational age-specific risk differences for stillbirths and 
neonatal deaths in monochorionic and dichorionic twin pregnancies after 34 weeks of 
gestation.  
Results 
Thirty-two studies (29,685 dichorionic, 5,486 monochorionic pregnancies) were included. In 
dichorionic twin pregnancies beyond 34 weeks (15 studies, 17,830 pregnancies), the 
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prospective weekly risk of stillbirths from expectant management and the risk of neonatal 
death from delivery were balanced at 37 weeks’ gestation (risk difference 1.2/1000; 95% CI -
1.3 to 3.6, I2 = 0%). Delay in delivery by a week (until 38 weeks) led to an additional 8.8 
perinatal deaths per 1000 pregnancies (95% CI 3.6 to 14.0 /1000, I2 = 0%) compared to the 
previous week.  In monochorionic pregnancies beyond 34 weeks (13 studies, 2,149 
pregnancies), there was a trend towards increase in stillbirths compared with neonatal deaths 
after 36 weeks, with an additional 2.5 per 1000 perinatal deaths, which was not significant 
(95% CI -12.4 to 17.4/1000, I2 = 0%). The rates of neonatal morbidity showed a consistent 
reduction with increasing gestational age in monochorionic and dichorionic pregnancies, and 
admission to the neonatal intensive care unit was the commonest neonatal morbidity. The 
actual risk of stillbirth near term may be higher than reported estimates due to the policy of 
planned delivery in twin pregnancies. 
Conclusion 
In order to minimise perinatal deaths, delivery should be considered at 37 weeks’ gestation in 
uncomplicated dichorionic twin pregnancies, and considered at 36 weeks in monochorionic 
pregnancies. 
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Twin pregnancies are at high risk of adverse fetal and neonatal outcomes.  The risk of 
stillbirth is increased thirteen-fold and five-fold for monochorionic and dichorionic twin 
pregnancies respectively compared to singleton pregnancies.43, 47, 235 Delivery before term 
predisposes to prematurity-associated neonatal mortality and morbidity.47  Current guidelines 
vary in their recommendations on the timing of delivery, ranging from 34 weeks of gestation 
in monochorionic twins and 37 weeks in dichorionic twins.236 
 
Pregnant women with twins, clinicians and policy makers need accurate and robust estimates 
of the stillbirth risk from continuing the pregnancy, and the neonatal risk from early delivery, 
to decide upon the optimal timing of delivery. Existing reviews have focused mainly on 
stillbirth risk without taking into account the neonatal outcomes.237 There are no published 
data on gestation and chorionicity specific perinatal mortality and morbidity in twins to guide 
decision-making on the timing of delivery. Furthermore, randomised trials on the timing of 
delivery in twins are not adequately powered to provide robust estimates of benefit.238 
 
Objective 
We undertook a systematic review to quantify the prospective risks of stillbirth by gestational 
age in uncomplicated monochorionic and dichorionic twin pregnancies. We evaluated the 
risks to the newborn when delivered after 34 weeks' gestation and at various gestational ages 




We conducted the systematic review according to the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) guidelines (Appendix 8)65  with a 
prospectively registered protocol. 
 
Study identification 
We performed electronic searches on Medline, Embase and the Cochrane Library databases 
from inception until December 2015 for studies on twin pregnancies reporting rates of 
stillbirth. The search terms ‘monochorionic’ OR ‘dichorionic’ OR ‘twin pregnancy’ OR 
‘multiple pregnancy’ were used to represent the population and these were combined with 
‘stillbirth’ OR (‘fetal or foetal or fetus or foetus’ AND ‘death or demise or mortality’) for the 
outcome. There were no language restrictions. We supplemented this search with an added 
search for neonatal outcomes in twin pregnancies (Appendix 9). Reference lists of included 
studies were interrogated. Additionally, we contacted individual authors members of 
collaborative research networks such as Global Obstetric Network (GONet),239 Evidence 
Based Medicine Connect (EBM Connect),240 and the Twin pregnancies Individual Participant 
Data (IPD) Meta-Analysis group for relevant data.241 
 
Study selection  
Studies were selected in a two-step process by two independent reviewers (FC and ES). In 
the first stage, the titles and abstracts were screened, and in the second stage, the full texts of 
the identified studies were evaluated in detail.   
 
We included studies that reported on the rates of stillbirth and neonatal outcomes in women 
with monochorionic and/or dichorionic twin pregnancies.  Both observational cohort studies 
and randomised control trials with nested cohorts were included.  Exclusion criteria were 
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unclear chorionicity, monoamnionicity, inability to exclude twin-to-twin transfusion 
syndrome and if the outcomes were not provided in weekly or 2-weekly gestational epochs.  
 
We defined stillbirth as a baby born without signs of life after the viability age, or any other 
definition used by the authors. Neonatal mortality was defined as neonatal death up to 28 
days from delivery.  
 
For neonatal morbidity we considered the following morbidity outcomes to be clinically 
relevant for delivery after 34 weeks' gestation: the need for assisted ventilation, respiratory 
distress syndrome (RDS), septicaemia, hypoxic ischaemic encephalopathy or neonatal 
seizures, and the need for admission to the neonatal intensive care unit. 
 
For moderate and extreme preterm infants, born between 26 and 33+6 weeks’ gestation, we 
evaluated the following additional complications: bronchopulmonary dysplasia, necrotising 
enterocolitis, cystic periventricular leukomalacia or grade 3 or 4 intraventricular haemorrhage 
with a significantly abnormal cranial ultrasound scan and retinopathy of prematurity (stages 3 
to 5). 
 
Quality assessment and data extraction 
We evaluated the qualities of the included studies for their internal and external validity. 12, 242, 
243 Representativeness of the cohort, study design, method of sampling, adequacy of follow-
up, ascertainment of the outcome and appropriate classification, such as determination of 
gestational age and chorionicity were assessed. Features such as prospective design, 
consecutive or random recruitment of patients, follow-up rates of over 80%, and use of first-
trimester ultrasound signs to determine chorionicity and gestational age assessment were 
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considered to have high quality. We evaluated the external validity from the 
representativeness of the population studied. Studies that provided a clear definition of 
uncomplicated twin pregnancies and excluded pregnancies with fetal growth restriction and 
congenital abnormalities in the baby were classified as high-quality studies. Study quality 
assessment and data extraction were performed by two independent reviewers (FC and ES). 




Separate analyses were undertaken for risks of stillbirth, neonatal mortality and morbidity in 
monochorionic and dichorionic twin pregnancies in two periods.  The first was from 34 
weeks’ gestation and beyond and the second, early preterm (<34 weeks) gestation.  
 
From 34 weeks onwards, we calculated the risks by weekly gestational ages, with the 34-
week period representing pregnant women entering the 34+0 to 34+6 weeks’ gestation with 
live fetuses. For early preterm (<34 weeks) gestation, we estimated risks of outcomes by two 
weekly intervals.  
 
We calculated the prospective risk of stillbirth by dividing the number of stillbirths seen that 
week by the number of women who were at risk in the same week. For a specific gestational 
age, we defined women at risk of stillbirth as those who were still pregnant at the beginning 
of that gestational week.  
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Deliveries during that week were corrected for by subtracting half the number of women who 
delivered that week. 244 For the risk of neonatal death, this was calculated by dividing the 
number of neonatal deaths in a given gestational week by the number of deliveries.  
 
In pregnancies after 34 weeks’ gestation, we assessed the competing risks of expectant 
management versus delivery at a given gestational age, for each study. We defined the risk of 
perinatal death at a given gestational week as the difference between stillbirth and neonatal 
death risk for deliveries in that week. This provided a direct measure of benefit or harm from 
expectant management vs. immediate delivery strategy. A risk difference < 0 represents a 
reduction in the risk of perinatal death with expectant management for the given gestational 
age, compared with immediate delivery.  
 
Risk differences from individual studies were pooled together using a fixed effect model 
weighted by the inverse of its variance. We computed I-squared as an estimation of between-
study heterogeneity and assumed values lower than 50% as little heterogeneity and I-squared 
greater than 75% as substantial heterogeneity. 
 
We estimated the weekly risk of neonatal outcomes by fitting multi-level random effects 
logistic regression models with gestational age as the independent variable. The units of the 
analysis were pregnancies (at the first level) that were clustered within studies (for the second 
level of the analysis). We calculated point estimates of the risk of each event by the 
gestational period along with its corresponding 95% confidence interval (CI). We planned 
before analysis to restrict our evaluation up to the gestational week for which robust, 
unbiased data were available.  
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Sensitivity analysis was planned a priori to analysis to exclude studies involving pregnancies 
complicated by congenital abnormalities, and those with low external validity. We assessed 
publication bias and small study effects using funnel plots to represent the overall event rate 
(logit scale) versus the inverse of the sample size for each study included in main analysis.63 
.56 To evaluate publication bias, we used Peters’s test, which evaluates funnel asymmetry 
and is advantageous for use with dichotomous outcomes due the appropriate type 1 error 
rates regardless of the degree of heterogeneity and the underlying effect size.245, 246 We fitted 
a weighted linear regression with the logit of event rate as the dependent variable and the 
inverse of sample size as the independent variable. computed the weights according to the 
number of events and non-events.246 We used a continuity correction for studies with zero 
events by adding 0.5 to the events and 1 to the total sample size.  
 
Results 
Identification of studies 
From 2574 citations, we identified 32 studies reporting on 35,171 women with twin 
pregnancies (Figure 5.1).43, 238, 247-273 Eighteen studies provided data on both monochorionic 
and dichorionic,43, 238, 249, 251, 253, 255, 257, 259, 261-264, 267-269, 272, 274, 275 seven on monochorionic 
twin pregnancies only, 248, 250, 256, 258, 260, 266, 271 and seven on dichorionic twin pregnancies 
only. 247, 252, 254, 265, 270, 273, 276 Twenty-three authors provided additional relevant unpublished 
data.43, 238, 247, 249, 251-254, 257, 258, 260-262, 266-272, 274-276 
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Figure 5.1 Study selection process in the systematic review on prospective risk of 
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Excluded, n = 108 
No gestational specific data, n = 31 
Letters/reviews/case study/protocol, n = 19 
Unknown chorionicity, n = 18 
Duplicate data, n = 16 
Monoamniotic twins/triplets, n = 6 
Cannot extract data, n = 5 
Cannot exclude TTTS, n = 10 
Specific group (surviving twins), n = 3 
Miscarriage outcome, not stillbirth, n = 1 
Studies included in the review 
n = 32 (35,171 twin pregnancies) 
Studies with data on 
monochorionic twin 
pregnancies only 
n = 7 (1661 pregnancies) 
Studies with data on monochorionic 
and dichorionic twin pregnancies 
 
n = 18 (19,415 pregnancies) 
Studies with data on 
dichorionic twin 
pregnancies only 
n = 7 (14,095 pregnancies) 
Citations excluded after review of 
abstracts for eligibility 
n=2470 
Citations from MEDLINE, Embase, Cochrane electronic 
databases from inception to December 2015 
n = 2574 
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Study characteristics and quality assessment 
Fifteen studies on dichorionic pregnancies (17,830 women) and 13 on monochorionic 
pregnancies (2,149 women) provided weekly data on stillbirth after 34 weeks’ gestation. The 
corresponding neonatal death rates were provided by 13 (n=10,333) studies for dichorionic, 
and 11 (n=1,461) for monochorionic pregnancies.  
 
Overall, there were 14 studies that excluded pregnancies complicated by fetal growth 
restriction, and 28 studies excluded pregnancies with major congenital abnormalities. The 
diagnosis of fetal growth restriction and congenital abnormalities were made antenatally. The 
postmortem findings of the stillborn babies were reviewed for evidence of growth restriction 
in two studies. The definitions of stillbirths, neonatal death, and morbidity outcomes did not 
differ much amongst the studies (Appendix 9). The number of stillbirths and neonatal deaths 
from 26 to 33+6 weeks, and beyond 34 weeks of gestation in individual studies for 
monochorionic and dichorionic pregnancies are demonstrated in (Appendix 10).  
 
The qualities of the studies were adequately representative in 27 (27/32, 84%), and 
inadequately or unclearly representative in 5 (5/32, 16%) (Figure 5.2). Fifteen of the included 
studies (15/32) were prospective, and of these 12 (12/32, 38%) were nested cohorts in 
randomised trials. The majority of studies used random or consecutive sampling methods 
(31/32, 97%), had achieved adequate follow-up (26/32, 81%), and we observed low levels of 
ascertainment bias in determining stillbirth outcome (31/32, 97%). For misclassification bias, 
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twenty studies had a low risk of bias for gestational age assessment (20/32, 63%), and 
twenty-five studies had a low risk of bias for chorionicity determination (25/32, 78%).   
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Figure 5.2 Risk of bias in studies included in the systematic review on prospective risk 
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Data presented as 100% stacked bars; figures in the stacks represent number of studies. 
Permission granted to reproduce this figure from The BMJ, BMJ Publishing Group. Licence 
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Stillbirth and neonatal mortality after 34 weeks’ gestation 
Dichorionic twin pregnancies 
At 34+0-6 weeks, the prospective risk of stillbirth was 1.2 per 1000 pregnancies (95% CI 0.7-
1.8) a and the corresponding risk of neonatal death was 6.7 per 1000 pregnancies (95% CI 3.3 
to 13.5) (Table 5.1). The risks of stillbirth were significantly lower than the risks of neonatal 
deaths at 34+0-6 (risk difference -5.8/1000, 95% CI -10.4 to -1.2/1000, I2=0%), and 35+0-6 
weeks’ gestation (risk difference -5.1/1000, 95% CI -8.7 to -1.6/1000, I2=0%).  
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At 37+0-6 weeks, the perinatal risks were balanced with a risk difference was 1.2/1000, (95% 
CI -1.3 to 3.6/1000, I2=0%). After this gestational week, the risk of stillbirth increases to 
10.6/1000, (95% CI 7.1 to 15.3), which significantly outweighs the neonatal death risk from 
delivery at 1.5/1000, (95% CI 0.7 to 3.3). The risk difference increases to 8.8/1000, (95% CI 
3.6 to 14/1000, I2=0%) (Figure 5.3). Analysis by excluding fetuses with congenital 
abnormalities showed results similar to the main analysis (Figure 5.4).  
 
When we excluded studies with low external validity, there was a trend towards increased 
stillbirth risk compared with neonatal death beyond 37+0-6 weeks, but this was not 




Figure 5.3 Prospective risks of stillbirths from expectant management compared to 
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Figure 5.4 Risks of stillbirths from expectant management compared to neonatal 
mortality risks from delivery at weekly intervals from 34 week's gestation in 
studies on twin pregnancies without major congenital abnormalities  
Permission granted to reproduce this supplementary figure from The BMJ, BMJ Publishing 
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Monochorionic twin pregnancies 
At 34 weeks, the prospective risks of stillbirth and neonatal mortality in monochorionic 
pregnancies were 0.9/1000 (95% CI 0.1 to 3.4) and 12.1/1000 (95% CI 4.2 to 34.3) 
respectively.  
 
The risks of neonatal death were higher than stillbirth at 34+0-6 (risk difference -15.6/1000, 
95% CI -40.4 to 9.1/1000, I2=0%) and 35+0-6 weeks (risk difference -2.4/1000, 95% CI -
17.6 to 12.8/1000, I2=0%), but these were not statistically significant (Figure 3). After 36+0-
6 weeks, we observed a trend where the risk of stillbirth (9.6/1000, 95% CI 3.9 to 19.7) was 
higher than neonatal deaths (3.6/1000, 95% CI 1.2 to 11.1) with a risk difference of 2.5/1000 
(95% CI -12.4 to 17.4/1000, I2=0%). Sensitivity analysis by excluding studies with 
congenitally malformed fetuses (Figure 5.4) and studies with low external validity showed 
similar findings.  
 
All analyses were restricted to 38 weeks for monochorionic twin pregnancies and until 39 
weeks for dichorionic twin pregnancies due to the lack of robust data beyond this timeframe. 
 
Neonatal morbidity beyond 34 weeks’ gestation 
The rates of need for assisted ventilation, septicaemia, respiratory distress syndrome and 
admission to the neonatal intensive care unit consistently reduced with increasing gestational 
age in babies of both monochorionic and dichorionic twin pregnancies (Table 5.2).  
Neonatal Intensive Care Unit (NICU) admission in the infants was the commonest 
complication in monochorionic and dichorionic twin pregnancies.  
 
Stillbirth and neonatal outcomes in early preterm twin pregnancies  
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The cumulative risks of stillbirth and neonatal deaths by two weekly gestational periods in 
early preterm twin pregnancies (between 26 to 33 weeks and 6 days gestation) are provided 
in (Appendix 13.). Early preterm neonatal outcomes in two-weekly epochs are shown in 
Appendix 14. Neonatal morbidity reduced with increasing gestational age in all twin 
pregnancies. The commonest neonatal complications were respiratory distress syndrome, 
septicaemia, admission to the neonatal intensive care unit (NICU) and the need for assisted 
ventilation, in both monochorionic and dichorionic pregnancies. 
 
Publication bias and small studies effect 
Funnel plots found a slight asymmetry for stillbirth outcome in dichorionic pregnancies 
(Peter's test p-value = 0.037) consistent with the finding that smaller studies are published if 
they show higher stillbirth rates. We found no more significant asymmetries for neonatal 
death outcome.  
 
Discussion 
We observed a consistent increase in the risk of stillbirth, and a decrease in risk of neonatal 
deaths, with advancing gestation in both monochorionic and dichorionic twin pregnancies. In 
monochorionic twin pregnancies, the increase in the cumulative risk of stillbirth when 
awaiting delivery beyond 36+6 weeks gestation appears to outweigh the reduction in neonatal 
deaths for the same period. In dichorionic twins, this phenomenon was observed at 37+6 
weeks. Our meta-analysis of twin pregnancies has provided comprehensive mortality and 
morbidity estimates required for decision-making on the timing of delivery. The rates of 
neonatal outcomes in twin gestations delivered early preterm provide crucial information on 
the prognosis.  
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We have undertaken the largest systematic review to-date with robust methodology, on 
stillbirths and neonatal outcomes in twin pregnancies. In addition to the stillbirth risk at each 
gestational week, we provided risk estimates of the other equally important consequence of 
early delivery, namely neonatal death. Furthermore, this is the first review to provide 
chorionicity and gestational age-specific neonatal morbidity estimates in twin pregnancies. 
The included studies were all published within the last ten years.  
 
A large proportion of our data were obtained from cohorts embedded within randomised 
studies, thereby improving the quality of the data. The sharing of unpublished data and 
individual patient data by authors has allowed us to provide the mortality and morbidity 
estimates at weekly intervals, in comparison to the commonly available published data in two 
weekly epochs. We specified the gestational timeframes to reduce bias from varied lengths of 
follow-up. We minimised heterogeneity by excluding studies without clear details on the 
exclusion of twin pregnancies that were complicated by twin-to-twin transfusion syndrome. 
Our sensitivity analyses enabled us to assess the risks in pregnancies uncomplicated by 
congenital abnormalities, and fetal growth restriction. 
 
Our findings were limited by elective delivery policy after 37 and 38 weeks gestation in most 
studies. This may have underestimated the risk of stillbirth in the last epoch due to the 
reduced available sample size near term. Although we observed an increased prospective risk 
of stillbirth than neonatal death beyond 36 weeks in monochorionic pregnancies, the 
differences were not statistically significant. This was due to the gradual decline in the 
number of pregnancies available for analysis, which may be attributed again to elective 
delivery near term. Most studies did not provide details on whether stillbirth was diagnosed 
antenatally or at birth. However, given the policy of regular ultrasound for fetal monitoring in 
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most units, we expect the interval between diagnosis and delivery to be short. Variations in 
the intensity of antenatal surveillance, mode and timing of delivery of twins, policies between 
studies and centres, may have influenced the outcomes.277 
 
Exploring the small study effects that we observed for monochorionic twin pregnancies 
outcomes, this could be due to selective reporting, the included published studies showing 
good outcomes and small sample sizes. Although we included data on women from 34 
weeks' gestation onwards from the randomised trials, it is possible that women who had an 
earlier stillbirth would not be in the analysis.  
 
We have taken a pragmatic approach by including all twin pregnancies uncomplicated by 
twin-to-twin transfusion syndrome. We were unable to provide separate estimates for 
individual causes of neonatal mortality, or for elective and emergency deliveries. The results 
did not vary after excluding pregnancies complicated by fetal growth restriction, one of the 
main indications for emergency delivery. We only focused on short-term neonatal morbidity 
due to the paucity of data.278, 279 Our analysis of risks as stillbirths per pregnancy and the 
neonatal outcomes per woman delivered, could not distinguish between those pregnancies 
with a single or double adverse outcome. This is especially relevant in monochorionic twin 
pregnancies when a stillbirth in one twin increases the risk to the other twin.  
 
Primary studies,238, 248, 258, 280, 281 systematic reviews,237 and guideline bodies1, 41 were limited 
in their interpretation of evidence on the optimal timing of delivery in twin pregnancies due 
to the paucity of data and methodological inadequacies. Firstly, they have compared the risks 
of stillbirth in twin pregnancies at various gestational epochs with those at (or) near term. 
These comparisons were made without considering the inherent longitudinal design with 
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women repeatedly observed during the pregnancy. 282 Secondly, some studies made risk 
estimations using survival analysis (Kaplan-Meier method) that was not appropriate. Delivery 
was not considered as a competing event for the outcome of stillbirth and may have 
overestimated the risk. 283Thirdly, studies did not provide gestational age-specific pooled 
estimates for significant neonatal morbidity.237, 284 Fourthly, the recommendations were 
mainly driven by the risks of fetal death.42, 237 Finally, the risks of fetal death in twins were 
not assessed beyond 36 weeks gestation, and the rationale behind the choice of the gestational 
ages for elective delivery is unclear.1 
 
Existing large epidemiological studies on perinatal outcomes in twins have been limited as 
population selection is broad with unclear details on chorionicity and the definition of 
uncomplicated monochorionic pregnancies.285, 286 
 
Some current recommendations offer expectant management of uncomplicated dichorionic 
twin pregnancies until 38+0-6.287, 288 Based on our findings; this poses a risk of additional 8.8 
perinatal deaths compared to delivery a week earlier. Although we observed a change in the 
direction of risk difference with more stillbirths than neonatal deaths beyond 36 weeks in 
monochorionic twin pregnancies, the observed difference was not statistically significant. 
The variation in policies for management of monochorionic twin pregnancies, with some 
advocating delivery as early as 34+0-6 weeks,287, 288 have contributed to the fall in the number 
of pregnancies available for analysis in later gestation. Based on our findings, there is no 
clear evidence to recommend early preterm delivery routinely before 36 weeks in 
monochorionic pregnancies. The information on risks provided in twin pregnancies will 
complement the ongoing national and international efforts to reduce the rates of stillbirths289 
and unexpected neonatal complications in babies born near term.  
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Preterm delivery in twin pregnancies is common with about 10% delivery before 32 weeks. 
The estimates on early preterm neonatal mortality and morbidity from this study provides 
crucial information to counsel mothers on the risks of early preterm delivery.290-292 Our work 
has fulfilled the unmet needs in this area, where current estimates on the predicted probability 
of survival of newborns, especially early preterm twins, are based on extrapolated data from 
small samples and do not take into account the effects of chorionicity.293 Although we did not 
incorporate economic evaluation in our review, avoiding early delivery has the potential for 
huge savings to the healthcare system, by up to $70,000 per infant.280 
 
The feasibility of a definitive randomised trial on optimal timing of delivery in twin 
pregnancies is low since huge numbers would be needed to assess outcomes. 228, 254Individual 
patient data (IPD) meta-analysis will allow us to assess the effect of factors such as 
monitoring of the fetuses, the level of newborn care, and mode of delivery on outcomes. 
There is a need to study the effects of delivery before 37 weeks and the loss of a co-twin in 
monochorionic pregnancies on long-term infant neurodevelopment. 279, 294,295 
 
CONCLUSION 
There appears to be a no additional gain in survival when pregnancy was prolonged beyond  
37 weeks and 6 days in dichorionic twin pregnancies. For monochorionic twin pregnancies, 
the risk differences were not statistically significant at any gestational age. Decisions on the 
timing of delivery will need to take into account the magnitude and precision of the benefit 
achieved by reducing stillbirths against the risks of neonatal mortality and morbidity from 
planned early delivery.  
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In this section, I have undertaken a systematic review of prediction models in obstetrics 
to provide an overview on the development process, performance and clinical 










CHAPTER 6.1: DEVELOPMENT AND CLINICAL APPLICABILITY OF 
PROGNOSTIC MODELS IN OBSTETRICS: A SYSTEMATIC REVIEW 
Abstract 
Objective: Pregnant mothers and their babies are at risk of adverse outcomes in pregnancy. 
The ability to predict the probability of a specified outcome empowers maternity caregivers 
to offer individualised risk counselling, and to target appropriate management stratified by 
the mother’s risk status. 
Methods: We searched the electronic database MEDLINE from inception until July 2012 
without language restrictions, for studies reporting the development of a prediction model in 
obstetrics. Studies were included if the model included three or more predictors. Two 
independent reviewers identified full texts and selected studies for inclusion in the review; 
data extraction and quality assessment were performed by four independent reviewers. 
Results: We included 177 studies from 10,152 citations that described the development of 
263 obstetric prediction models for 40 different outcomes. The obstetric conditions for which 
the models were most commonly developed to predict were pre-eclampsia (69), preterm 
delivery (63), mode of delivery (22), and small for gestational age neonates (10). Internal and 
external validation was reported for 21.7% (57/263) and 8.7% (23/263) of the prediction 
models. Discrimination and calibration of the models were calculated in 62.7% (165/263) and 
17.5% (46/263) respectively. 
Conclusion: The development of obstetric prognostic research models is increasing. There is, 
however, a distinct lack of appropriate validation of existing models and little guidance on 






Prognostic research in medicine has garnered much attention over the last decade.296, 297 Each 
patient wants to know his or her own prognosis. Understanding the prognostic factors that 
can accurately predict the development of conditions or complications contributes towards a 
better understanding of each condition or disease and its pathogenesis. It empowers clinicians 
to move away from the one-size-fits-all counselling and treatment to providing individualised 
outcome prediction. Treatment strategies on health outcomes can be stratified.  
 
Prediction models enable delivery of personalised medicine in various ways. Examples 
include an alert such as a screening tool to decide which patients require immediate medical 
care; using the model to predict outcomes (such as survival or complications) for the 
individual patient in order to better counsel or guide decision making; using the model on a 
larger scale to streamline resources so that they can be focussed more upon the ‘high risk’ 
patients.298-301   
 
To date, the most widely used prediction models in obstetrics were developed back in the 
1950s-1960s, and they include the Bishop score to assess cervical ripeness before and during 
induction of labour and the Apgar score for the need of immediate neonatal care.49, 50 There is 
currently no overview of the prediction models that have been developed and published in the 
field of obstetrics. Recently, the PROGRESS framework48, 296, 297, 302 highlighted standards 
and recommendations on the conduct of prognostic research and criticised the external 
validity and clinical applicability of many published models in other specialties. 
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We undertook a systematic review of the literature to provide an overview of the published 
prediction models in obstetrics, their performance and clinical applicability. 
  
Methods 
We conducted the review in compliance with PRISMA guidelines.65 We defined a prediction 
model as a model that could be used to estimate risks for individual patients or to distinguish 
groups of patients at different risks, based on three or more predictor variables. Obstetric 
conditions were restricted to those that could develop from diagnosis of pregnancy to 6 
weeks’ postpartum.  
Identification of studies and study selection 
The MEDLINE database was searched using the PubMed platform from inception to July 
2012 without language restrictions. The search strategy was developed to capture terms 
related to women, pregnancy and obstetric conditions and prognostic research modelling in 
all stages of development. The full search strategy is presented in Appendix 15. 
Study selection 
Studies were selected in a two-stage process. In the first stage, two independent reviewers 
identified relevant citations from 300 abstracts. The kappa-statistic was calculated for a 
measure of agreement. The subsequent abstracts were screened by one reviewer only. In the 
next stage, we reviewed full texts of selected abstracts for inclusion. The citations were 
divided into four groups, and four reviewers were assigned per group for data abstraction and 
quality assessment. Disagreements were resolved by discussion with another reviewer. 
Where there was more than one publication describing the same prediction model, the most 
recent published study was included. Authors were not contacted to provide further 
information.   
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The inclusion criteria were: a) the primary or secondary aim of the study was to develop a 
prediction model from identified predictor variables; b) the prediction model consisted of at 
least 3 predictor variables; c) the development process of the prediction model was described, 
and d) the prediction model was designed to predict a future outcome. Studies were excluded 
if they involved animal research only; non-obstetric conditions and if they were non-original 
publications such as case reports, case series, reviews, comments, letters, editorials, protocols 
and conference abstracts. 
 
Data were abstracted from each study to assess the study characteristics in addition to 
concepts identified to be important in the development and validation of clinical prediction 
models.303 These included discrimination, calibration, internal validity, external validity, 
prediction rule or score and guidance for the use of the model in practice. (Box 1)  
Box 1 Explanation of important concepts in prediction model development and 
evaluation 
Concept Description 
Discrimination How well a model discriminates between different patients, commonly presented as 
the area under the receiver operating characteristics curve (AUC) or the 
concordance index (C-index). Both the AUC and the C-index provide the 
probability that the model will give a higher probability of the outcome to a patient 
with the outcome than a randomly chosen patient without the outcome, or that the 
patient with the higher probability will have the outcome sooner. 
Calibration The agreement between observed outcomes and prediction.  
Internal validity The process of determining internal validity, or “reproducibility” of the prediction 
model for the underlying population, the setting where the development data 
originated from. Techniques include apparent validation (model performance is 
directly assessed in the development data), split-sample validation or cross-
validation (the sample is (randomly) divided, part of the data is used to develop the 
model and the part that was not used for development is used to evaluate 
performance) and bootstrapping (bootstrap samples are drawn with replacement 
from the original study sample, reflecting the drawing of study samples from the 
underlying population. Each sample is used to develop and evaluate the model, the 
difference in performance of the model between the bootstrap sample and the 
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original sample indicates the ‘optimism’ of the model that arises since model 
parameters are optimized for the sample).  
External validity The process of determining external validity, or “generalizability” of the prediction 
model for populations that are similar to, or related to, the development sample 
population. External validation can be performed by the same investigators who 
developed the model, for example in patients more recently attending for care 
(temporal) or in another hospital or centre (geographical) but is preferably done by 
other, fully independent investigators.  
Prediction rule or score The format in which the prediction model is presented and that can be used to 
calculate risks for individual patients or groups of patients. Ideally, for a logistic 
regression model the intercept and regression coefficients would be reported, and 
for a Cox model the baseline survival and regression coefficients (regression 
formula). Alternatives include a nomogram (a graphical presentation of the model 
with lines for scoring points for each predictor and a line to obtain risk from the sum 
of points), a score chart, and a table with predictions for certain groups based on 
combinations of predictor variables. 
  
Permission granted to reproduce this box from American Journal of Obstetrics and 
Gynecology, Elsevier. Licence number 399160443071.  
 
Results 
Study identification  
From 10,152 citations, we included 177 studies describing the development of one or more 
obstetric prediction models in this systematic review.57, 304-474 A flowchart of the study 
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Citations Identified From Electronic Databases (n = 10,512) 
Articles Excluded After Evaluation 
of Abstracts (n = 9893) 
Full Text Articles Assessed for Eligibility (n = 259) 
Articles Excluded (n = 82) 
 Not obstetrics (n = 10) 
 Not prognostic or model with <3 
predictors (n = 55)  
 Duplicate (n = 5) 
 Unable to translate from Russian/ 
Chinese (n = 7) 
 Full text not available (n = 5) 
Studies Included in Review (n = 177)  
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There were 263 models for 40 different outcomes and the years of publication ranged from 
1976 to 2012. The number of obstetric prediction models that have been published has 




Figure 6.2 Cumulative number of published papers describing prediction models and 
externally validated models  
 
Permission granted to reproduce this figure from American Journal of Obstetrics and 
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Prediction Model Development 
The 263 obstetric prediction models were developed to predict 40 different outcomes. These 
included hypertensive disorders in pregnancy, preterm delivery, gestational diabetes mellitus, 
fetal growth and birthweight, labour and delivery, breech to cephalic presentation, fetal loss, 
complications of pregnancy and delivery (placenta praevia, placental abruption, postpartum 
haemorrhage, shoulder dystocia, birth trauma, anal sphincter injury, thrombosis) and 
combined adverse maternal outcome. Study characteristics including study design, 
population, type of model, statistical power, discrimination and calibration of the model, and 











































































































































































The most common conditions or outcomes the models were developed to predict were: pre-
eclampsia (69/263, 26%), preterm delivery (63/293, 24%), mode of delivery (22/263, 8%), 
gestational hypertension (11/263, 4%) and small for gestational age neonate (10/293, 3%). 
For the remaining 35 outcomes, fifteen outcomes had one published prediction model; 
fourteen outcomes had two or three prediction models developed, and six outcomes had 
between four to ten models developed each. (Table 6.1.1)   
 
Internal validation of the prediction model was performed in 57 models (21.7%) and external 
validation in only 23 models (8.7%). Details of model calibration were presented for 46 
models (17.5%) and details of discrimination for 165 models (62.7%). A prediction formula, 
rule or score that could be used by others was reported for 164 models (62.4%) and guidance 
for clinical use was discussed for 29 (11.0%). 
 
For the five most prevalent outcomes, detailed characteristics of the developed models are 
presented in Table 6.1.2. The most common study design was a prospective cohort study (50-
70%); a multivariable logistic regression model was used to develop the majority of models 
(54-69%) and the number of events per variable in the model (an indication of study sample 
size) was ≥10 for 49-82% of models for the five outcomes. 
  
There were very few models that had been externally validated, with only 7.2% (5/69) for 
predicting pre-eclampsia and 6.3% (4/63) for predicting preterm delivery and none for the 
other outcomes. Of those models that presented discrimination values in the development 
phase, the area under the receiving operator curve (AUC) was high (0.90-1.00) for 25% of 
the pre-eclampsia prediction models and 24% of the preterm delivery prediction models. At 
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the external validation phase, the AUC of models ranged between 0.70 to 0.85 for pre-
eclampsia prediction models and 0.65 to 0.72 for preterm delivery prediction models. The 
newer prediction models published more recently did not have better performance than the 
older models for predicting pre-eclampsia and preterm delivery. None of these models is 




The number of prediction models in obstetrics has significantly increased over the past 
decade. Recognised standards for prognostic research studies are not universally followed in 
study design, conduct, analysis and reporting in the development of obstetric prediction 
models. Despite the abundance of published obstetric prediction models, only a handful has 
been externally validated, and none are in clinical practice.  
There are many possible reasons as to why prediction models are not in use.  Firstly very few 
prediction models progress beyond the stage of development and hence the evidence for 
improvement in clinical outcomes with the use of these models is lacking. Prior to external 
validation, these models are only specific to the population that they were developed in.  
External validation is important to verify the robustness and generalizability of the developed 
model before the model can undergo impact studies to see if they improve clinical outcomes.   
The obstetric conditions that have received the most attention in the development of 
prediction models are pre-eclampsia and preterm delivery. This may well be explained by the 
high prevalence of these two conditions in the pregnant population and the significant 




The ability to predict pregnant women most at risk of these conditions enables potential 
preventative strategies, such as aspirin in pre-eclampsia and elective cerclage or progestogens 
to prevent preterm delivery; timely intervention to optimise outcomes such as administration 
of steroids and transfer to an appropriate unit when delivery is anticipated and expediting 
delivery in pre-eclampsia; and streamlining resources to focus intensive surveillance on the 
pregnant women most at risk.  
 
Strengths and limitations 
This is the first systematic review of prediction models in obstetrics, providing a 
comprehensive overview of the quality of these models by assessing the development 
process, validation, reporting and clinical applicability. We used recent recommendations to 
robustly assess each prediction model.51 We limited our search to one online database and as 
such may have missed studies.   
 
Obstetric prediction models in practice 
The lack of prediction models in wide clinical practice may be due to multiple reasons. 
Firstly many of the models were extremely complex and may not be suitable for daily clinical 
use without computer support as may often be the case in clinical practice.475 Secondly, 
external validation of the prediction models is crucial to confirm that the model is clinically 
applicable and has face validity.476 Thirdly our review highlighted the poor reporting of 
prediction models regarding methodology and guidance on clinical applicability.477-480  
Obstetric prediction models that are based on routinely measured indices are more likely to 
be incorporated into clinical use, as long as they demonstrate acceptable performance. A few 
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of the models identified in our review incorporated additional biomarkers and expensive 
tests370, 402, 407 which may deter from routine clinical use.  
With regard to external validation of the prediction model, this is of crucial importance; 
prediction models should, ideally, be externally validated by independent investigators and 
compared to competing models. Surprisingly only 10% of the prediction models that we 
identified were external validated. For the remaining 90%, nearly half of the studies did not 
present sufficient data (prediction rule or score) to enable future researchers to perform 
external validation.  
There should be clear recommendations for how the models should be used in practice. Only 
10% of the identified models discussed guidance for future use. Also, the sheer number of 
prediction models on the same outcomes suggests a lack of awareness of other prediction 
models. Researchers should check if there is an existing prediction model for that specific 
outcome with acceptable performance.  
The quality of reporting on all stages of model development was poor (62%) with a 
consistent lack of transparency and detail, rendering it difficult for the clinician or researcher 
to fully appreciate the potential of the model. The advent of the PROGRESS framework that 
provides a consensus on reporting guidelines hopes to improve the quality and robustness of 
the underlying methodology in prognostic research. Although methodological quality is of 
less importance when a model shows good performance at external validation, the likelihood 
of developing a generalizable model (which is not overfit) is higher when recommended 
statistical methods have been used.303  
Prediction model development is costly and can be complex. There is a huge amount of 
potential in this area but it is still unclear whether the obstetric prediction models identified in 
this review will be able to impact upon clinical practice and improve patient outcomes. 
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Researchers with an interest in this area, should appreciate that developing the prediction 
model is only one of the steps. External validation, transparent reporting, clear guidance on 
the use of the model in practice, comparing the model to existing models and assessing the 
impact of the prediction model on health outcomes are crucial steps that need to be taken.  
Accurate prognostication and timely intervention have great potential to improve patient 
outcomes. We have identified pitfalls through this systematic review and hope that future 
obstetric prediction models may focus more on building on the previous efforts, collaboration 
with other research groups, without ignoring the next important steps of validity assessment 
and clinical impact.  
 
My contribution to this work: 
Study selection in stages 1 and 2, data extraction as second reviewer, analysis, first draft of 










CHAPTER 6.2: AN OVERVIEW OF CHALLENGES IN DEVELOPING 
OBSTETRIC PROGNOSTIC MODELS IN PRE-ECLAMPSIA AND POTENTIAL 
SOLUTIONS 
Abstract 
Objective: Prognostic models in obstetrics are often developed from large observational 
studies. The precision in selecting the ‘best’ predictors for a prognostic model is affected by 
many factors, in particular by a phenomenon called ‘treatment paradox’. The aim of this 
review is to provide an overview of prognostic modelling challenges in obstetrics with 
potential solutions.  
Methods: Using an example of developing a prognostic model for predicting complications 
of early-onset pre-eclampsia (PREP), a symposium was convened of experts in prognosis 
medicine and obstetrics to discuss and propose potential solutions for treatment paradox and 
other prognostic modelling challenges. 
Results: For treatment paradox, seven potential solutions are proposed: standardisation of 
treatment, removal of factors that influence treatment decisions, inclusion of interaction 
between ‘decision to treat’ as a predictor, use of treatment as a modifying factor, treatment 
becoming an outcome, use of a propensity score and inverse probability weighting.  
Conclusion: Prognostic models have the potential to be powerful tools but much caution is 
needed in each part of the development process.  
 
Citation from work: 
Cheong-See F, Allotey J, Marlin N, Mol BW, Schuit E, Ter Riet G, Riley RD, Moons K, 
Khan KS, Thangaratinam S. (2016) Prediction models in obstetrics: understanding the 
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Prognostication in obstetrics can be complex with both maternal and fetal outcomes to 
consider. From the first encounter taking the booking history from the pregnant woman, we 
predict the probability of a pregnancy being low or high-risk and dictate the level of antenatal 
surveillance and need for further tests or intervention. For example, we use prognostic 
research to predict the probability of developing maternal conditions such as gestational 
diabetes mellitus, the probability of developing adverse maternal and fetal outcomes in such 
conditions and to provide estimates of long-term outcomes in the baby according to the 
timing of delivery. 
In many obstetric situations, the prognostic factors undergo changes due to the advancing 
pregnancy or as a result of an intervention that cannot be ethically withheld. An effective 
treatment may prevent a certain proportion of adverse outcomes from occurring, making a 
good prognostic factor and factors associated with it (that triggered the treatment in the first 
place) look poorer in their predictive performance, a phenomenon that can be described as 
‘treatment paradox’.53, 481 These pose significant challenges in the development of prediction 
models in pregnancy-specific conditions such as pre-eclampsia. 
 
Prediction of complications in women with pre-eclampsia: 
Numerous models for prediction of pre-eclampsia have been developed, but very few for 
prediction of complications.57 Early-onset pre-eclampsia is a pregnancy-specific condition 
characterised by hypertension and proteinuria before 34 weeks of gestation. Currently, the 
only cure for pre-eclampsia is delivery. In women with early onset pre-eclampsia, the 
mainstay of management is to make the best balance between preventing maternal 
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complications by expediting delivery compared to increasing the risk of neonatal 
complications from early delivery. An accurate prediction model will help identify women 
and babies most at risk of adverse outcomes to guide clinical treatment decisions and 
outcomes. 
 
PREP study: an example 
PREP is an ongoing study, funded by National Institute of Health Research, Health 
Technology Assessment (NIHR HTA) for the development and validation of a prediction 
model in women admitted with early onset pre-eclampsia (PREP).482 The primary objectives 
are twofold: firstly to develop and internally validate a prediction model to assess the risk of 
any adverse maternal outcome at 48 hours and at any time until discharge, and secondly to 
externally validate the model through two external datasets of patients diagnosed with early 
onset pre-eclampsia. The secondary objective is to assess the risk of adverse fetal and 
neonatal outcomes at birth and at any time until discharge and to summarise the unadjusted 
and adjusted prognostic ability of a set of candidate predictor variables. 
The candidate predictor variables consist of patient symptoms, signs and investigations 
performed in clinical practice and pre-selected based on previous research and expert 
consensuss.57, 84, 86-88, 184 These include symptoms of a headache, epigastric pain, chest pain, 
vomiting, visual disturbance; signs such as hyperreflexia, papilloedema; history of pre-
existing medical conditions; maternal age; and results from investigations such as uterine 
artery Doppler flow, umbilical artery Doppler flow, cardiotocography, estimated fetal weight 
by ultrasound, blood pressure, serum uric acid, level of proteinuria, liver function tests, renal 
function tests, pulse oximetry, and the gestational age at which early onset pre-eclampsia was 
diagnosed.  
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The maternal outcomes include mortality, Glasgow Coma Scale <13, eclampsia, stroke, 
cortical blindness, posterior reversible encephalopathy syndrome, reversible ischaemic 
neurological deficit (RIND), retinal detachment, need for positive inotropic support, 
myocardial infarction, acute renal impairment, need for renal dialysis, hepatic dysfunction, 
hepatic haematoma or rupture, platelet count <50,000 without blood transfusion, need for 
transfusion of blood products, need for >50% oxygen for more than one hour or intubation 
and pulmonary oedema. 
The study is designed to examine ten candidate predictor variables for inclusion into the 
prediction model. We convened a meeting of experts in the field of prognosis and 
obstetricians to deal with the unique challenges in the development of the model. 
Currently, in clinical practice, interventions such as anti-hypertensives are usually given 
based on blood pressure readings that are also evaluated as a predictor in the model 
performance. If the predictor (blood pressure) is accurate in prediction of high(er) risk, this 
will lead to underestimation of how informative this particular (and correlated) prognostic 
indicators will be, as the intervention it triggers leads to non-occurrence of the outcome in 
some patients. This weakens the predictor-outcome association and natural outcome 
(prevalence). This is often the case when the decision to treat, is based on the levels of one or 
more (candidate) prognostic factors that are also being considered for the prediction model.  
 
Interventions that contribute to treatment paradox in pre-eclampsia prediction modelling 
Women with a diagnosis of pre-eclampsia have varied management depending on the clinical 
findings. Mothers with mild disease routinely do not receive any treatment. Interventions 
such as oral antihypertensives are given for moderate hypertension and women with severe 
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hypertension receive parenteral antihypertensives and magnesium sulphate anticonvulsant to 
prevent or to treat eclampsia. Delivery is often expedited at a preterm gestation in the latter 
group.38  
 
Solutions for treatment paradox 
The PREP prognostic group discussed in detail the various options to overcome the bias in 
the estimates of the prediction model for complications in pre-eclampsia due to treatment 
paradox. 
 
Standardisation of treatment  
By ensuring that the predictor in question is collinear with treatment and this is standardised 
across all patients, either the test or treatment can be chosen as a predictor. By incorporating 
treatment into the care plan, this renders the study similar to that of an observational 
effectiveness study where we are not interested in the treatment effect parameter but the 
linear predictor.  
For example, the prediction model developed to predict postoperative nausea and vomiting 
has included the intervention into the prediction model.483 In the PREP study, although the 
commencement of antihypertensives and magnesium sulphate anti-convulsant are 
standardised by NICE guidelines in the UK, the decision to deliver an early preterm baby is 
influenced primarily by the clinician. This phenomenon, therefore, limits the applicability of 
this model.  
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Remove all factors that influence treatment decisions 
The bias due to treatment effect can be minimised by removing all the prognostic factors on 
which the decision to intervene is based, and substitute these for an alternative prognostic 
factor. This may be possible in certain settings, for example, Cukjati et al. substituted wound, 
patient and treatment attributes by weekly follow-ups of the wound healing process to predict 
wound healing rate.484 However, in women with pre-eclampsia, this poses a problem, as 
clinicians rely on more that one predictor such as blood pressure, symptoms, haematological 
and biochemical indices to decide on treatment. Removal of these will severely restrict our 
ability to include any meaningful predictors in the model. This means that at the baseline, we 
cannot predict anything. There are also too many factors associated with the decision to treat 
to identify a single alternative prognostic factor.  
 
Include interaction between decision to treat factors as a predictor 
The decision to treat can, by itself, be considered a prognostic factor itself. The variable 
‘decision to treat’ is not an independent prognostic factor, but is often based on a 
combination of one, or more of the other prognostic factors, and carries a risk of false 
treatment effect. By accounting for the interaction between ‘decision to treat’ as a predictor 
and each of the other prognostic factors, these biases can be overcome. When more 
interactions are involved, the more complex this approach becomes, and a larger sample size 
is needed.  
 
Use treatment as a modifying factor for the prognostic factor 
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If the treatment is specific for one prognostic factor, e.g., high blood pressure and 
administration of antihypertensive medication, we can combine the two as a single prognostic 
factor. There needs to be standardised care, however with no variation in the treatment, i.e., 
the same antihypertensive medication and the same threshold before treatment is given.  
 
Treatment becomes an outcome 
If treatment may likely have led to avoidance of an outcome, those who received treatment 
can be regarded as having had an outcome. In this situation, we decided to include decision 
for delivery prior to 34 weeks as an outcome. 
For example, in a prediction model to predict the risk of exacerbations in chronic obstructive 
pulmonary disease, the focus was not on mortality as an outcome but instead need for 




The propensity score is the probability of treatment being assigned to an individual based on 
observed pre-treatment variables.485 We can designate propensity scores to each individual in 
the study taking into account the interactions with other prognostic factors (on which the 
decision to treat was based): 
P (probability of receiving treatment) = α + βaX1BP + βbX2proteinuria +...  
                                                = Propensity Score 
This can be fitted into the prediction model by logistic regression: 
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ln (p/1-p) = α + β1BP + β2proteinuria + β3Propensity Score + β4treatment 
This prediction model will not, however, be clinically helpful as the decision to treat was not 
based on prior knowledge of the propensity score.  
 
Inverse Probability Weighting 
We can use the propensity scoring and take it one step further with inverse probability 
weighting. By taking into account each patient’s propensity score, we can assign a different 
weight for the contribution of that particular patient towards the logistic model analysis and 
development of the prognostic model. Patients who received little or no treatment (and hence 
less treatment effect) should carry more weighting compared to the patients who had a high 
probability of being treated. An example of the use of this method was in determining the 
effectiveness of potent antiretroviral therapy (HAART) in preventing AIDS and death.486 
Sterne et al. used weighted Cox proportional hazards models to create a statistical population 
in which the probability of being treated was unrelated to prognostic factors (i.e., the placebo) 
compared to the population who received HAART.  
 
Clinical interpretation of prediction models in women with pre-eclampsia 
There is currently an internally validated prediction model for adverse maternal outcomes in 
pre-eclampsia known as PIERS (Pre-eclampsia Integrated Estimate of Risk).57 The model 
uses six prognostic indicators: gestational age at diagnosis, maternal symptoms of chest pain 
or dyspnoea, oxygen saturation on air, platelet count, serum creatinine level and aspartate 
transaminase level. Although it is well known that severe high blood pressure is associated 
with adverse maternal outcomes, this was surprisingly not found to be a predictor in the 
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PIERS final model. This may be due to dilution of the predictive accuracy by treatment 
paradox. Those with higher blood pressure are given treatment X, and this causes a reduction 
in outcome risk: thus there may be little or no observed association between blood pressure 
and outcome, but only as treatment has removed this association. The issue is that if a 
prediction model that did not include blood pressure was used to decide treatment decisions, 
it might overlook patients with high blood pressure.  
The consensus views were limited to the specific topic of prognostic modeling for 
complications in pre-eclampsia. Although many of these proposed solutions to overcome 
treatment paradox were unsuitable for the PREP model, they have been used in other 
prediction models as mentioned and may be useful in the design of other clinical prediction 
models.   
There are however many clinical conditions similar to pre-eclampsia, with the same difficulty 
of a multiplicity of different managements and the different timings of those managements, 
combined with the fact that management choice is not independent of the other predictors in 
the model.  It is therefore very difficult to control for this treatment paradox.    
Another option to consider is to incorporate the clinician’s decision-making process into the 
prognostic modeling, by prospectively gathering data when a management decision is made 
about the specific predictors that resulted in the clinician’s decision to ‘treat.  This can give 
us a better understanding and insight into which variables are less informative as predictors, 




Obstetric prognostic research modelling faces many challenges. Any models developed in the 
circumstances outlined above would offer rules that might benefit from assessment of their 
impact in future research.    
 
PREP Prognostic Meeting Expert Panel 
Joost Akkermans PhD student, LUMC, Netherlands; John Allotey, PREP Study Co-
ordinator, Women’s Health Research Unit, QMUL; Gary Collins, Senior Statistician, Head of 
Prognosis Methodology, Oxford; Thomas Debray, Assistant Professor, UMC Utrecht; Julie 
Dodds, Senior Clinical Trials Manager, Women’s Health Research Unit, QMUL; Fiona Fong, 
Clinical Research Fellow, Women’s Health Research Unit, QMUL; Wessel Ganzevoort, 
Consultant Obstetrician & Gynaecologist, AMC, Amsterdam; Bill Grobman, Professor of 
Obstetrics & Gynaecology, Maternal Fetal Medicine, Chicago; Henk Groen, Professor in 
Epidemiology, UMC, Groningen, Netherlands; Richard Hooper, Senior Statistician, PCTU, 
QMUL; Miland Joshi, Statistician, PCTU, QMUL; Brenda Kazemier PhD student, AMC 
Amsterdam; Sally Kerry, Senior Statistician, PCTU, QMUL; Khalid Khan, Professor of 
Women’s Health and Clinical Epidemiology, PREP Chief Investigator, Women’s Health 
Research Unit, QMUL; Emily Kleinrouweler PhD student, AMC Amsterdam; Nadine 
Marlin, Statistician, PREP Study Statistician, Primary PCTU, QMUL; Ben Mol, Professor of 
Obstetrics & Gynaecology and Clinical Epidemiology, AMC Amsterdam; Carl Moons, 
Professor of Clinical Epidemiology, UMC Utrecht, Netherlands (PREP Study Senior 
Statistician); Gerben ter Riet, Professor in Clinical Epidemiology, AMC, Amsterdam; 
Ewelina Rogozinska, PhDstudent, WHRU QMUL; Ewoud Schuit Epidemiologist, UMC 
Utrecht, Netherlands; Jonathan Sterne, Professor of Medical Statistics & Epidemiology, 
Bristol; Shakila Thangaratinam, Professor of Maternal and Perinatal Health, PREP 
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Project/Obstetric Lead, WHRU QMUL; Richard Riley, Reader in Biostatistics, PREP Study 
Senior Statistician, Birmingham  
 
 
My contribution to the work 
Invited the experts and convened the meeting, set the discussion points to address with the 






CHAPTER 7: CONCLUSION 
Summary of findings 
This chapter provides an overview of the results of the individual chapters. Detailed results 
are included in the individual chapters. I have addressed the objectives pre-specified in my 
thesis. In collaboration with my co-reviewers listed in Chapter 4, we have quantified the 
strength of association of genetic and clinical predictors of complications in pre-eclampsia; 
we have estimated the level of increasing fetal and neonatal risks with advancing gestation in 
mothers with multiple pregnancy (uncomplicated monochorionic and dichorionic twin 
pregnancies). We have identified the components of maternal and fetal composite outcomes 
for reporting in primary studies on pre-eclampsia management and we have provided an 
overview of methodological deficiencies in prognostic research in obstetrics, and explored 
methods to address the challenges.  
 
The table below summarises the objectives of my thesis and a column of findings from the 
chapters of this thesis. 
Chapter 
Number 
Population Intervention or Test Outcome(s) Research Design Results 
Objective A: In women with pre-eclampsia:  
- What maternal genetic factors predispose women with pre-eclampsia to complications in pregnancy? 
- How accurate are the routinely performed tests in women with pre-eclampsia to predict maternal and fetal 
complications? 
- What outcomes are clinically relevant for evaluation in clinical trials on late onset pre-eclampsia? 
4 Women with pre-
eclampsia 









I found an increased risk 
of severe pre-eclampsia 
with thrombophilic 




associations with severe 
pre-eclampsia for F5 
(rs6025) (OR 1.90, 95% 
CI 1.42, 2.54), F2 
mutation G20210A 
(rs1799963) (OR 2.01, 
95% CI 1.14, 3.55) and 
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leptin receptor (LEPR) 
polymorphism 
(rs1137100) (OR 1.87, 
95% CI 1.43, 2.45).  










Systematic review Urine protein creatinine 
ratio is sensitive for 
many maternal and fetal 
outcomes (eclampsia. 
81%, 95% CI 52-95%; 
placental abruption 
81%, 95% CI 64-91%; 
caesarean delivery 97%, 
95% CI 26-100% and 
pulmonary oedema 
85%, 95% CI 71-93%). 
No single test showed 
high sensitivity and 
specificity. 










Delphi survey  The final maternal 
composite outcome 






haemorrhage or need for 
positive inotropic 
support, HELLP 
syndrome and placental 






ventilator support and 
neurological outcomes 
such as cystic 
periventricular 
leukomalacia and grade 
III/IV intraventricular 
haemorrhage. 
Objective B: In women with multiple pregnancy 
- What are the prospective risks of stillbirth, neonatal morbidity and mortality associated with delivery at different 
gestational ages in monochorionic and dichorionic twin pregnancies?  
- What is the optimal timing of delivery with the lowest stillbirth risk and serious neonatal adverse outcomes in 
uncomplicated monochorionic and dichorionic twin pregnancies? 










Systematic review In dichorionic twin 
pregnancies, the delay in 
delivery by a week 
(until 38 weeks) led to 
an additional 8.8 
perinatal deaths per 
1000 pregnancies (95% 
CI 3.6 to 14.0 /1000) 
compared to the 
previous week. In 
monochorionic 
pregnancies, there was a 
trend towards increase 
in stillbirths compared 
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with neonatal deaths 
after 36 weeks, with an 
additional 2.5 per 
1000 perinatal deaths, 
which was not 
significant (95% CI -
12.4 to 17.4/1000,).  
Objective C: In the field of prognostic research in obstetrics 
- What is the quality of published obstetric prognostic models and what is their clinical usefulness? 
- What are the methodological challenges of developing and applying an obstetric prognostic model and how can they 
be overcome? 




Systematic review 177 studies reported the 
development of 263 
prediction models for 40 
different outcomes. 
Internal and external 
validation was reported 
for 21.7% and 8.7% of 
the prediction models. 
The assessment of 
discrimination and 
calibration was carried 
out for 62.7% and 
17.5% of the models 
respectively. The 
clinical applicability of 
the model was discussed 
in 11%.  
3 Women with 
early-onset pre-
eclampsia 




Consensus  Methods to minimise 
bias from treatment 
paradox where it is not 
possible or unethical to 
withhold treatment 
include, standardisation 
of treatment, predictor 
substitution, treatment 
as a predictor, treatment 
as an outcome and use 
of propensity scores.  
 
Predictors for adverse outcomes in pre-eclampsia 
In pre-eclampsia, my systematic review showed that maternal thrombophilic genes are 
associated with an increased risk of severe pre-eclampsia. The review of accuracy of tests to 
predict complications in pre-eclampsia demonstrated that no single test is adequately 
sensitive or specific enough to predict pre-eclampsia complications. Urine PCR, uric acid, 
mean arterial pressure >105mmHg and symptoms of headache were highly sensitive in 
predicting eclampsia. The sensitivity was high for urine PCR in predicting Caesarean 
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delivery. The specificities were highest for blood pressure greater than 160/110mmHg in 
predicting eclampsia, placental abruption, pulmonary oedema, Caesarean delivery and 
hepatic dysfunction. Symptoms of nausea, abdominal pain and visual disturbances were 
highly specific in predicting eclampsia. For fetal outcomes, urine PCR was highly sensitive in 
predicting small for gestational age fetus and fetal death. I identified and prioritised the 
complications associated with pre-eclampsia that are considered to be useful outcomes to 
address in trials involving women with late onset pre-eclampsia and developed composite 
maternal and neonatal outcomes for this purpose. The composite outcomes consisted of 
maternal death, eclampsia, placental abruption, major obstetric haemorrhage, pulmonary 
oedema, need for positive ionotropic support, stroke, reversible ischaemic neurological 
deficit (RIND) or HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome 
for the maternal components; neonatal death, respiratory distress syndrome (RDS) needing 
ventilation, grade III/IV intraventricular haemorrhage or cystic periventricular leukomalacia 
for the neonatal components. 
 
Risks of stillbirth and neonatal deaths in women with multiple pregnancy 
I undertook the largest systematic review to-date on the prospective risks of stillbirth, 
neonatal morbidity and mortality by gestational week of delivery in uncomplicated 
monochorionic and dichorionic twin pregnancies. The risks of stillbirth significantly 
outweighed the risk of neonatal death by 38 weeks in dichorionic pregnancies. My work also 
provided estimates of neonatal morbidity and mortality before 37 weeks gestation to inform 
mothers expecting or experienced early preterm birth involving twin pregnancies.  
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Prognostic research in obstetrics 
My work assessed the the quality of reporting in published obstetric prognostic models. The 
systematic review assessed characteristics in model development and validation and found 
areas of methodological deficiency. There was little guidance on their clinical applicability.  
 
The methodological challenge of dealing with treatment paradox in the context developing 
and applying a prognostic model in early onset pre-eclampsia was addressed and solutions 
proposed through expert consensus.  
 
Strengths and limitations 
The questions set in this thesis were addressed through systematic reviews, Delphi survey 
and expert consensus. For the systematic reviews, these were performed with robust 
methodology as appropriate. For the systematic review of maternal genotype and severe pre-
eclampsia, I adhered to the HuGENet systematic review criteria specific to genetic 
association studies. The reviews were prospectively registered, sensitivity analyses were 
planned a priori and extensive literature searches were done in the relevant databases without 
language restrictions to avoid missing studies. Study selection, data extraction and study 
quality assessments were all done in duplicate to minimise bias.  Meta-analyses was 
performed where appropriate, assessing for heterogeneity.  
 
For the systematic review of prospective risk of stillbirth, we took a new statistical approach 
to consider delivery as a competing event to avoid the methodological inaccuracies of 
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overestimating risk as done in previously published papers on this subject. Publication bias 
was assessed and explanations sought.  
 
Limitations were based mainly on heterogeneity of data. For the HuGENet review, there was 
inconsistent and poor reporting of genotyping methods, success rates, blinding of staff, any 
deviation from the Hardy Weinberg equilibrium and unclear exclusion criteria for adequate 
quality assessment. Furthermore there was a lack of consistency in definition of the 
phenotype of pre-eclampsia and severe pre-eclampsia. 
There was also paucity in reported data for the studies assessing accuracy of tests to predict 
pre-eclampsia complications, studies varied in the description of populations, tests, thresholds 
and outcomes. This heterogeneity rendered it difficult to combine all relevant data and 
therefore meta-analysis was not possible.  
 
Implications for clinical practice 
There is sufficient evidence now to justify incorporating genetic data into clinical algorithms 
for risk assessment for pre-eclampsia and evaluation of this approach in clinical trials to 
improve accuracy of screening programmes. Clinicians should be aware that the individual 
test performances are very limited for accurately predicting adverse maternal and fetal 
outcomes in pre-eclampsia. Elevated PCR was sensitive for predicting small for gestational 
age and fetal death. Women with uncomplicated dichorionic pregnancies should be offered 
delivery by 37 weeks, and delivery considered for monochorionic pregnancies by 36 weeks 
to prevent stillbirth. 
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Clinicians should be aware of the limitations in published prognostic models. External 
validation of models is required before they could be introduced to clinical practice. There 
should be clear recommendations for how prognostic models should be used in practice. Only 
10% of the identified models from the systematic review of obstetric prognostic models 
discussed guidance for future use. Also, the sheer number of prognostic models on the same 
outcomes suggests a lack of awareness of other prognostic models. Researchers should check 
if there is an existing prognostic model for that specific outcome with acceptable 
performance. 
Implications for research 
The identification of further genetic risk factors for complications of pre-eclampsia is an 
important research objective, which may lead to early identification and targeted 
management of high-risk pregnancies. Future work is needed to evaluate the potential 
benefits of integrating genetic data with clinical information to develop more accurate 
predictive algorithms. Future randomised controlled trials on women with mild or moderate 
pre-eclampsia, especially at late preterm gestations, should consider the maternal and 
neonatal composite outcomes we developed and their components to assess the effect of 
intervention. Additional input from the patient and public is needed in the development of 
composite outcomes.  
 
The feasibility of a definitive randomised trial on optimal timing of delivery in twin 
pregnancies is limited, given the huge numbers needed to assess outcomes. Individual patient 
data (IPD) meta-analysis will allow us to assess the effect of factors such as monitoring of the 
fetuses, level of newborn care, and mode of delivery on outcomes. There is a need to study 
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the effects of delivery before 37 weeks and the loss of a co-twin in monochorionic 
pregnancies on long-term infant neurodevelopment.  
 
Researchers with an interest in prognostic research in the field of obstetrics should appreciate 
that developing the prediction model is only one of the steps. External validation, transparent 
reporting, clear guidance on use of the model in practice, comparing the model to existing 
models and assessing the impact of the prediction model on health outcomes are crucial steps 







Table 4.1.1 Genotoype by function or system involved of the studies included in the 
meta-analysis of relationships between maternal genotype and severe pre-eclampsia 
Function/system 
involved 
Gene Genotype rs number 
Immune related CD28 
Cytotoxic T lymphocyte antigen 4 (CTLA-4) 
Inducible costimulator (ICOS) 
 
Interferon gamma (IFNγ) 
Interleukin 10 (IL-10) 
 
 
Interleukin 6 (IL-6)  
Intracellular Adhesion Molecule-1 (ICAM-1) 
Killer immunoglobulin like receptor 
(KIR3DL2) 
Mannose Binding Lectin (MBL2) 












































Vasoactive genes Aldosterone synthase gene 
Angiotensin converting enzyme (ACE) 
Angiotensinogen gene 
Angiopoietin 1 (ANGPT1)  






















CX3CR1 (CX3 chemokine receptor 1) 
 
E-selectin 
Guanine nucleotide binding protein (GNB3) 
NADPH*/NADH oxidase† gene 
P-Selectin 




























































Other Dopamine B hydroxylase (DBH) 
Epithelial sodium channel β subunit 
Estrogen Receptor α (ESR1) 
 
Fas  
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Table 4.1.2 Subgroup analysis for F5 (Factor V Leiden) rs6025  
Permission granted to reproduce this table from American Journal of Epidemiology, Oxford 















2.04 (1.45, 2.86, 34%) 
1.56 (0.92, 2.64, 2%) 









1.91 (1.34, 2.73, 17%) 




<100 cases (19) 





1.97 (1.35, 2.85, 40%) 





Table 4.1.3 Subgroup analysis for F2 (Factor 2 Prothrombin G20210A) rs1799963 
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2.18 (1.22, 3.91, 0%) 
0.49 (0.04, 5.58, 0%) 









2.77 (1.36, 5.65, 2%) 








Table 4.1.4 Epidemiologic credibility based on Venice criteria 
Permission granted to reproduce this table from American Journal of Epidemiology, Oxford 
University Press. Licence number 3998150855655 
 
Criteria Amount of 
evidence 






F5 rs6025 A B C Weak evidence 
F2 rs1799963 B A C Weak evidence 




Table 4.3.1 Criteria for developing maternal composite outcome 
Permission granted to reproduce this figure from Hypertension in Pregnancy, Informa 
Healthcare. Licence number 3998151234270.  
 







of each other  




















Pre-eclampsia is one of the 
major contributors to maternal 
death from organ dysfunction 
Yes 
 
No No Yes 
Neurological       
Eclampsia 
Occurrence of 






Cerebral vasospasm and 
vasoconstriction associated with 
increased blood pressure, 
cerebral oedema or infarction  
Yes 
 
Yes Yes Yes 





Endothelial dysfunction in 
severe pre-eclampsia leads to 
leaky capillaries resulting in 
pulmonary oedema with 













Pre-eclampsia is a risk factor 
for major obstetric 
haemorrhage, mainly 
postpartum haemorrhage from 
consumptive coagulopthy and 
endothelial dysfunction  
Yes 
 













Severe hypertension due to 
vasoconstriction may be 
difficult to control with 
parenteral anti hypertensives. 





Yes Yes Yes 
Other       
HELLP 
syndrome 
1-2% Microangiopathic haemolysis 
and platelet consumption, and 
hepatocellular damage from 
periportal or focal parenchymal 
necrosis result in HELLP 
syndrome (haemolysis, elevated 
liver enzymes and low platelets) 
Associated with major maternal 









Inadequate placentation due to 
absence of spiral artery 
remodelling leads to abruption 
placentae resulting in increased 
maternal morbidity 




Table 4.3.2 Criteria for developing neonatal composite outcome 
Permission granted to reproduce this figure from Hypertension in Pregnancy, Informa 
Healthcare. Licence number 3998151234270.  
 















Neonatal death 0.7% Late preterm newborns 
are at higher risk of 
mortality during the 
neonatal period and later 
Yes 
 
No No Yes 









Delayed lung fluid 
clearance and relative 
deficiency of surfactant 
can result in increased 
incidence of RDS. 
Yes 
 
Yes Yes Yes 







0.5% Prematurity is a risk 
factor for brain injury as 
the last part of fetal 
development is an 
intensive period for 
cerebral growth and 
development. PVL and 





Yes Yes Yes 
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Table 5.1 Prospective risk of stillbirth and neonatal death risk in weekly intervals in uncomplicated 







No. of stillbirths 






No. of neonatal deaths 










Dichorionic twin pregnancies (15 studies) 
34+0 - 6 21/17,830 1.2 (0.7, 1.8) 12/1,742 6.7 (3.3, 13.5) -5.8 (-10.4, -1.2) 
 
35+0 - 6 12/15,470 0.8 (0.4, 1.4) 15/2,611 4.6 (2.4, 8.7) -5.1 (-8.7, -1.6) 
 
36+0 - 6 18/11,824 1.5 (0.9, 2.4) 12/4,238 3.2 (1.7, 5.9) -1.3 (-3.6, 0.9) 
 
37+0 - 6 23/6,824 3.4 (2.1, 5.1) 10/5,141 2.2 (1.1, 4.3) 1.2 (-1.3, 3.6) 
 
38+0 - 6 28/2,633 10.6 (7.1, 15.3) 5/2,581 1.5 (0.7, 3.3) 8.8 (3.6, 14.0) 
 
39+0 - 6 7/752 9.3 (3.8, 19.1) 3/751 1.1 (0.4, 2.6) 3.8 (-8.5, 16.1) 
 
Monochorionic twin pregnancies (13 studies) 
34+0-6 2/2,149 0.9 (0.1, 3.4) 4/247 12.1 (4.2, 34.3) -15.6 (-40.4, 9.1) 
 
35+0 - 6 5/1,797 2.8 (0.9, 6.5) 2/367 8.1 (3.4, 19.3) -2.4 (-17.6, 12.8) 
 
36+0 - 6 6/1,325 4.5 (1.7, 9.8) 3/534 5.4 (2.2, 13.3) -1.5 (-14.4, 11.4) 
 
37+0 - 6 7/730 9.6 (3.9, 19.7) 4/532 3.6 (1.2, 11.1) 2.5 (-12.4, 17.4) 
 
38+0 - 6 2/264 7.6 (0.9, 27.1) 0/307 2.4 (0.6, 10.3) 7.0 (-19.7, 33.7) 
 
a Risk of neonatal death was computed by multilevel logistic regression model (see text). 
b Individual studies risk differences were pooled by a fixed-effect model meta-analysis (see text).  
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Table 5.2 Individual neonatal morbidity outcomes in monochorionic and dichorionic twin pregnancies after 34 weeks gestation  
Gestational age  Assisted ventilation Hypoxic Ischaemic 
Encephalopathy or neonatal 
seizures 
 





 n/N Risk 
(95% CI) 
n/N Risk  
(95% CI) 
n/N Risk  
(95% CI) 
n/N Risk  
(95% CI) 
n/N Risk  
(95% CI) 
Monochorionic 7 studies  3 studies 
 
 10 studies  11 studies  9 studies 
34+0-34+6 23/143 112.9 
(49.2-238.3) 






35+0-35+6 17/206 61.3 
(26.9-133.3) 






36+0-36+6 14/289 32.4 
(13.7-74.3) 






37+0-37+6 7/308 16.9 
(6.6-42.5) 






38+0-38+6 2/163 8.7 
(3.0-25.0) 






Dichorionic 9 studies  2 studies  13 studies  11 studies  11 studies 





























































Risks are per thousand deliveries. 
n = number of adverse outcomes 
N = number of women delivered in that 1 weekly gestational epoch 
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Total  262 57 
(21.8%) 
23 (8.8%) 46 (17.6%) 165 (63.0%) 164 
(62.6%) 
29 (11.1%) 
Pre-eclampsia 69 14 5 8 60 45 9 
Eclampsia 1 1 0 0 1 0 0 
Gestational hypertension 11 0 0 0 7 9 0 
Preterm delivery 62 15 4 7 34 33 7 
Gestational diabetes 9 2 1 1 8 3 2 
Insulin treatment for gestational 
diabetes 
1 0 0 1 0 0 0 
Abnormal glucose challange test 1 0 1 0 1 1 0 
Congenital malformations 3 0 0 0 3 0 0 
Small for gestational age neonate 10 3 0 2 6 5 0 
Intra-uterine growth restriction 4 2 0 1 1 4 1 
Birthweight 3 1 2 0 1 3 1 
Low birthweight 1 1 0 1 0 1 0 
Vaginal birth after caesarean 9 4 2 3 4 6 0 
Induction of labour 1 0 0 0 1 1 0 
Successful induction of labour 8 0 0 0 2 4 0 
Mode of delivery 22 3 5 10 14 18 4 
Time to delivery 1 0 0 0 0 0 0 
Successful external cephalic version 4 3 3 3 1 4 3 
Vaginal delivery after external 
cephalic version 
1 1 0 0 1 1 0 
Mode of delivery in breech 
presentation 
1 0 0 0 0 0 0 
Intra-amniotic infection and/or 
inflammation 
2 0 0 2 2 2 0 
Clinical infection 1 1 0 0 1 1 0 
Histologic signs of infection 1 0 0 0 1 0 0 
Miscarriage or early fetal loss 2 0 0 0 1 1 0 
Stillbirth 3 0 0 0 2 2 0 
Perinatal mortality or survival 2 1 0 1 0 2 0 
Poor perinatal outcome 2 0 0 0 0 1 0 
Hypertensive disorders (combined) 
or placenta-related complications 
3 1 0 0 3 1 0 
Placenta praevia 1 0 0 0 1 0 0 
Shoulder dystocia 3 1 0 1 2 1 0 
Birth trauma 3 0 0 0 0 3 0 
Placental abruption 4 0 0 0 1 3 0 
Postpartum haemorrhage 3 1 0 1 1 2 0 
Anal sphincter injury 1 0 0 0 0 1 0 
Thrombosis 2 0 0 0 0 2 2 
Maternal complications of attempted 
VBAC 
2 0 0 0 2 0 0 
Maternal complications of pre-
eclampsia 
2 2 0 2 2 1 0 
Combined adverse pregnancy 
outcome 
1 0 0 0 0 1 0 
Short cervix 1 0 0 1 1 1 0 
Higher CRH levels 1 0 0 1 0 1 0 
Permission granted to reproduce this table from American Journal of Obstetrics and 
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Table 6.1.2: Characteristics of prediction models for the five most frequently predicted 
outcomes 
 









Number of models 69 63 22 11 10 
Study design 
- prospective cohort 
- retrospective cohort 
- crossectional cohort 
- case-control 





































Type of model 
- logistic 
- multinomial regression 
- bayesian 
- linear regression 
- artificial neural network 
- other 















































Sample size: number of events per variable 
- ≥10 




























Internal validation presented 
- bootstrapping 
- split sample 
- crossvalidation 







































External validation presented 
- in the same paper 






















Calibration of the model presented 
- calibration plot 
- calibration table 



























Discrimination with the model (AUC) 
- 0.90 – 1.00 
- 0.80 – 0.90 
- 0.70 – 0.80 
- 0.60 – 0.70 
- < 0.60 




































Prediction rule presented 
- regression formula 
- risk score 
- risk table or curve 
- nomogram 





































Clinical guidance: treatment or decision 
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Appendix 1 Search strategy for maternal genotype on complications of pre-eclampsia 
(Medline) Permission granted to reproduce this supplementary file from American Journal 
of Epidemiology, Oxford University Press. Licence number 3998150855655 
Pre-eclampsia and genotype 
1. pre-eclampsia.mp. or exp Pre-Eclampsia/ 
2. (pre-eclampsia or preeclampsia or pre eclampsia).mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
3. 1 or 2 
4. exp Genes/ 
5. exp Genetics/ 
6. exp Alleles/ 
7. allel*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
8. exp Polymorphism, Genetic/ 
9. polymorph*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, protocol supplementary concept, rare disease supplementary concept, unique identifier] 
10. 4 or 5 or 6 or 7 or 8 or 9 
11. 3 and 10 
 
Complications 
1. cardiovascular disease.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, protocol supplementary concept, rare disease supplementary concept, unique 
identifier] 
2. exp Cardiovascular Diseases/ 
3. hypertension.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, protocol supplementary concept, rare disease supplementary concept, unique identifier] 
4. exp Hypertension/ 
5. high blood pressure.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, protocol supplementary concept, rare disease supplementary concept, unique 
identifier] 
6. exp Pre-Eclampsia/ 
7. exp Recurrence/ 
8. 6 and 7 
9. (recurren* and (pre-eclampsia or pre eclampsia or preeclampsia)).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
10. 1 or 2 or 3 or 4 or 5 or 8 or 9 
11. exp Fetal Growth Retardation/ 
12. ((fetus or foetus or foetal or fetal or intrauterine) and growth and (restrict* or retard*)).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier] 
13. (infant, small for gestational age or small for gestational age).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
14. (small for date infant or small for date baby or small for date newborn or small for date 
neonate).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
15. 11 or 12 or 13 or 14 
16. exp Abortion, Spontaneous/ 
17. exp Abortion, Habitual/ 
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18. (miscarriage or spontaneous abortion or pregnancy loss).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
19. exp Fetal Death/ 
20. ((fetal or foetal or fetus or foetus or intrauterine) and (death or loss)).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
21. exp Infant Mortality/ 
22. exp Stillbirth/ 
23. ((newborn or neonat*) and death).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
24. stillbirth.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
25. or/16-24 
26. limit 25 to humans 
27. exp Infant, Premature/ 
28. exp Obstetric Labor, Premature/ 
29. exp Premature Birth/  
30. ((preterm or pre-term or pre term or premature) and (delivery or birth or labour or labor)).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier] 
31. or/27-30 
32. limit 31 to humans 
33. venous thromboembolism.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
34. exp Venous Thromboembolism/ 
35. deep vein thrombosis.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, protocol supplementary concept, rare disease supplementary concept, unique 
identifier] 
36. exp Venous Thrombosis/ 
37. dvt.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
38. exp Pulmonary Embolism/ 
39. pe.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
40. or/33-39 
41. limit 40 to humans 




Appendix 2 Study characteristics of the included studies for meta-analysis of relationships between maternal genotype and severe pre-
eclampsia (8 pages) Permission granted to reproduce this figure from American Journal of Epidemiology, Oxford University Press. Licence 
number 3998150855655 
Author (year) Study design  Country/ 
ethnicity 











or mean no of 
pregnancies) 

















Severe PE 90 (severe PE) 


















Other: Oliguria, cerebral or visual 
disturbances, pulmonary oedema, epigastric 
or right upper quadrant pain, impaired liver 
function, thrombocytopenia. 
Criteria: PE plus ≥1 above criteria and 
diagnosis after 20 weeks gestation. 
English 
Agorastos (2002) Case-control Greece Severe PE 16 (severe PE) 
100 (controls) 
No details No details No details BP>160/110mmHg 
Proteinuria: >5g/24hour 




Case-control Iran Severe PE 70 (severe PE) 




29 (mild PE) 
27.4 (controls) 
No details No details BP>160/110mmHg 
Proteineuria:> 3+ protein 
Headache, visual disturbance, upper 
abdominal pain, elevated serum creatinine, 
transaminase; thrombocytopenia and fetal 
growth restriction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Criteria: Combination of clinical signs and 
laboratory tests (not specified how).  
English 





63 (severe PE and 
eclampsia) 
44 (controls) 




66% (severe PE 
and eclampsia) 
41% (controls) 
No details BP and proteinuria as per Davey and 
MacGillivray criteria.  
Criteria: Above and requiring obstetric 
intensive care or placental abruption, FGR 
requiring delivery before 36 weeks, 




















or ≥ 2+ dipstick 
SGA: Birthweight <10th customized centile 
adjusted for maternal height, weight, parity, 
ethnicity, gestational age at delivery and 
infant sex. 
English 






Eclampsia 73 (eclampsia) 
92 (PE)  
18 (eclampsia) 
23 (PE) 
No details 37 (eclampsia) 
37 (mild PE) 
Criteria of report of National High Blood 







39 (controls) BP >140/90mmHg 
Proteinuria: ≥0.3g protein in 24 hours. 
Eclampsia defined as occurrence in a woman 
with pre-eclampsia of seizures that cannot be 
attributed to other causes. 





HELLP 32 (HELLP) 
111 (controls) 
31.6 (controls) 66% (controls) 39.3 (controls) HELLP: LDH>600iu/l or serum bilirubin 
>1.2mg/dl or schistocytes in peripheral 





















48 (severe PE) 
46 (controls) 








BP: SBP≥170mmHg or DBP≥110mmHg 
Proteinuria:≥300mg/24h or 2+ dipstick 
Other: ALT≥55iu/l); FGR<3rd centile; visual 
disturbances; persistent headaches; epigastric 
pain; eclampsia; elevated creatinine 
(≥0.09mml/l); hyperreflexia; clonus; 
thrombocytopenia (≤100,000cels/uL); 
disseminated intravascular coagulation 
Criteria: PE plus >1 of the above 
English 





37 (severe PE) 
11 (eclampsia) 
163 (controls) 
28 (controls) No details No details BP: DBP ≥110mmHg 
Proteinuria: ≥2+ dipstick 
Criteria: Above. 
English 
Derzbach (2007) Case-control Hungary/ 
Caucasian  
 
Severe PE 126 (severe PE) 
106 (controls) 
 
28 (severe PE) 





33 (severe PE) 
40 (controls) 
BP≥ 160/110mmHg 
Proteinuria: 3+ or 4+ protein or ≥5g/24 hr. 
Criteria: Above only. 
English 












BP: ≥160 systolic or ≥110 diastolic 
Proteinuria: ≥5g/24 hr or ≥3+ 
Other: Oliguria, cerebral or visual 
disturbances, pulmonary edema or cyanosis, 
epigastric or right upper quadrant pain, 
impaired liver function, thrombocytopenia, 













Severe PE 158 (severe PE) 
403 (controls) 
No details No details No details BP: ≥160/110mmHg 
Proteinuria: 3+/ 4+ dipstick or ≥5g/24 hr 
Other: Oliguria, cerebral or visual 
disturbances, pulmonary oedema or 
cyanosis, epigastric or right upper quadrant 
pain, impaired liver function of unclear 
etiology, thrombocytopenia. 
Criteria: Above and ≥1 of other features. 
English 
















Other: platelets <100,000mm3; HELLP 
(hemolysis, high AST and platelets 
<100,000mm3); eclampsia defined by ACOG 
bulletin no 219 as pre-eclampsia with central 




Criteria: ≥1 of the above 





















168 (severe PE) 
53 (FGR) 
679 (controls) 




1.9 (All cases) 
2.4 (controls) 
36 (all cases) 
38.9 (controls) 
BP >160/110mmHg 
Proteinuria: >3g/24 hr 
Other: Eclampsia, epigastric pain, visual 
symptoms, oliguria, dyspnoea.  
Criteria: BP and proteinuria above with or 
without other features.  
FGR: Birthweight minus ≥ 2SD for 
gestational age (customised for sex and 
Finland) 
English 
Kaiser (2004) Case-control Australia / 
Caucasian  
Eclampsia 51 (eclampsia)  
122 (PE) 
100 (controls) 
No details  No details No details BP ≥ 140/90mmHg or SBP≥25mmHg rise or 
DBP ≥15mmHg rise above baseline 
Proteinuria: ≥2+ or ≥0.3g in 24 hours  
Eclampsia – Above BP and proteinuria with 
convulsions or unconsciousness in perinatal 
period 
English 
Kaur (2005) Prospective 
case control 










35.9 (all cases) 
35.8 (controls) 
BP ≥140/90mmHg 
Proteinuria: >0.3g/l  
Eclampsia – Above BP and proteinuria and 
presence of convulsions. 
English 
Kim (2001) Case-control USA/ 
White 
Severe PE  
HELLP 
169 (severe PE) 
18 (HELLP) 
253 (controls) 
No details No details No details BP: SBP>160mmHg or DBP >110mmHg 
Proteinuria: >5g/24hr or 4+ dipstick 
Other: platelets<100,000/ml; oliguria 
<400ml/24h; pulmonary edema, elevated 
AST or ALT 
Criteria: ≥1 of the above 
HELLP: platelets <100,000/ml; AST and 
ALT >70iu/l; total bilirubin >1.2mg/dl, 
LDH≥600u/l and evidence of 
microangiopathic hemolytic anemia on 
smear. 
English 
Kim (2010) Cohort  Korea/ Asian Severe PE  
Fetal growth 
restriction 
117 (severe PE)  
57 (FGR)  
47 (PE) 
182 (controls) 







36.4 (All cases) 
39.1 (controls) 
BP: DBP>110mmHg 
Proteinuria: >5g.24 hr or ≥3+ dipstick 
Other: pulmonary oedema, seizures, oliguria, 
thrombocytopenia or severe central nervous 
system symptoms  
Criteria: Above BP and proteinuria and ≥1 
other features.  
English  
Kobashi (2000) Case-control Japan/ Asian Severe PE 73 (All cases) 
215 (controls) 
 
30.4 (All cases) 
29.8 (controls) 















Severe PE 34 (severe PE) 
110 (controls) 
29 (all cases) 
28 (controls) 
92% (all cases) 
62% (controls) 
32.2 (all cases) 
39.5 (controls) 
BP: >160/110mmHg 
Proteinuria: >5g/24 hr 







of haemolysis, high serum aminotransferase 
concentrations and platelet count of 
<100,000; eclampsia defined by ACOG 
bulletin no 219 as pre-eclampsia with central 
nervous involvement leading to seizures. 







Severe PE 63 (severe PE) 
126 (controls) 










Other: platelets<100,000mm3; HELLP 
(hemolysis, elevated enzymes and low 
platelets); eclampsia defined by ACOG 
bulletin no 219 as pre-eclampsia with central 
nervous involvement leading to seizures. 











No details 37 (eclampsia) 
38.7 (PE) 
39.7 (controls) 
Eclampsia: Occurrence of convulsions 
during pregnancy or in first 10 days 
postpartum with at least two (within 24 
hours after convulsions) thrombocytopenia, 
increased aspartate aminotransferase 
concentration.  
English 
Kwon (2012) Case-control Korea/ Asian Severe PE 27 (severe PE) 








 0% (controls) 
35.6 (all cases) 
38.9 (controls) 
BP: DBP ≥110mmHg  
Proteinuria: ≥2+ dipstick 
Other: headache, visual disturbances, upper 
abdominal pain, oliguria, convulsion, 
elevated creatinine, thrombocytopenia, 
marked liver enzyme elevation and 
pulmonary oedema. 
Criteria: BP or proteinuria above (in context 
of pre-eclampsia) and ≥ 1of other features. 
English 
Lim (2010) Case-control Korea/ Asian Severe PE 
Fetal growth 
restriction  



















BP: DBP≥110 ≥5g/24h  
Proteinuria: ≥3+ dipstick 
Other: severe central nervous system 
symptoms, pulmonary oedema, seizures, 
oliguria, thrombocytopenia. 
Criteria: BP or proteinuria and ≥1 other 
feature.  
























BP: SBP ≥160mmHg or DBP ≥110mmHg  
Proteinuria: >300mg/24hr  












 27.4 (controls)  




Proteinuria: >3+ dipstick 
Other: headache, visual disturbances, upper 
abdominal pain, elevated serum creatinine 
English 
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and transaminase, thrombocytopenia, fetal 
growth restriction 
Criteria: ≥1 of the above in the context of 
pre-eclampsia.  
Mando (2009) Case-control Italy / 
Caucasian 











Other: multi organ involvement eg FGR or 
HELLP syndrome (platelet count 
<100,000mm3, serum aminotransferase level 
≥70IU/l, total bilirubin <1.2mg/dL or LDH 
≥600IU/l. 
Criteria: Above BP and/or proteinuria or BP 
above and ≥1 other feature.  
English 
Molvarec (2007) Case-control Hungary/ 
Caucasian 
Severe PE 119 (severe PE) 
103 (controls) 











Criteria: BP and proteinuria above after 20 
weeks and resolving by 12 weeks 
postpartum. 
English 




















PE: BP ≥140/90 and proteinuria: ≥0.3g/24h 
HELLP– serum AST >70 U/l, LDH >600 
U/l, platelets <150,000/uL 
FGR – birthweight <10th centile (population 
based) 
English 
Muetze (2008) Case-control Germany/ 
Caucasian 









Serum haptoglobin <0.3g/l or LDH >300iu/l, 




Nagy (1998) Case-control Hungary/ 
Caucasian 





No details 39.4 (controls) BP: ≥160/90mmHg 
Proteinuria: ≥1g/24h 
Criteria: BP and proteinuria above.  
English 









77 (HELLP)  
79 (severe PE) 
















Criteria: Above BP and proteinuria after 20 
weeks gestation. 
HELLP – AST or ALT >70 IU/l, LDH>600 
IU/l, platelets ≤100x10^9/l 
English 
Pazarbasi (2007) Case-control Turkey/ 
Caucasian 







No details 33.7 (severe 
PE)  
34.7 (PE) 38.7 
(controls) 
Eclampsia – Pre-eclampsia (BP 
≥140/90mmHg and proteinuria ≥0.3g/24h) 
and convulsions or unconsciousness in 
perinatal period 
English 
Pegoraro (2004) Case-control South Africa/ 
Afro-
caribbean 
Eclampsia  120 (eclampsia) 
204 (PE) 
338 (controls) 
No details No details No details Eclampsia – Pre-eclampsia (BP ≥140/90 
and proteinuria ≥1+ dipstick) and seizures 




Case-control Brazil/ Latin 
American 






1.9 (All cases) 
2.51 (controls) 
No details BP >160/110mmhg 
Proteinuria: ≥0.3g/24h 
Other: abnormal platelet count, abnormal 
liver enzymes, maternal symptoms 









 55 (HELLP) 













34.9 (PE)  
Eclampsia – Tonic-clonic seizures occurring 
in a hypertensive pregnancy 
(BP>140/90mmHg), with or without 
proteinuria. 
HELLP – haemolysis (LDH>600 U/l or 
serum total bilirubin 1.2mg/dl), elevated 
liver enzymes (AST and/or ALT >40 U/l) 













22.88 (PE)  
28.83 (controls) 
No details No details BP >160/110mmHg 
Proteinuria: ≥0.3g/24h 
Other: renal disease, hepatic abnormalities, 
neurological and haematological 
modifications, persistent headaches, 
thrombocytopenia. 






















BP: ≥160 systolic or ≥110 diastolic 
Proteinuria: ≥5g/24 hr or ≥3+ 
Other: Oliguria, cerebral or visual 
disturbances, pulmonary edema or cyanosis, 
epigastric or right upper quadrant pain, 
impaired liver function, thrombocytopenia, 












No details 30 (HELLP)  
33 (PE) 
 
HELLP – haemolysis LDH>600iu/l, 
elevated liver enzymes, AST and ALT 
>70IU/l and low platelet count <100 x 109/l. 
English 




















1.55 (controls)  
No details BP ≥160/100mmHg 
Proteinuria ≥0.3g/24h 
Other: persistent headache, visual 
disturbance, epigastric pain, platelet count 
<100 x109/l, serum glutamicoxaloacetic acid 
transaminase >50u/l, oliguria, hyperreflexia. 
Criteria: BP and proteinuria above and ≥1 of 
other features. 
English 
Rigo (2006) Case-control Hungary/ 
Caucasian  
 
Severe PE 124 (severe PE) 
104 (controls)  
28 (severe PE) 








Criteria: BP and proteinuria above, no 
urinary tract infection and new onset 
hypertension after 20 weeks. 
English 
Roberts (2004) Case-control South Africa/ 
Afro-
caribbean  
Eclampsia 120 (eclampsia)  
204 (PE) 




1 (All cases) 
1 (controls) 
34.4 (All cases) 
38.8 (controls) 
BP ≥140/90mmHg 
Proteinuria: ≥1+ protein 
Eclampsia defined as presence of seizures 
for the first time in pregnancy together with 
associated pre-eclampsia or early onset pre-
eclampsia. 
 English 












39.5 (controls) Proteinuria: ≥0.3g/24h 
FGR defined as birthweight below 10th 
percentile for gestation age and gender 
















Working Group on High Blood Pressure in 
Pregnancy definition. 
HELLP defined as after 20 weeks gestation 
platelet <100,000 cells/uL, evidence of 
microangiopathic haemolytic anemia (with 
increased LDH >200 units/l), elevated 
hepatic enzymes (ALT and AST >20 units/l) 

























Proteinuria: ≥1g/24h or ≥2+ 
Other: biochemical, haematological 
disturbances (thrombocytopenia, elevated 
liver enzyme level) or clinical signs 
(epigastric pain, visual disturbances). 
Criteria: BP and ≥1 of other features or 
severe proteinuria. 
English 
Stepanian (2009) Case-control France/  
Caucasian or 
Maghrebian 
Severe PE 148 (severe PE) 
36 (PE) 
185 (controls) 
31.1 (All cases) 
31.2 (controls) 
11% (All cases) 
5.5% (controls) 
No details BP ≥160/110mmHg 
Proteinuria ≥5g/24h 
Other: oliguria, cerebral or visual 
disturbances, pulmonary oedema or 
cyanosis, epigastric pain, impaired liver 
function AST≥70iu/l, thrombocytopenia 
platelets <100 x 109/l, fetal growth 
restriction Z-score <-1.88. 
Criteria: ≥1 of above in context of pre-
eclampsia (≥140/90mmHg after 20 weeks 
and proteinuria ≥0.3g/24hr) 
English 
Sziller (2005) Case-control Hungary/ 
Caucasian  
 
FGR 14 (FGR) 
24 (PE) 
89 (controls)  
 
29.8 (All cases) 
30.0 (controls) 





Proteinuria: ≥0.3g/24h  
FGR defined as birthweight below 10th 
percentile for gestation in context of pre-
eclampsia. 
English 
Sziller (2007) Case-control Hungary/ 
Caucasian  
 















HELLP defined as thrombocytopenia 
(<150,000 cells/uL-1), hepatic dysfunction 
(AST or ALT >70iu/l), LDH>600iu/l), 
haemolysis (serum bilirubin >1.2mg/dl). 
English 
Tempfer (2004) Case-control Austria/ 
White 
Severe PE 24 (severe) 
24 (controls) 
29 (severe PE) 
29 (controls) 
0 (severe PE) 
0 (controls) 
38 (severe PE) 
40 (controls) 
BP >160/110mmHg 
Proteinuria: ≥5g/24hr or ≥3+ on dipstick 
(two random samples 4hr apart) 
Other: oliguria, cerebral or visual 
disturbances, pulmonary edema or cyanosis, 




impaired livere function, thrombocytopenia 
and fetal growth restriction. 
Criteria: ≥1 of above features in context of 
pre-eclampsia (SBP≥140mmHg and/or 








severe PE, HELLP, 
eclampsia) 
67 (controls) 
No details No details No details DBP ≥110mmHg 
Proteinuria: ≥0.5g/l  
Criteria: Above BP and proteinuria before 34 
weeks and delivery before 36 weeks or with 
HELLP (LDH>600 U/L, AST or ALT >50 
U/L and platelet count <100 x 109/L) or 
eclampsia irrespective of gestational age of 
fetus.  
English 
Varkonyi (2010) Case-control Hungary/ 
Caucasian  
 
HELLP 75 (HELLP) 







HELLP defined as haemolysis 
(LDH>600iu/l), elevated liver enzymes 
(AST and ALT >70iu/l), thrombocytopenia 






Severe PE  
HELLP 
 
29 (severe PE) 
32 (HELLP) 
61 (controls) 




HELLP defined as hemolysis, elevated liver 
enzymes, low platelets. 
English 
Wang (2011) Cross-sectional 
study 
China/ Asian Severe PE 88 (severe PE) 
17 (PE) 
103 (controls)  
No details  No details No details BP >140/90mmHg 
Proteinuria: ≥0.3g/24h 
No details for ‘severe’ pre-eclampsia 












32.5 (All cases) 
46.7 (controls) 
 
1.4 (All cases) 
2.03 (controls) 
34.7 (All cases) 
No details 
No definitions given or referenced.  English 
Youpeng (2010) Case-control China/ Asian Severe PE 
 
87 (severe PE) 
20 (PE) 










No details BP >140/90mmHg or single DBP 
≥110mmHg 
Proteinuria ≥0.3g/24h 
No definition given for severe PE although 




Case-control China/ Asian Eclampsia  
Severe PE 
19 (Eclampsia)  
49 (severe PE) 
95 (controls)  
26.3 (All cases) 
27.1 (controls) 
 
No details 38.2 (All cases) 
39.5 (controls) 








Appendix 3 Methodological quality assessment for included studies  
















reporting for genotypes 
 
HWE Sample size 
estimation 











No No AGT  
ACE DD  
MTHFR  









Case-control Medium Medium Medium Caucasian 
(Greek) 
(homogenous) 
None for cases.  No  Yes  
 
Not done  No 
Ahmadi, 
2012  
Case-control Medium Low Medium Caucasian 
(Kurdish) 
(homogenous) 




renal disease or any 
collagen diseases. 
No No Not done  No 
Alfirevic, 
2001 
Case-control Low Low Medium Caucasian 
(British) 88% 
Congenital 
anomalies or history 
of 
thromboembolism. 







Low Medium Medium No data Multiple pregnancy, 
multiparous. High 
risk of pre-
eclampsia, small for 
gestational age 
infants or preterm 
birth because of 





















any infection, cancer 








 94-96% for 
controls.  
 
No TNFα rs1800629  
IL6 rs1800795 




TGF β1 codon 10 
rs1982073,  
TGF β1 codon 25 

























systemic diseases.  
No  No Not done  Yes 
(PE) 








None for cases.  No No Not done  No 
de Groot, 
1999  









diseases, cancer, or 
thrombosis before 
first pregnancy. 











No No P selectin Thr715Pro 
(<5 in group), 
 E selectin Ser128Arg 






Deveer, 2012  Cross-
sectional 












MTHFR 1298  























No  No Not done  No 
Gerhardt, 
2005  
Case-control High Medium Medium Caucasian 
(German) 
(homogenous) 
Previous history of 
venous or arterial 
thromboembolic 
disease. Cases - 



























No No LEPR G1019A,  
Leptin PPAR gamma 













delivery, small for 
gestational age, 
venous or arterial 









Yes Factor V Leiden 
(rs6025) (<5 in group) 
 
0.75 No 





chronic renal disease 
or autoimmune 
disorders. 
No No TNFα 307 (rs1800629)  0.70 No 
Kaur, 2005  Prospective 
case control 
High Medium High Asian (India) 
(homogenous) 
Chronic medical 














Kim, 2001  Case-control Medium High Medium Caucasian 
(USA) 
(homogenous) 
None for cases. No No Not done 
Factor V Leiden rs6025 





































Case-control Low Low Medium Other (Israel) None specified for 
cases 
No No Not done 




Case-control Medium Medium Medium Other (Israel) None specified for 
cases 
No No Not done 

























GNB3 C825T (rs5443)  
AGTR1 A1166C 
(rs5186)  
















No ICAM-1 K469E 
(rs5498)  
0.89 No 












































 No No  MTHFR C677T 
(rs1801133) 



























(rs1799963)  0.02 























and renal disease. 
No No Estrogen receptor PvuII 
(rs2234693) 


















and renal disease. 




– PE with 
SGA) 





No No MTHFR C677T 
(rs1801133) 
FVL (rs6025) (<5 in 
group) 
Prothrombin 








( post hoc 
analysis 
(HELLP) 
Nagy, 1998  Case-control High Medium Medium Caucasian 
(Hungary) 
(homogenous) 
No exclusion criteria  No No Unable to calculate  No 






















No. No TNF-α G308A 
(rs1800629) 








Case-control High Low Medium Afro-caribbean 
(Africa) 
(homogenous) 
 No exclusion 
criteria 
No  No Epithelial sodium 
channel beta subunit 



































Percin, 2006  Case-control High  Medium  High  Caucasian 
Turkish 
(homogenous) 








No   No Aldosterone synthase 





Case-control High  High High  Caucasian 
Romanian 
No exclusion criteria No  No Angiotensinogen gene 
M235T (rs699) (<5 in 





Case-control High Low High Caucasian 
Romanian 
(homogenous) 





to affect thyroid 
function. 
 
No No Deiodinase D1 C785T  
 
0.39 No  
Raijmakers, 
2002  
Case-control High  Medium High  Caucasian 
Dutch 
(homogenous) 
No exclusion criteria No No Unable to calculate  No  





renal disease, or 
autoimmune 
disorders 
No No Unable to calculate  No 



















Hypertension in a 
previous pregnancy 
for controls. 
No No ACE (rs4646994) 
Unable to calculate for 
ATR,  

















No SOD3 G172A 
(rs1799895)  
0.68 Yes  
(severe PE)  
(PE with 
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and renal disorder. SGA) 
Schlembach, 
2003  





No  No Unable to calculate  No 
Seremak-
Mrozikiewicz
, 2010  













persisting 12 weeks 
after delivery. 
No  No Factor V Leiden 
G1691A (rs6025), 
Prothrombin G20210A 














reb (3 pairs) 
Accounted for 
ethnicity 
< 20 weeks  
 
















No  Yes 
(negative 
controls) 
Fas gene TNFRSF62 at 
670G>A  
0.164 No 
Sziller, 2007  Case-control Low  Medium  High  Caucasian 
Hungarian 
(homogenous) 





Mannose Binding lectin 
codon 54 (rs1800450) 



































vascular or renal 
disease or diabetes.  






Case-control Medium  Low  High Caucasian 
Hungarian 
(homogenous) 




























Case-control Medium High  Medium  Caucasian 
German 
(homogenous) 
Arterial or venous 
thrombosis, diabetes 
or vascular disease. 





Wang, 2011  Cross-
sectional 
study 





diabetes and chronic 
renal disease 
No  No Killer Immunoglobulin-










No  No Leptin TTTCn,  
LEPR R223Q 
(rs1137101),  


















No  No Adiponectin +45T/G 






















No Dopamine β 
Hydroxylase (DBH) 






Appendix 4 PRISMA checklist for the systematic review of accuracy of individual tests to predict 
complications in women with pre-eclampsia (Part 1/2) 
 
Section/topic  # Checklist item  Reported on page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  79 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
79-80 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  81 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
81 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
69 (82) 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
82 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and date 
last searched.  
82 
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
Reference 
184 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 




10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators.  
82 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
82 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome level), 
and how this information is to be used in any data synthesis.  
82-83 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  83-84 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if 









Appendix 4 PRISMA checklist for the systematic review of accuracy of individual tests to predict 
complications in women with pre-eclampsia (Part 2/2) 
 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
84 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 




Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.  
Appendix 5 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
Figure 
4.2.2 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 




Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
Figure 
4.2.3 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  88 
Figure 
4.2.2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 16]).  
N/A 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
96 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias).  
96-97 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research.  
99-100 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
100 
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Jaiswar, 2011 English, 
India 
Case-control, 
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 223 
Africa singleton LDH 
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Appendix 6 List of maternal and neonatal outcomes considered to be relevant in the 
management of women with mild and moderate pre-eclampsia between 34 and 37 weeks 
of gestation 
 









Posterior reversible encephalopathy 
Haematological - need for transfusion of any blood product 
Hepatic - dysfunction 
Hepatic - capsule rupture 
Hepatic – failure 
HELLP syndrome 
Cardiac - need for positive ionotrope support 
Cardiac - myocardial ischaemia or infarction 
Cardiac - infusion of any third parenteral antihypertensive 
Respiratory - need for intubation 
Respiratory - need for at least 50% FIO2 for >1hr 
Respiratory - pulmonary oedema 
Renal - acute renal insufficiency (creatinine >200uM) 
Renal - need for dialysis 





b. Neonatal outcomes  
Abnormal level of consciousness (coma/stupor) 
Apgars (<4 at 5 min) 
Assessment of neurodevelopmental status at follow-up 
Assisted ventilation (needed for >4hr) 
Assisted ventilation (needed for >24hr) 
Birthweight 
CRIB score (Clinical Risk Index for Babies) 
Special Care - no of days at this level 
High Dependency Care and short term Intensive Care - no of days at this level 
Maximal Intensive Care - no of days at this level 
Death - Early neonatal (within 7 days) 
Death - Late neonatal (within 28 days) 
Feeding – need for parenteral feeding 
Feeding – day of life tolerating feeds 
 228 
Gastrointestinal - Necrotising enterocolitis 
Hypoglycaemia (symptomatic) 
Infection - (sepsis, meningitis) within 72hrs 
Infection – late onset sepsis 
Inotropic support 
Neurological - Cystic periventricular leukomalacia 
Neurological - Grade III/IV intraventricular haemorrhage 
Neurological - Hypoxic ischaemic encephalopathy 
Neurological - Need for brain cooling 
Neurological - Neonatal seizures (>2 before 72hrs regardless of cause) 
NICU - admission at any time 
NICU - length of stay >7 days 
Opthalmological - Stage 3-5 retinopathy of prematurity 
Respiratory - Bronchopulmonary dysplasia 
Respiratory - Respiratory illness requiring admission to hospital during the first year of life 
Respiratory - Respiratory Distress Syndrome 




Appendix 7 Definitions of components of maternal and neonatal composite outcomes 
 
a. Maternal outcomes 
Maternal death Maternal death occurring within six weeks of pregnancy or if later, 
attributable to complications of pre-eclampsia 
Eclampsia Occurrence of a seizure in association with pre-eclampsia 
Pulmonary oedema Clinical diagnosis with X-ray confirmation or requirement of diuretic 
treatment and oxygen saturations on air (SpO2 <95%) 
Need for at least 50% FiO2 for 
more than 1 hour 
Oxygen given at greater than 50% concentration based on local criteria for 
longer than 1 hour 
Need for intubation Intubation may be by ventilation, electric impedance tomography (EIT) or 
continuous positive airways pressure (CPAP). 
Major obstetric haemorrhage Loss of more than 1000ml of blood before or after delivery necessitating 
transfusion of blood or blood products 
Cardiac morbidity - positive 
inotropic support 
The use of vasopressors to maintain a sBP > 90 mmHg or mean arterial 
pressure > 70 mmHg (inotropic support) 
HELLP syndrome  Haemolysis, elevated liver enzymes, low platelet count. Defined as new 
onset of elevated liver enzymes (serum aspartate aminotransferase (AST) 
≥70 U/L or gamma-glutamyltransferase (γGT) ≥70 U/L or alanine 
aminotransferase (ALT) ≥70 U/L and low platelets defined as platelet count 
< 100 x 109/L and either haemolysis, defined by abnormal peripheral blood 
smear or serum lactate dehydrogenase levels (LDH) ≥600 U/L or total 
bilirubin level ≥20.5μmol/L 
Placental abruption Premature separation of a normally located placenta from the uterine wall 
occurring before delivery of the fetus. Diagnosed clinically by evidence of 
retroplacental clot, sonographic visualisation of abruption or vaginal 
bleeding accompanied by non-reassuring fetal status or uterine hypertonicity 
and signs of hypovolaemic shock in the mother.  
 
b. Neonatal outcomes 
 
Neonatal death Death before 28 completed days following live birth.  
Respiratory distress syndrome Clinical presentation of neonatal acute respiratory distress with cyanosis, 
grunting, retractions and tachypnoea, supplemental oxygen requirement and 
admission to the neonatal unit for further respiratory support with the 
diagnosis verified by chest radiograph findings of reticulogranular patterns 
and air bronchograms. 
Cystic periventricular 
leukomalacia; Grade III/IV 
intraventricular haemorrhage 
Ischaemic brain injury. Diagnosed by periventricular echodensities or cysts 
on cranial ultrasound or MRI scan. (PVL)  
Grade III IVH is subependymal haemorrhage with extension into lateral 






Appendix 8 PRISMA checklist for the systematic review of stillbirth and neonatal 
complications in uncomplicated twin pregnancies (Part 1/3) 
Section/topic  # Checklist item  Reported on page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  124 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
121-122 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  124 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
124-5 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
125 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
126 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and date 
last searched.  
126 
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
Appendix 9 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 




10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators.  
127 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
127 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome level), 
and how this information is to be used in any data synthesis.  
128 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  129-131 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if 







Appendix 8 PRISMA checklist for the systematic review of stillbirth and neonatal 
complications in uncomplicated twin pregnancies (Part 2/3) 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
131 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified.  
131 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
131,  
Figure 5.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.  
Appendix 
10 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 




Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 




App 12, 13 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 




App 12, 13 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Figure 5.2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 16]).  
134,  
Figure 5.4 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
139-143 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias).  
140-141 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research.  
142-144 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
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Appendix 8 PRISMA checklist for the systematic review of stillbirth and neonatal 
complications in uncomplicated twin pregnancies (Part 3/3) 
 










































From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
Records identified through 
database searching 



























Additional records identified 
through other sources 
(n = 36) 
Records after duplicates removed 
(n = 2610) 
Records screened 
(n = 2610) 
Records excluded as 
inappropriate population 
and outcome  
(n = 2470) 
Full-text articles assessed 
for eligibility 
(n = 140) 
Full-text articles excluded, 
with reasons 
(n = 108) 
Studies included in 
qualitative synthesis 
(n = 32) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 31) 
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Appendix 9 Search strategy in Medline for the systematic review on prospective risk of 
stillbirth and neonatal complications in uncomplicated twin pregnancies 
Permission granted to reproduce this supplementary file from The BMJ, BMJ Publishing 
Group. Licence number 3998160881661.  
 
a. Stillbirth outcome 
1. Pregnancy.ti.ab 
2. Twin.ti.ab 
3. (Monochorionic or dichorionic).ti.ab 
4. (Fetal or foetal or fetus or foetus).ti.ab 
5. Multiple.ti.ab 
6. 1 and 2 
7. 1 and 5 
8. 3 or 6 or 7 
9. (Death or Demise or Mortality).ti.ab 
10. Stillbirth.ti.ab 
11. 4 and 9  
12. 10 or 11 
13. 8 and 12 
b. Neonatal outcomes  
1. Pregnancy.ti.ab 
2. Twin.ti.ab 
3. (Monochorionic or dichorionic).ti.ab 
4. Multiple.ti.ab 
5. Twins 
6. 1 and 2 
7. 1 and 4 
8. 3 or 5 or 6 or 7 
9. Neonatal death.ti.ab 
10. Neonatal morbidity.ti.ab 
11. Neonatal mortality.ti.ab 
12. Neonatal outcome*.ti.ab 
13. /or 9-12 
14. Bronchopulmonary dysplasia.ti.ab 
15. Assisted ventilation.ti.ab 
16. Retinopathy of prematurity.ti.ab 
17. Hypoxic ischaemic encephalopathy.ti.ab 
18. Neonatal sepsis.ti.ab 
19. Neonatal meningitis.ti.ab 
20. /or 14-19 
21. 13 or 20 
22. 8 and 21 




Appendix 10: Study characteristics of included studies in the systematic review on prospective 
risk of stillbirth and neonatal complications in uncomplicated twin pregnancies (12 pages) 
Permission granted to reproduce this supplementary table from The BMJ, BMJ Publishing Group. 
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ascertainment bias 
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or more than 
32 to >40 
weeks  
Scans at least 
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ascertainment bias 














between 34 and 


































a 2015 (UK) 









Low risk of 
ascertainment bias 




















by TTTS and 
deliveries 
between 26 to 
>40 weeks 
Excluded TTTS 26 weeks 
until 
delivery 
Scans every 2 
weeks for 
growth (MC); 




weeks (MC); 38 
















Low risk of 
ascertainment bias 


















































from 16 weeks 
(MC) and from 













but all delivery 





























Low risk of 
ascertainment bias 







































Scans every 3 
weeks for 































Low risk of 
ascertainment bias 
































34 to ≥39 
weeks 
 




(MC and DC) 





testing from 32 
weeks (MC) and 
34 weeks (DC). 
Delivery: 36-37 





















99.9% follow up 
Low risk of 
ascertainment bias 
















































































carrying a high 


























100% follow up 
Low risk of 
ascertainment bias 



















demise of one or 
both twins at 











































for study as 
women were 
randomised at 
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ascertainment bias 


































TRAP, IUFD of 















































Scans every 2 
weeks (no 
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s) *  








Low risk of 
ascertainment bias 

































































Low risk of 
ascertainment bias 











delivering in the 
participating 












data so that 
population did 
not overlap with 
Hack 2008.  
 
32 to >40 
weeks  
Scans at least at 
20, 24, 28 
weeks and 2 























policy in 7/10 
centres) In the 






































who delivered at 
the centre in the 
timeframe 




twins, twin sets 




24 to >38 
weeks 
 










Low risk of 
ascertainment bias 














TTTS. No cases 


























Low risk of 
ascertainment bias 














































Scans at 12, 16 
weeks and then 
2 weekly until 
32 weeks and 
weekly from 32 
to 36 weeks for 







































Low risk of 
ascertainment bias 
































Doppler every 2 
weekly from 14 












37 weeks (MC), 













































Low risk of 
ascertainment bias 





















weeks, death of 



































Low risk of 
ascertainment bias 











delivered at the 
centre within the 
timeframe, 




with two viable 
foetuses at 23+6 
week and 
delivery at 24+0 
















24 to >38 
weeks 
Scans every 4 
weeks (MC and 
DC prior to 
2002) 
Scans at least 
every 2 weeks 






Scans every 4 
weeks until 28 
weeks then 2 





















Low risk of 
ascertainment bias 















at 17-22 weeks 
at the centre in 





20 to >38 
weeks. 
 
2 weekly scans 




4 weeks growth 














33.9 (SD 4.8) 
for MC and 34.8 




































Unclear risk of 
ascertainment bias 


























Unclear risk of 
ascertainment bias 
















delivered at the 
centre.  
Excluded single 





















weekly from 16 
weeks’ 
gestation.  
Detailed scan at 
20 and 30 
weeks’ 
gestation. 















Low risk of 
ascertainment bias 


















































Scans every 2 






stress tests from 
32-34 weeks. 
Scans every 4 
























2009 (UK) * 




Random sampling  
97.6% follow-up 
Low risk of 
ascertainment bias 







































































& Austria) * 






Low risk of 
ascertainment bias 





















treatment for or 














































scans every 2 
weeks from 18 
weeks (MC); 
scans every 4 
weeks from 20 
weeks (DC).  





Denmark – 38 
weeks (MC and 
























Low risk of 
ascertainment bias 




















death of a fetus 




















Scans at 12 and 
20+6 weeks, 

































10,000 or more 
units of 
unfractionated 


























Low risk of 
ascertainment bias 












delivered in the 
centre in the 
timeframe.  
Excluded 






with fetal death 




cases and fetal 
abnormalities. 











growth every 4 
weeks from 
20/40 (DC) 
Delivery – await 




















s of either twin, 
arrest of fetal 













Low risk of 
ascertainment bias 






















































Scans at 12, 20, 




– according to 
local protocols 




























Low risk of 
ascertainment bias 












ultrasound at the 




















26 to >40 
weeks. 
Scans to check 













from 32 weeks. 
Delivery at 35-






































4 weeks from 28 







Low risk of 
ascertainment bias 
Low risk of 
misclassification 
bias 
abnormalities. at 17 and 19 
weeks for TTTS 
(MC) 
Delivery at 36 
weeks CS (MC) 







Policy may vary 
among different 














Low risk of 
ascertainment bias 













34 to 40 weeks’ 
at the centre in 




26 to >40 
weeks 
No details of 
scanning policy. 
No details of 
delivery policy 
Stillbirth  


















Low risk of 
ascertainment bias 










in which the 
fetuses survived 
until 























prenatal care not 
available.  







* Authors sent additional data 
Quality assessment: Quality of representativeness reflects the representativeness of an uncomplicated twin population (high quality if excluded congenital 
abnormalities/major structural malformations, intrauterine fetal growth restriction and/or significant intertwin growth discordance >25%). Level of 
ascertainment bias reflects the accuracy of definition of stillbirth (>24 weeks’ gestation or >500g birthweight). Level of misclassification bias reflects the 
accuracy of the chorionicity determination and of gestational age assessment.  
^ The neonatal morbidity outcome definition deviated from our standard definitions detailed :Bronchopulmonary dysplasia – need for oxygen at a 
postnatal gestational age of 36 completed weeks and an x-ray compatible with bronchopulmonary dysplasia; Need for assisted ventilation – for more than 
24 hours within 72 hours of birth; Necrotising enterocolitis (NEC) – Bell’s staging 2 or 3 (ie definite or severe NEC) radiological signs of significant 
intestinal dilatation, pneumatosis intestinalis, portal vein gas, with or without ascites, persistently abnormal gas pattern, with or without 
pneumoperitoneum; Septicaemia – confirmed by positive blood cultures within 72 hours of birth.; Intraventricular haemorrhage – grade 3 or 4 – 
ventricular enlargement due accumulated blood and/or bleeding extends into brain tissue around the ventricles.; Cystic periventricular leukomalacia – 
periventricular cystic changes in the white matter excluding subependymal and choroid plexus cysts); Retinopathy of prematurity (stages 3, 4 or 5); 
Hypoxic ischaemic encephalopathy (clinical or laboratory evidence of subacute brain injury due to asphyxia); Respiratory distress syndrome (requiring 
ventilation); Neonatal seizures (seizures that occur from birth until the end of the neonatal period); NICU admission (any admission to the neonatal 
intensive care unit). 
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Appendix 11: Individual study data for stillbirths and neonatal deaths for monochorionic and dichorionic twin pregnancies  
 
                     Monochorionic pregnancy (13 studies) Dichorionic pregnancy (15 studies) 













Aboulghar 2013 Early preterm - - - 2 1 91 
 34 weeks and after    0 2  
Awwad 2014 Early preterm 0 0 39 1 4 220 
 34 weeks and after 0 0  0 4  
Barrett 2013 Early preterm 0 1 656 3 0 1925 
 34 weeks and after 4 3  9 9  
Bhattacharya 2015 Early preterm 10 11 443 41 19 2098 
 34 weeks and after 6 13  16 12  
Breathnach 2011 Early preterm 0 4 193 0 2 785 
 34 weeks and after 0 2  0 0  
Burgess 2014 Early preterm 0 0 151 0 0 547 
 34 weeks and after 0 0  4 1  
Coombs 2011 Early preterm - - - 1 0 236 
 34 weeks and after    0 0  
Hack 2008 Early preterm 9 7 126 16 7 955 
 34 weeks and after 0 2  1 3  
Hack 2011 Early preterm 16 6 469 - - - 
 34 weeks and after 2 1     
Lewi 2008 Early preterm 1 1 151 - - - 
 34 weeks and after 0 1     
Liem 2013 Early preterm 2 2 175 1 2 591 
 34 weeks and after 0 3  0 4  
Lim 2011 Early preterm 0 1 108 1 1 525 
 34 weeks and after 0 0  3 7  
Morikawa 2012 Early preterm - - - 21 31 6514 
 34 weeks and after    20 34  
Nakayama 2012 Early preterm 2 1 192    
 34 weeks and after 1 3     
Norman 2009 Early preterm 0 1 90 2 3 394 
 34 weeks and after 1 0  1 2  
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Rode 2011 Early preterm 0 1 100 0 2 570 
 34 weeks and after 0 0  1 2  
Serra 2013 Early preterm    1 1 286 
 34 weeks and after - - - 0 2  
Wood 2015 Early preterm    20 21 6704 
 34 weeks and after - - - 5 33  
N=13 studies     N=15 studies   
*Early preterm: 26+0 – 33+6 weeks gestation 
Permission granted to reproduce this supplementary table from The BMJ, BMJ Publishing Group. Licence number 3998160881661.  
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Appendix 13 Risks of stillbirths and neonatal deaths in dichorionic and monochorionic 





No. of stillbirths 




rate x 1000 
pregnancies  
(95% CI) 
No. of neonatal 








26+0 - 27+6 20/26685 0.7 (0.5-1.2) 40/316 195.5 (92.8-365.9) 
28+0 - 29+6 38/26247 1.4 (1.0-2.0) 40/513 72.0 (32.7-151.0) 
30+0 - 31+6 40/25511 1.6 (1.1-2.1) 17/905 24.2 (10.5-54.6) 
32+0 - 33+6 49/24178 2.0 (1.5-2.7) 9/1514 7.8 (3.2-19.3) 
Monochorionic pregnancies 
26+0 - 27+6 21/4115 5.1 (3.2-7.8) 12/44 203.4 (66.3-478.5) 
28+0 - 29+6 18/3998 4.5 (2.7-7.1) 12/79 84.5 (26.6-237.6) 
30+0 - 31+6 15/3830 3.9 (2.2-6.5) 11/132 32.3 (9.4-105.1) 
32+0 - 33+6 16/3546 4.5 (2.6-7.3) 3/202 11.9 (3.02-46.5) 
 
 
Permission granted to reproduce this supplementary table from The BMJ, BMJ Publishing 
Group. Licence number 3998160881661.  
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Appendix 14 Rates of neonatal complications for monochorionic and dichorionic twin pregnancies delivered at various gestational ages between 26+0 







 Respiratory distress 
syndrome 
 Retinopathy of 
prematurity 
 
 Neonatal seizures  Septicaemia 
 n/N Risk x1000 
 (95% CI) 
n/N Risk x1000 
 (95% CI) 
n/N Risk x1000 
 (95% CI) 
n/N Risk x1000  
(95% CI) 
n/N Risk x1000 
 (95% CI) 
Monochorionic 8 studies  7 studies  4 studies  3 studies  8 studies 
26+0-27+6 4/35 99.7 (43.3-212.9) 32/35 902 (795.5-956.1) 0/1 N/A 0/0 N/A 14/35 522.4 (385.4-656.1) 
28+0-29+6 3/62 67 (38.8-113.1) 48/61 752.9 (609.4-856.1) 0/6 N/A 0/1 N/A 30/62 375.6 (290.8-468.7) 
30+0-31+6 5/95 44.5 (26.4-73.9) 46/86 501.9 (360.9-642.6) 0/12 N/A 0/11 N/A 21/95 248.5 (192.1-315) 
32+0-33+6 4/141 29.3 (13.1-64.4) 38/124 250 (150.1-386.2) 0/24 N/A 0/19 N/A 21/141 153.9 (104.7-220.5) 
Dichorionic 9 studies  10 studies  4 studies  3 studies  9 studies 
26+0-27+6 5/45 156.2 (84.6-270.7) 43/46 919.3 (831.9-963.2) 1/5 236.3 (58.4-606.8) 0/0 N/A 25/45 571.1 (405.5-722.2) 
28+0-29+6 8/73 75.1 (48.6-114.2) 53/74 798.6 (669.6-885.8) 1/16 104 (40.1-243.8) 1/5 N/A 35/73 377 (259.3-511.3) 
30+0-31+6 6/144 34.3 (20.5-57) 90/146 580 (436.1-711.6) 3/27 41.7 (15.3-108.5) 0/10 N/A 48/144 215.7 (143.2-311.5) 

















 n/N Risk x1000 
(95% CI) 
n/N Risk x1000 
 (95% CI) 
n/N Risk x1000 
 (95% CI) 
n/N Risk x1000  
(95% CI) 
n/N Risk x1000 
 (95% CI) 
Monochorionic 5 studies  4 studies  3 studies  6 studies  8 studies 
26+0-27+6 5/9 524.7 (121.1-898.4) 2/4 456.8 (65.4-909.9) 0/8 N/A 11/11 990.4 (566.1-999.9) 14/35 170.8 (34.8-540.4) 
28+0-29+6 8/13 352.4 (75.7-783.4) 0/2 172.3 (27.3-607.3) 1/7 N/A 12/13 976.3 (550.6-999.3) 13/62 76.5 (15.1-308.6) 
30+0-31+6 16/30 211.5 (40.7-629.3) 2/15 49.0 (6.5-290.2) 0/20 N/A 30/32 942.5 (464.4-996.8) 12/95 32.3 (6.1-154.2) 
32+0-33+6 17/59 116.8 (18.6-480.4) 0/36 12.6 (0.9-152.0) 0/37 N/A 57/68 867.2 (278.8-991.0) 5/141 13.2 (2.2-74.1) 
Dichorionic 8 studies  7 studies  7 studies  9 studies  9 studies 
26+0-27+6 9/13 805.6 (378.1-965.8) 2/8 246.9 (77.7-560.5) 1/13 66.8 (12.3-291.2) 14/15 985.3 (831.6-998.9) 26/45 360.8 (182.9-587.5) 
28+0-29+6 20/30 552.7 (176.2-877.1) 3/19 116.8 (49.9-250.0) 1/32 38.5 (11.3-123.7) 30/33 957.8 (722.3-995.0) 14/73 152.0 (73.1-289.7) 
30+0-31+6 29/59 269.2 (62.6-670.3) 1/47 50.7 (22.2-111.7) 2/70 22.0 (7.0-67.1) 68/74 885.1 (532.6-981.2) 19/144 53.9 (24.4-115.0) 
32+0-33+6 32/129 99.0 (18.0-397.1) 3/104 21.1 (6.3-67.9) 2/154 12.4 (2.7-55.3) 124/158 723.1 (277.9-946.6) 5/231 17.8 (7.1-44.0) 
n = number of adverse outcomes; N = number of women delivered in that 2 weekly gestational epoch
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Appendix 15 Search strategy for the systematic review of prognostic models in 
obstetrics (Medline) 
Permission granted to reproduce this supplementary table from American Journal of 
Obstetrics and Gynecology, Elsevier. Licence number 399160443071.  
 




Validat*(ti.ab) OR predict*(ti.ab) OR rule*(ti.ab) 
 
2 Predict*(ti.ab) AND (outcome*(ti.ab) OR risk*(ti.ab) OR model*(ti.ab)) 
3 (History(ti.ab) OR variable*(ti.ab) OR criteria(ti.ab) OR scor* (ti.ab) OR 
characteristic*(ti.ab) OR finding*(ti.ab) OR factor*(ti.ab)) AND (predict*(ti.ab) OR 
model*(ti.ab) OR decision*(ti.ab) OR identif*(ti.ab) OR prognos*(ti.ab)) 
4 Decision*(ti.ab) AND (model*(ti.ab) OR clinical*(ti.ab) OR logistic model*(ti.ab) 
5 Prognostic(ti.ab) AND (History(ti.ab) OR Variable*(ti.ab) OR Criteria(ti.ab) OR 
Scor*(ti.ab) OR Characteristic*(ti.ab) OR Finding*(ti.ab) OR Factor*(ti.ab) OR 
Model*(ti.ab) 
6 “risk score”[All fields] OR “prediction model”[All fields] OR “prediction rule”[All 
fields] OR “risk assessment”[All fields] OR “algorithm”[All fields] 
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 
8 pregnan*(ti.ab) OR obstetric*(ti.ab) OR woman(ti.ab) OR women(ti.ab) 
VBAC(ti.ab) OR anal sphincter rupture(ti.ab) OR post partum haemorrhage(ti.ab) OR 
vacuum extraction(ti.ab) OR forceps extraction (ti.ab) OR caesarean (ti.ab) OR 
casarean (ti.ab) OR caesarian (ti.ab) OR cesarian (ti.ab) OR shoulder dystocia(ti.ab) 
OR manual placenta removal(ti.ab) OR gestational diabetes(ti.ab) OR placenta 
praevia(ti.ab) OR abruption (ti.ab) OR cervical incompetence(ti.ab) OR cervical length 
(ti.ab) OR growth restrict* OR external cephalic version(ti.ab) OR breech OR rupture 
of membranes(ti.ab) OR PROM(ti.ab) OR PPROM (ti.ab) OR preeclampsia(ti.ab) OR 
pre-eclampsia (ti.ab) OR pregnancy induced hypertension(ti.ab) OR HELLP(ti.ab) OR 
vaginal deliver* (ti.ab) OR preterm deliver* (ti.ab) OR preterm labour (ti.ab) OR 
preterm labor (ti.ab) OR preterm birth (ti.ab) 
9 #7 or #8 
10 #9 NOT (Animals[MeSH] NOT Humans[MeSH)] 
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Appendix 16 Details of all prognostic models included in systematic review, organised by predicted outcome (43 pages) 
Hypertensive disorders 
 









































Logistic None None None 0.85 None No 
Myatt 2012 Pre-
eclampsia 
Nulliparous women at 




683 (174; 7) Logistic None None None 0.73 None No (low 
sensitivity and 
therefore do not 




Pregnant women Prospective 
cohort 






Women with third 









pregnancies without a 
recognised high risk 
for pre-eclampsia, 
small for gestational 





3347 (186; 12) 
(model A) 3347 
(186; 13) 
(model B) 
Logistic Crossvalidation  None “Reasonable” (as 
stated in paper) 
0.71 (internal 
validation for 














82 (41; 7) 
(model A) and 
82 (41; unclear) 
(model B) 
Logistic None None None 0.82 (model A) 
















Women with clinical 




1121 (190; 6) 
(development 
sample) 
Logistic Split-sample None Fair (based on 








not good enough 








































Logistic None None None 0.82 None No 
Farina 2010 Pre-
eclampsia 





14 weeks in which 
no major fetal 
defects were 
detected 






















considered at high 
risk of PE, SGA or 














for development of 
final model 






































































Emonts 2008 Pre-eclampsia Women hospitalized 
with severe PE and 
women with a 
successful term 
delivery after a 
normotensive 
pregnancy 
Unclear 151 (101; 14) Logistic None None None None Regression 
formula 
No 





534 (8; 3) Logistic None None None Only ROC curve, 
AUC not reported 
None No 





4376 (83; 5) Logistic None None None 0.81 Regression 
formula 
No 







4376 (46; 5) Logistic None None None 0.83 Regression 
formula 
No 
Poon 2008 Pre-eclampsia Pregnant women Prospective 
cohort 
4619 (104; 5) Logistic None None None 0.85 Regression 
formula 
No 





6015 (107; 5) Bayesian 
and 
logistic 










16806 (369; 9) Bayesian None None None 0.79 None Yes 





15392 (315; 3) 
(development 
sample) 







August 2004 Superimposed 
pre-eclampsia 




110 (37; 3) Logistic Jackknifing 
procedure 
None P=0.40 0.69 Probability 




Mello 2002 Pre-eclampsia White normotensive 
pregnant women 
with singleton 










None None 0.98 None No 
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eclampsia matched to 
controls for gestational 
age and date blood 
sampling. Women with 
chronic hypertension or 
diabetes were excluded 









626 (44; 7) 
(model A) and 
626 (44; 3) 
(model B) 
Logistic None None None Only ROC curve, 










Women with singleton 
pregnancies without a 













attending in the first 
trimester 
Case-control 90 (30; 6) (model 
A), 90 (30; 7) 
(model B), 90 
(30; 7) (model 
C), 90 (30; 9) 
(model D) 
Logistic None None None 0.90 (model A), 
0.98 (model B), 
0.84 (model C),  

























33602 (112; 17) Logistic Monte 
Carlo 
simulations 
None None Only ROC curve, 





















































Women with early onset 
pre-eclampsia in their 
first singleton pregnancy 
(including HELLP) 
resulting in delivery <34 
weeks, having a singleton 




























452 (12; 4) Logistic None None Not reported, 
only “goodness 





Seed 2011 Early-onset 
pre-
eclampsia 
Women with clinical risk 




1121 (34; 5) 
(development 
sample) 
Logistic Split-sample None Fair (based on 









not good enough 







Nulliparous women with 
singleton pregnancies 



































































627 (29; 6) Logistic None None None Only ROC curves, 


















































3107 (22; 5) Logistic None None None 0.98 Regression 
formula 
No 








15392 (72; 3) 
(development sample) 













1366 (109; 9) (model 
A), 1366 (109; 5) 
(model B), 1366 (109; 
11) (model C) and 
1366 (109; 7) (model 
D) 















33602 (187; 17) Logistic Monte Carlo 
simulations 
None None Only ROC curve, 







































627 (89; 6) Logistic None By Farina et 
al., 20111 
None Only ROC curves, 















8051 (124; 5) Logistic None By Farina et 
al., 20111 































2884 (78; 5) Logistic None By Farina et 
al., 20111 
















3107 (71; 6) 
(model A); 3107 
(71; 7 (model B) 
Logistic None By Farina et 
al., 20111 
None 0.78 (model A); 0.78 
(model B) 















6015 (unclear; 4) Bayesian 
and 
logistic 
None By Farina et 
al., 20111 and 
by Herraiz et 
al., 20092 
None 0.84 (development); 
0.72 (external 
validation by Farina); 
0.64 (external 





























































683 (72; 5) Logistic None None None 0.75 None No (low sensitivity 
and therefore do 
not recommend 













Logistic None None None 0.89 None No 

















1998 (49; 4) Logistic None None “good fit”, 
statistics not 
reported 
0.75 Risk score Yes 
Eclampsia            
Koopmans 
2011 
Eclampsia Women with mild 
PE or PIH ≥ 36 
weeks (controls) and 
women who 
developed eclampsia 


































2218 (46; 4) Logistic None None None None Regression 
formula 
No 
Khalil 2012 Gestational 
hypertension 
















































































627 (82; 4) Logistic None None None Only ROC 


























6015 (107; 3) Bayesian and 
logistic 












after 32 weeks 
Retrospective 
cohort 
1189 (305; 4) Linear regression 
















after 32 weeks 
Retrospective 
cohort 
 957 (192; 4) Linear regression 














































Preterm delivery <28 weeks in asymptomatic women 
Celik 2008 Preterm 
delivery <28 
weeks 




58807 (139; 3) Logistic None None P=0.49 0.90 Regression 
formula 
No 
Preterm delivery <30 weeks in asymptomatic women 
Celik 2008 Preterm 
delivery 28-30 
weeks  




58807 (215; 3) Logistic None None P=0.97 0.82 Regression 
formula 
No 












85 (37; 4) Logistic None None None 0.85 (0.88 for 
score chart) 
Score chart No 














None None None None No 
Tan 2007 Preterm 
delivery <32 
weeks 










None None 0.73 Regression 
formula 
No 
Tan 2007 Preterm 
delivery <32 
weeks 









None None 0.65 Regression 
formula 
No 
Tan 2007 Preterm 
delivery <32 
weeks 









None None 0.65 Regression 
formula 
No 
To 2006 Preterm 
delivery <32 
weeks 















High-risk patients who 
received cerclage at 























pregnancies with ≤3 
cm (multiparous 






100 (50; 6) Logistic None None None None (authors feel 





Preterm delivery <34 weeks in asymptomatic women 









Logistic None None None 0.84 None No 
Kiefer 2012 Preterm delivery 
<34 weeks (with 
















None In same 
paper 
















Logistic None None None 0.67 None No 





live newborns at ≥ 
24 weeks gestation 
Prospective 
cohort 
522 (28; 13) 
(total 
sample) 
Bayesian Split-sample None None None None No 
Celik 2008 Preterm delivery 
31-33 weeks 
Women attending 





Logistic None None P=0.20 0.78 Regression 
formula 
No 








































Preterm delivery <35 weeks in asymptomatic women 
















pregnancies with ≤3 
cm (multiparous 





254 (127; 7) Logistic None None None None (authors feel 





Preterm delivery <36 weeks in asymptomatic women 
Celik 2008 Preterm 
delivery 34-36 
weeks 





















None None None None No 
Preterm delivery <37 weeks in asymptomatic women 
Greco 2012 Preterm 
delivery 34-36 
weeks 


































































program based on 
statistical, case-




None None None 0.72 None No 






live newborns at ≥ 
24 weeks gestation 
Prospective 
cohort 




















Logistic None None None 0.65 Regression 
formula 
No 




Pregnant women Nested case-
control 








Women with a first 










None In same 
paper 




Catley 2006 Preterm 
delivery <37 
weeks 









None In same 
paper 





























Preterm delivery <37 weeks in asymptomatic women 
Catley 2006 “High-risk preterm 
delivery” (delivery <33 
weeks or delivery 33-36 
weeks with low Apgar 
score, low birthweight, 
NICU admission and/or 
neonatal resuscitation) 











None In same 
paper 
None 0.71 None No 










Logistic None None None 0.67 for delivery 24–
28 weeks, 0.65 for 
delivery 29–32 
weeks, and 0.62 for 




Preterm delivery <37 
weeks 










Preterm delivery <37 
weeks 
























































Women without a 
previous preterm 





35 (2; 3) Logistic None None None 0.94 Regression 
formula 
Yes 








314 (38; 5) Logistic None None None None None No 
Ruiz 2002 Gestational age at 
delivery (preterm 
delivery defined 






76 (6; 4) Linear 
regression 
































































None Calibration plot: 
no clear 
interpretation 






















2884 (153; 9) Logistic None None None None Regression 
formula 
No 
Ross 1986 Preterm delivery 
<37 weeks 





































Women without a 
previous preterm 





35 (2; 3) Logistic None None None 0.94 Regression 
formula 
Yes 








314 (38; 5) Logistic None None None None None No 
Ruiz 2002 Gestational age at 
delivery (preterm 
delivery defined 






76 (6; 4) Linear 
regression 
































































None Calibration plot: 
no clear 
interpretation 






















2884 (153; 9) Logistic None None None None Regression 
formula 
No 
Ross 1986 Preterm delivery 
<37 weeks 






































women with preterm 
contractions in level I and 
level II facilities 
Retrospective 
cohort 






high- and low-risk 
pregnant women in a level 
III perinatal center 









None None None None No 
Preterm delivery <48 hours in symptomatic women 
Park 2011 Preterm 
delivery 
<48 hours 
women diagnosed with 
PPROM with live 
singleton with GA 23-34, 
dilatation < 3 cm 
Prospective 
cohort 
102 (24; 3) 
(model A) and 
102 (24; 3) 
(model B) 
Logistic None None P=0.18 (model 
A) and P= 0.11 
(model B) 
0.80 (model A) 










Women with idiopathic 
preterm labour without 
ruptured membranes and 
treated with magnesium 
sulfate between 24 and 34 
completed weeks of 
gestation  






Women with preterm 
labour pregnant between 
26 and 34 weeks gestation  
Prospective 
cohort 
50 (20; 3) 
(model A),  
50 (20; 4) model 
B. 
50 (20; 5) model 
C 
Logistic None None None None None No 






Women with spontaneous 
preterm labour between 
24 and 34 weeks 
Prospective 
cohort 






Women with a singleton 
pregnancy with threatened 

































Preterm delivery <7 days in symptomatic women 
Park 2011 Delivery 
within 7 days 
Women diagnosed with 
PPROM with live 
singleton with GA 23-34, 
dilatation < 3 cm 
Prospective 
cohort 
91 (51; 3) Logistic None None None 0.77 Regression 
formula 
No 




Healthy women with 
singleton pregnancies who 
were in preterm labour (22-




89 (34; 4) 
(model A) 
and 89 (34; 
3) (model B) 
Logistic None None None 0.91 (model A); 







Women between 24 and 34 
weeks’ gestation who 
sought treatment for 
uterine contractions with 
cervical dilatation ≤2 cm, 
received tocolysis with 
magnesium sulfate, 
without spontaneous 
rupture of membranes on 
admission 
Case-control 200 (50; 3) Logistic None None None None None No (“because of the 
modest performance 
we do not believe 
that our clinical rule 






7 days (and 
<34 weeks) 
Women with preterm 
contractions in level I and 
level II facilities 
Retrospective 
cohort 
239 (26; 5) Logistic None None None None None Yes 
Faber 1995 Delivery 
within 7 days 






Logistic None None None None Regression 
formula 
No 




within 10 days 
Women with a singleton 
pregnancy at 22-33+6/7 




583 (90; 3) Logistic Bootstrapping None None 0.75 (0.76 for 
score chart) 




Gestational diabetes mellitus 




























Women without a previous history 





Logistic None None None None Regression 
formula 
No 
Zhou 2012 Gestational 
diabetes 
mellitus 










Women without pre-pregnancy 
diabetes mellitus type 1 or 2 with 
singleton pregnancies delivering a 
phenotypically normal neonate at or 
after 30 weeks of gestation, 













Women with previous gestational 
diabetes but without pre-pregnancy 
diabetes mellitus type 1 or 2 with 
singleton pregnancies delivering a 
phenotypically normal neonate at or 
after 30 weeks of gestation, 











Women without previous 
gestational diabetes and without 
pre-pregnancy diabetes mellitus 
type 1 or 2 with singleton 
pregnancies delivering a 
phenotypically normal neonate at or 
after 30 weeks of gestation, 







Logistic None None None 0.81 None No 
Teede 2011 Gestational 
diabetes 
mellitus 




Logistic None In same 
paper 
None 0.70 (external 
validation) 






































372 (124; 11) 
(model A) and 
372 (124; 5) 
(model B) 
Logistic Bootstrapping None None 0.82 (model A) 















202 (44; 11) 
(model A) and 
202 (44; 5) 
(model B) 
Logistic Bootstrapping None None 0.75 (model A) 


















Insulin treatment for gestational diabetes 









3009 (1535; 7) Logistic None None Calibration 
table: good 
calibration 
None None No 


























(one or more) 











































































Fetal growth and weight 






































Logistic Monte Carlo 
simulations 




























neonate in absence 
of pre-eclampsia 




























Logistic None None None 0.75 Risk curve No 










1121 (255; 6) 
(development 
sample) 
Logistic Split-sample None Fair (based on 








not good enough 
for use in practice) 












1121 (104; 4) 
(development 
sample) 
Logistic  Split-sample None Fair (based on 








not good enough 
















































4376 (532; 5) Logistic None None None 0.63 None No 



















6015 (760; 7) Bayesian 
and 
logistic 
None None None 0.66 Regression 
formula 
No 





























RCT 114 (43; 4) 
(model A); 114 





None None Only ROC curve, 















None Calibration plot: 
no clear 
interpretation 






Pregnant women Prospective 
cohort 
766 (71; 6) Logistic None None None Only ROC curve, 
AUC not reported 
Score chart Yes 
Birthweight            






661 (NA; 6) 
(model A) and 




None In same 
paper 
None 0.94 (model A); 
0.78 (model B); 
when cut-off of 




































661 (NA; 6) 
(model A) and 




None In same 
paper 
None 0.94 (model A); 
0.78 (model B); 
when cut-off of 







weight limit of an infant 
(taking into account 
genetic growth potential, 















71778 (NA; 6) Linear 
regression 





Birthweight Pregnant women 
likely to deliver 
preterm (<34 




















Low birthweight Women with 
singleton 
deliveries 





None Calibration plot: 
no clear 
interpretation 






Labour and delivery 




























underwent a trial of 
labour at ≥37 weeks 
with 1 previous low-





























Women with one prior 
low transverse 
caesarean who 
underwent a trial of 












et al., 20095 
None 
Fair on external 
validation 
(curve) 
0.75 (for formula 
and nomogram in 
internal validation 
sample) 






































Women with a prior 




581 (268; 5) Logistic None None None None Score chart No 






singletons with one 
prior Caesarean 
delivery who 
attempted vaginal birth 










None P=0.95 0.71 Regression 
formula 
No 
Gonen 2004 Vaginal birth 
after caesarean 
Women with history of 









Women with a prior 
caesarean who 
attempted vaginal birth 
Retrospective 
cohort 
471 (368; 4) Logistic None None None None Score chart No 
 
 279 






















Vaginal birth after caesarean 
Jakobi 1993 Vaginal birth 
after 
caesarean 
Women with a previous 
caesarean who were allowed 
to trial of labour 
Unclear 261 (147; 6) Logistic None None None None None No 
Induction of labour 
Rao 2008 Induction of 
labour 
Singleton pregnancies with a 
live fetus at 40+4 to 41+6 
weeks of gestation 
Prospective 
cohort 
1864 (328; 4) Logistic None None None 0.76 Regression 
formula 
No 








Women with singleton live 




190 (119; 4) Logistic None None None 0.81 Regression 
formula 
No 





Women with singleton 
pregnancy who underwent an 




558 (53; 4) Logistic None None None None Scoring 
system 
No 





Women admitted for induction 
of labour  
Unclear 196 (144; 5) Logistic None None None None None No 





Women with singleton live 
pregnancies in cephalic 
presentation undergoing 
induction of labour at 35 to 




822 (530;  
3) 
Logistic None None None None Regression 
formula 
No 





Women with singleton live 
pregnancies in cephalic 
presentation (occiput posterior 
position) undergoing induction 
of labour at 35 to 42+6 weeks 
































Vaginal delivery within 24 hours after induction of labour 





Women with intact 
membranes and minimal 
uterine activity, who 
underwent induction of 
labour with misoprostol 






Logistic None None None None None No 






with live fetus in 
cephalic presentation 
undergoing induction of 
labor with Dinoprostone 
Gel at 37– 42 weeks, 




240 (142; 3) Cox None None None None None No 
Vaginal delivery within 12 hours after induction of labour 
Riboni 2012 Delivery 
within 12 
hours 
Women who underwent 
induction of labour at 




115 (42; 6) Logistic None None None None None No 







induction of labour 
Prospective 
cohort 
177 (63; 5) Logistic None None None None Regression 
formula 
No 




women with premature 
rupture of membranes 





















Nulliparous women with 
vertex singleton 
undergoing induction of 
labour at term and 




5610 (4224; 4) Logistic Bootstrapping In same 
paper 































Women undergoing labour 
induction for pre-
eclampsia with euploid 


















Singleton live pregnancies 
in cephalic presentation 
undergoing induction of 
labour at 35 to 42+6 




822 (91; 5) Logistic None None None None Regression 
formula 
No 
Rane 2005 Caesarean 
section (all 
indications) 
Singleton live pregnancies 
in cephalic presentation 
undergoing induction of 
labour at 35 to 42+6 




822 (161; 5) Logistic None By 
Verhoeven 








Rane 2004 Caesarean 
section 
Women with singleton 




induction of labour at 35 
to 42+6 weeks gestation 
for a variety of indications 
Prospective 
cohort 
604 (120; 3) Logistic None None None 0.81 Regression 
formula 
No 
Rane 2004 Caesarean 
section 
Women with singleton 




induction of labour at 35 
to 42+6 weeks gestation 
for a variety of indications 
Prospective 
cohort 





























































singleton live term 




190 (130; 4) Logistic None None None 0.80 Regression 
formula 
No 
Schuit 2012 Operative delivery 
(instrumental 
vaginal (IVD) or 
caesarean (CS)) 
for fetal distress 
(FD) or failure to 
progress (FTP) 
Labouring women 
with high-risk vertex 
singleton pregnancies 
>36 weeks gestation 
Randomized 
trial 
5667 (375 + 
212 + 433 + 
571; 7) 
(model A), 
5667 (375 + 










(model A) and 
0.73 (modelB2); 
CS-FD: 0.70 
(model A) and 
0.73 (model B);  
IVD-FTP: 0.78 
(model A) and 
0.80 (model B);  
CS-FTP: 0.78 
(model A) and 














Logistic None None P=0.87 0.65 None No 




with singletons in 
vertex position, no 
pregnancy 
complications, ≥ 37 
weeks, intact 
membranes, no 


































Mode of delivery 
Nader 2010 Vaginal 
delivery 
Nulliparous women with 
singleton pregnancies 
between 36 and 38 weeks 















Rao 2008 Caesarean 
section 
Singleton pregnancies with a 
live fetus at 40+4 to 41+6 
weeks of gestation 
Prospective 
cohort 













2478 (705; 9) Logistic None None None 0.72 Scoring 
system 
No 






Nulliparous women with an 
uncomplicated singleton 




202 (124; 4) Logistic None None P=0.48 0.85 Regression 
formula 
Yes  





Nulliparous women with an 
uncomplicated singleton 






















Women with singleton 
pregnancies in cephalic 
presentation in the early stage 
of active labour between 37-











women ≥44 years old who 
delivered singleton infants; 
the control group included 
the women 20–29 years old 
who delivered singleton 
infants at immediately after 
each study subject 
Case-control 418 (56; 3) Logistic None In same 
paper 






































childbirth who received 







































Successful external cephalic version 






























Women with a fetus 
in breech 
presentation at ≥36 
weeks who 
underwent external 
cephalic version with 
the use of tocolytics 
Prospective 
cohort 









None Risk score Yes 







version for breech 
presentation at ≥36 
weeks of gestation 
Prospective 
cohort 
243 (169; 3) 
(total sample) 





















































Successful vaginal delivery after external cephalic version 






Women with singleton 
pregnancies who had a 
single attempt of 
external cephalic 
version at or after 36 
weeks of gestation 
Prospective 
cohort 










enough for routine 
use) 









singletons in breech 
presentation > 37 
weeks indexed for 
vaginal birth trial 
Retrospective 
cohort 











Infection and inflammation 























Intra-amniotic infection and/or inflammation 
Park 2012 Intra-amniotic 
infection and/or 
inflammation 







171 (63; 4) Logistic None None P=0.52 0.85 Regression 
formula 
No 
Jung 2011 Intra-amniotic 
inflammation 
Women admitted with 
preterm labour and intact 
membranes between 21 
and 35 weeks gestation, 
with a singleton live fetus 
without major congenital 
















371 (21; 5) Logistic Crossvalidation None None 0.82 
(development) 
Risk score No 
Histologic signs of infection 
Cobo 2012 Histological 
funisitis 











Fetal health and survival 


































Logistic None None None 0.78 Regression 
formula 
No 







Unclear  None None None None None No 
Stillbirth 
Reddy 2010 Antepartum stillbirth Singleton 






Cox None None None None None No 
Smith 2007 Stillbirth ≤ 33 weeks Pregnant women 






Logistic None None None 0.87 Regression 
formula 
No 
Smith 2007 Stillbirth ≥ 34 weeks Pregnant women 






Logistic None None None 0.67 Regression 
formula 
No 




(fetal death with 
birthweight >500 g 
or death within 7 
days of live birth) 
Singleton 
deliveries 




None Calibration plot: no 
clear interpretation 
None Score chart No 








None None None None None Score chart No 
Poor perinatal outcome 
Romero 2001 Fetal wellbeing (1 
minute Apgar score 































































Complications of pregnancy and delivery 



























disorders (PE and 
PIH) 
Women with singleton 
pregnancies without a 















Women who underwent 
first trimester screening 
Retrospective 
cohort 
28566 (1074; 4) Logistic None None None 0.56 Regression 
formula 
No 
Mello 2001 Pregnancy 
induced 
hypertensive 
disorders (PE and 
IUGR) 
Normotensive white 
women with singleton 
pregnancies at high risk 
for PE and IUGR 
(insulin-dependent DM, 
previous PE, recurrent 




187 (47; 9) 









None None 0.95 (model A) 





































Dodd 2012 Shoulder 
dystocia 
Pregnant women Retrospective 
cohort 
114827 (1303; 4) Logistic None None P=0.04 0.73 None No 
Gupta 2010 Shoulder 
dystocia 
Women without pre-
existing or gestational 
diabetes or previous 
shoulder dystocia 
with singleton vaginal 
live cephalic 




20142 (120; 3) 
(model A) and 






None results not 
reported but "no 
strong evidence 
of poor fit" 
0.90 (model A 











neonates with birth 
weights ≥ 4000 g 
Unclear 394 (29+20; 3) Three-way 
discriminant 
analysis 









Women with a 











Women with a 











Women with a 
































Odibo 2007 Placental 
abruption 








Logistic None None "good fit" but 
statistics not 
reported 
















































Women with a 
singleton vaginal 
delivery ≥ 37 
weeks 
Unclear 6011 (1435; 
6) 
Logistic Bootstrapping None Based on 
calibration plot: 
good fit 
0.70 Nomogram No 


















Case-control 653 (151; 5) Logistic None None None Only ROC curve, 































Anal sphincter injury 
Williams 
2005 
Anal sphincter injury Women with 
term singleton 
deliveries 
Case-control 246 (123; 
unclear) 
Logistic None None None Not shown but 
“ROC curve 




Risk score No 
Thrombosis            
Lindqvist 
2002 
Thrombosis in pregnancy 
(deep venous thrombosis, 
















Thrombosis within 3 
months postpartum (deep 
venous thrombosis, 














Maternal complications of attempted VBAC 
Scifres 2011 Major maternal morbidity 
after attempted VBAC 
(any of the following): 
uterine rupture, bladder or 
ureteral injury, bowel 












Logistic None None None 0.65 None No 
(performance 














799 (134; 4) 
(model A) 
and 799 (134; 
6) (model B) 
Logistic None None None 0.68 (model A) and 


































Maternal mortality or one 
or more serious CNS, 
cardiorespiratory, hepatic, 
renal, or haematological 
morbidity in women with 
pre-eclampsia 



















Progression to a high risk 
situation (any of the 
following: diastolic blood 
pressure ≥ 110 mmHg, 
systolic blood pressure ≥ 
170 mmHg and ⁄ or 
proteinuria ≥5 g in 24 h,  
eclampsia, HELLP 


















Logistic Bootstrapping None P=0.40 0.71 None No 
Combined adverse pregnancy outcome 
Magann 
2011 









infection, neonate born 
LGA, perinatal death, and 











































Souka 2011 Short cervix 
(≤15 mm) at 
20-24 weeks of 
gestation 
women with viable 
singleton 
pregnancies 




800 (12; 3) 
(model A); 
800 (12; 4) 
(model B) 
Logistic None None P=0.22 (model A); 
P>0.05 (model B) 
0.81 (model A); 
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